var title_f3_17_3344="Algorithm abnormal mammogram";
var content_f3_17_3344=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Management algorithm for patients with abnormal mammograms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 580px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This algorithm helps to guide management of the patient who presents with an abnormal mammogram, whether it is performed at your institution or outside. BIRADS 4 is a broad category that includes patients with a probability of malignancy that ranges from 2 to 95 percent. The management of more suspicious lesions (&gt;50 percent probability) should include surgical evaluation before percutaneous biopsy. The designation often implies lower suspicion of malignancy. Also, some patients and some lesions are not appropriate candidates for percutaneous biopsy.",
"    <div class=\"footnotes\">",
"     BI-RADS: Breast Imaging Reporting and Data System.",
"     <br>",
"      * A situation in which it may be useful to incorporate staging MRI. FNA: fine-needle aspiration.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Esserman, L, et al. Current Oncology Reports 2000; 2:572.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_17_3344=[""].join("\n");
var outline_f3_17_3344=null;
var title_f3_17_3345="Shoulder osteoarthritis treatment";
var content_f3_17_3345=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Shoulder osteoarthritis treatment (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?3/17/3345/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/17/3345/contributors\" id=\"au5319\">",
"       Bruce C Anderson, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?3/17/3345/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/17/3345/contributors\" id=\"se247\">",
"       Peter Tugwell, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?3/17/3345/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/17/3345/contributors\" id=\"de4792\">",
"       Jerry M Greene, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?3/17/3345?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      SHOULDER ARTHRITIS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Arthritis of the shoulder (the ball-and-socket joint) is an uncommon problem. In almost every case, the shoulder has been injured months or years earlier, leading to an abnormal wearing down of the cartilage. Injuries include bony fracture, dislocation, or heavy blow to the outer shoulder.",
"    </p>",
"    <p>",
"     Fortunately, arthritis of the shoulder progresses slowly. Treatment focuses on reduction of inflammation, physical therapy stretching exercises to preserve motion, shoulder muscle strengthening exercises, and avoidance of activities to prevent further wear and arthritic flare-ups.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      SHOULDER ARTHRITIS TREATMENT",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Limit activities",
"     </span>",
"     &nbsp;&mdash;&nbsp;Avoiding painful activities in general will alleviate strain on the injured area. Restrict lifting, overhead reaching, and reaching behind (eg, reaching into the backseat) as much as possible during the early recovery period. It is safest to keep the arm down and in front of and close to the body.",
"    </p>",
"    <p>",
"     Some general rules to decrease shoulder strain with activities include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Lift objects close to the body.",
"      </li>",
"      <li>",
"       Only lift light weights, and limit lifting to below shoulder level.",
"      </li>",
"      <li>",
"       Do sidestroke or breaststroke when swimming (avoid the backstroke and classic crawl stroke).",
"      </li>",
"      <li>",
"       Throw balls underhand or sidearm.",
"      </li>",
"      <li>",
"       Avoid pushing exercises at the gym (eg, pushups, bench press, flies, shoulder press).",
"      </li>",
"      <li>",
"       Do not serve overhand in tennis or volleyball.",
"      </li>",
"      <li>",
"       Maintain good posture with writing, assembly work, and other tasks by keeping the shoulder blades down and back.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Pain relief",
"     </span>",
"     &nbsp;&mdash;&nbsp;If needed, a non-prescription pain medication, such as acetaminophen (Tylenol&reg;), ibuprofen (eg, Advil&reg;, Motrin&reg;), or naproxen (eg, Aleve&reg;), can be taken. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"      \"Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)\"",
"     </a>",
"     .) No more than 4000 mg of acetaminophen are recommended per day. Anyone who has liver disease or who drinks alcohol regularly should speak with his or her healthcare provider before taking acetaminophen.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      SHOULDER ARTHRITIS STRETCHING EXERCISES",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Heat",
"     </span>",
"     &nbsp;&mdash;&nbsp;Heat helps prepare the tissues for stretching and should be performed prior to exercise sessions. The preferable method of heating is whole-body, deep heating in a warm shower or bath for 10 to 15 minutes. Local heat (for example, with a moist heating pad or a towel warmed in a microwave) is an alternative but, generally, is not as effective.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Weighted pendulum stretching exercise",
"     </span>",
"     &nbsp;&mdash;&nbsp;These exercises are intended to help maintain joint mobility and flexibility of the muscles and tendons in the shoulder. Range of motion and flexibility exercises should not cause more than a mild level of pain; patients who feel sharp or tearing pain while stretching should stop exercising immediately and should consult their healthcare provider.",
"    </p>",
"    <p>",
"     This exercise should be performed once or twice per day, after the shoulder is warmed with whole-body deep heating, cardiovascular exercise, or a directly applied warm pack.",
"    </p>",
"    <p>",
"     The exercise is performed as follows (",
"     <a class=\"graphic graphic_figure graphicRef50148 \" href=\"UTD.htm?12/37/12895\">",
"      figure 1",
"     </a>",
"     ):",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Relax your shoulder muscles.",
"      </li>",
"      <li>",
"       While standing or sitting, keep your arm vertical and close to your body (bending over too far may pinch the rotator cuff tendons).",
"      </li>",
"      <li>",
"       Allow your arm to swing forward to back, then side to side, and then in small circles in each direction (no greater than one foot in any direction). Only minimal pain should be felt.",
"      </li>",
"      <li>",
"       Stretch the arm only (without added weight) for three to seven days. Progress this exercise by adding 1 to 2 lbs (0.5 to 1 kg) per week and by gradually increasing the diameter of the movements (not to exceed 18 to 24 inches or 45 to 60 cm).",
"      </li>",
"      <li>",
"       After a few weeks, this exercise should be supplemented or replaced by other exercises to target specific areas of tightness or restriction. The pendulum stretch may be recommended as a warm-up for more localized flexibility exercises",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       strengthening exercises.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     When performed correctly, the pendulum exercise should not result in more than mild discomfort. If more pain is felt, consult a healthcare provider for instructions.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Passive stretching exercises",
"     </span>",
"     &nbsp;&mdash;&nbsp;Passive stretches are performed after the pendulum stretch exercise (",
"     <a class=\"graphic graphic_picture graphicRef51493 graphicRef78109 graphicRef77955 \" href=\"UTD.htm?42/28/43461\">",
"      picture 1A-C",
"     </a>",
"     ). These exercises, performed once or twice a day for several months, should further loosen the tightened shoulder lining and should help to restore more normal range of motion. Sets of 10 to 20 of the following three exercises are performed daily:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Armpit stretch &mdash; Use your good arm to lift the affected arm onto a shelf, dresser, or any object about breast high. Gently bend at the knees, opening up the arm pit. Try to push the arm up a little farther with each stretch.",
"      </li>",
"      <li>",
"       Finger walk &mdash; Face a wall about three-quarters of an arm&rsquo;s length away. Using only your fingers (not your shoulder muscles) raise your arm up to shoulder level.",
"      </li>",
"      <li>",
"       Towel stretch &mdash; Take a three-foot-long towel, grasp it with both hands, and hold it at a 45 degree angle. Use the upper, good arm to pull the arm toward the lower back. This can be repeated with the towel in the horizontal position.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The goal of these exercises is to stretch the shoulder to the point of tension but not pain.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      SHOULDER-STRENTGTHENING EXERCISES",
"     </span>",
"    </p>",
"    <p>",
"     Muscle-toning exercises should be performed after your initial pain has resolved. These exercises are necessary to restore any lost muscle strength.",
"    </p>",
"    <p>",
"     The joint should always be heated and stretched (as outline above) prior to beginning toning exercises. Following a two- or three-minute rest, perform sets of 15 to 20 exercises daily, each held for five seconds. Flexible rubber tubing, bungee cords, or large rubber bands are used for each exercise (",
"     <a class=\"graphic graphic_figure graphicRef70846 \" href=\"UTD.htm?26/2/26656\">",
"      figure 2",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Outward rotation exercise",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hold your elbows at 90 degrees, close to your sides. Grasp the rubber band with your hands, and rotate your forearms outward only two or three inches, holding for five seconds (",
"     <a class=\"graphic graphic_picture graphicRef53514 \" href=\"UTD.htm?36/14/37089\">",
"      picture 2",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Inward rotation exercise",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hold your elbow at 90 degrees, close to your side. Hook the rubber band onto a door handle, and grasp with only one hand. Rotate your forearm inward two or three inches, and hold for five seconds. The forearm swings like a door (",
"     <a class=\"graphic graphic_picture graphicRef67577 \" href=\"UTD.htm?3/14/3298\">",
"      picture 3",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Lifting exercise",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bend your elbow to 90 degrees. Place the rubber band near the elbows, and lift your arms up four or five inches away from the body, holding for five seconds (",
"     <a class=\"graphic graphic_picture graphicRef55598 \" href=\"UTD.htm?18/9/18577\">",
"      picture 4",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Mild soreness should be expected with these exercises. Sharp or severe pain may indicate a flare of the underlying problem; stop these exercises for a few days if this occurs.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11284649\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11284656\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=see_link\">",
"      Patient information: Osteoarthritis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11284680\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11284702\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10663?source=see_link\">",
"      Acromioclavicular joint injuries",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25991?source=see_link\">",
"      Biceps tendinopathy and tendon rupture",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=see_link\">",
"      Brachial plexus syndromes",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link\">",
"      Evaluation of the patient with shoulder complaints",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33912?source=see_link\">",
"      Frozen shoulder (adhesive capsulitis)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26630?source=see_link\">",
"      Glenohumeral osteoarthritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41592?source=see_link\">",
"      Multidirectional instability of the shoulder",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6887?source=see_link\">",
"      Presentation and diagnosis of rotator cuff tears",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21289?source=see_link\">",
"      Rotator cuff tendinopathy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32280?source=see_link\">",
"      Shoulder impingement syndrome",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American Physical Therapy Association",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.apta.org/\">",
"        www.apta.org",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 6, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?3/17/3345?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f3_17_3345=[""].join("\n");
var outline_f3_17_3345=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           SHOULDER ARTHRITIS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           SHOULDER ARTHRITIS TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           SHOULDER ARTHRITIS STRETCHING EXERCISES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           SHOULDER-STRENTGTHENING EXERCISES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/37/12895\" title=\"figure 1\">",
"           Pendulum stretch exercise PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/2/26656\" title=\"figure 2\">",
"           Shoulder strength PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/4/9295\" title=\"picture 1A\">",
"           Armpit stretch PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/8/13455\" title=\"picture 1B\">",
"           Walk up wall stretch PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/47/21247\" title=\"picture 1C\">",
"           Towel stretch PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/14/37089\" title=\"picture 2\">",
"           Outward rotation PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/14/3298\" title=\"picture 3\">",
"           Inward rotation exercise PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/9/18577\" title=\"picture 4\">",
"           Lifting exercise PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f3_17_3346="Choroidal TB";
var content_f3_17_3346=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F87842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F87842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Posterior uveitis due to ocular TB",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 389px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGFAgMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3n4ofEDSvhxoFvq+uW99PbTXS2irZojOHZHYEhmUYwh7+leYf8NV+B/8AoFeJP/AeD/49R+2t/wAks0r/ALDUX/oievKfgN8HvC3jr4f6p4h8TajqtmbK8lhY2ssaRrEkUbliGjY5+du/QDigD1b/AIar8D/9ArxJ/wCA8H/x6j/hqvwP/wBArxJ/4Dwf/Hq4r4XfBz4W/EnTLy80HUfGEItJhDLDdy2ySDK5VsLGw2nnHP8ACeK+X6APtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+K6sQw5AY/lSbsNJt2R9nr+1N4LbGNJ8S8/wDTvB/8ep3/AA1F4NyB/ZHiTP8A1wt//j1fHcaDbxTiMENzxwaydRnQqCtqfYy/tO+EGzjRvEn/AH4t/wD49Tx+0x4TPTRfEn/fm3/+PV8gwOm75iADjmtSBVK89u4rCeJlHoV9XifVf/DS3hT/AKAniX/vzb//AB+kX9pfwm20jRPEuG4H7m35/wDI1fLEy7Ld2Xkn5R7Zq0Y0jh2AdsVk8bJdB/V4n1GP2jvDJGRoXiX/AL9W3/x+lH7RvhknjQvEv/fq2/8Aj9fLEMzM2yQ//Xq9E46EZxUSx1WPRf18x/VUfTR/aM8NDroPiT/v1bf/AB+j/hozw1/0AvEn/fq2/wDj9fNRcMMBRTVGTg4BqP7Qqdl/XzF9WifSx/aO8MjroXiT/v1bf/H6b/w0j4Xzj+w/Euf+uNt/8fr5rlT5feq4jKjpVLMJvohrDRPpz/hpDwxnH9h+JP8Av1bf/H6av7SfhVs7dD8SnHX9zb//AB+vmQrk4HHrTIUCSuo780/r07bIf1aJ9Pn9pLwsP+YH4l/7823/AMfpD+0p4VB50TxJ/wB+bb/4/XzKyZOfSq1xD8ucU446b6In6vE+nV/ad8IMWA0bxJ8vB/cW/wD8epf+GnPCOM/2N4l/78W//wAer5Kto9zSNjgtUzx/LnHNdDxLTsH1eJ9WN+0/4OXro/iT/vxb/wDx6o3/AGpvBSfe0nxKP+3eD/49XyVOoHHc1TnjBJFaRrN7kSoJLQ+vv+Gq/BH/AECvEn/gPB/8eo/4ar8D/wDQK8Sf+A8H/wAer4xmiKHI6VBW6dznasfav/DVfgf/AKBXiT/wHg/+PUf8NV+B/wDoFeJP/AeD/wCPV8VUUxH2r/w1X4H/AOgV4k/8B4P/AI9R/wANV+B/+gV4k/8AAeD/AOPV8VUUAfpJ8UPiBpXw40C31fXLe+ntprpbRVs0RnDsjsCQzKMYQ9/SvMP+Gq/A/wD0CvEn/gPB/wDHqP21v+SWaV/2Gov/AERPXiXwx+HfhDVvhDrnjbxfca+qaZfG2aLS3hBZNsOCBIpyd0p/iAwPzAPbf+Gq/A//AECvEn/gPB/8eo/4ar8D/wDQK8Sf+A8H/wAerkPCPwQ+HfiTXL/R1k8b6dqVlBFcyQ3k9mcxyDKMGiV15HYkH2r5ZoA+1f8AhqvwP/0CvEn/AIDwf/HqP+GqvBH/AECvEv8A4Dwf/Hq+LFUswAGSa0bWzCkGQZb0qZSUVqXCDm7I+yF/ag8HMARo/iX/AL8W/wD8eqQftOeET00bxJ/34t//AI9XyLAgbipiAvTP1rmeIa0R2xwkXuz61/4aa8JYz/YviTGM/wCpt/8A49QP2mfCR6aL4k/782//AMer5QQccikjHAHcfrUfWZdi3gqfdn1j/wANMeE/+gL4k/782/8A8epw/aV8KE/8gTxJ/wB+bf8A+P18pBep7VNGAcEjipeLmuiD6lDuz6o/4aS8LDP/ABI/EnH/AExtv/j9Kv7SPhdgCND8Sn/tlbf/AB+vlwKMZ7HikhBXcndT+lR9dn2RX1CFt2fUx/aQ8MDrofiT/v1bf/H6aP2kfC56aH4l/wC/Vt/8fr5gcbVJ68UInAyaX16fZCWBh3Z9Qj9o/wAMH/mBeJP+/Vt/8fpkv7SfhaJdz6J4kA/65W3/AMfr5oRQwHSo7uDdC425JHFJY+d7NIawNPq2fTS/tK+FWUFdE8Skf9cbf/4/Qf2lPCo5OieJf+/Nt/8AH6+WbNVkt9y53Dhh6YpCrDKnqelafXJ3tZA8BBO12fUp/aY8JjroviT/AL82/wD8fpR+0v4TPTRfEn/fm3/+P18qJbsRlwc9hUyR454pvGSXYTwMF1Z9S/8ADS/hPdj+xfEmfTybf/4/Th+0p4VPTRPEn/fm2/8Aj9fJ8yN5wwMDsanmk2xAqOR6UPFz0skH1GHdn1O37S3hRThtE8Sf9+bf/wCP1Wm/aj8GQkCTSPEq5/6d4D/7Wr5bZi4GeDWVfxhxggMDWlPESk7SMZ4RJaM+tf8AhqvwP/0CvEn/AIDwf/HqP+Gq/A//AECvEn/gPB/8er4wnhMZ9V9ahrrTvscTTTsz7V/4ar8D/wDQK8Sf+A8H/wAeo/4ar8D/APQK8Sf+A8H/AMer4qopiPtX/hqvwP8A9ArxJ/4Dwf8Ax6ug8BftAeFfG/iyx8PaVYa3De3nmeW9zDEsY2Rs5yVkJ6Kex5r4Kr1X9lz/AJLt4Z/7ev8A0lloA+/6KKKAPAP21v8Aklmlf9hqL/0RPXH/AAE0HWfFH7N/ifQ/DtxaWt3f6w8Ek1yzKqwmG38zG1SSSuRj3PNdh+2t/wAks0r/ALDUX/oieviqgD7/APAnwy1DwP8AEKXUtK1Rbvw/d6ZFZ3UV1sScSwgLEyrFGqFQgC888knNfAFFT28W45PApN2GlfRDoIs8nrVnys528N/OrEMPyjg49alRAkw3D5TXPKpqdcKdkVAJe2KesUjnazHHtWukSHnHWpEt1Ckj1rB1zRIoxWERA3Kc/WpFEtg6gszQMcc9jWhFHwCB34FOuYfNiKY5NYurd2lsaRSIDP5kyIoJVfmbA6+lXmYyKDjANZ+mn92yN/rEODWkhIwMdfSsqlk7IsYY8jAOCOhqeNgU+bqOtORAMFj9BUc6HduUcd6yvfQe5MrAjIqzGOeOtQBdkag8luas28Ts3A4rGT0JZJt6ilWEMeSRUsrLH6E96r/atzADpWSu9iUmOa1IPc/SqdxF5bK2CMH9KsG9YNjNR3EpljYE9s1pHmT1KV7kiwhlyrcVFLCCMcGrNqp2hgQKdMNkbtkcAnpU8zTsJ7nO2EH765UYKK3Bp9ygAOPwq7pcapYK3dyW+uar3gxk9a6+e82DWtjGkT9706Cq8qYNXipILY6nNVZRtBJ7V2RkEkZ04wMevaqEsTJyRx/KtUISSx6nmo5YwR0rqhO2hzVKfNqZNFSTJsfHao66NzjegUUUUAfav7a3/JLNK/7DUX/oieuP+A3hm88Zfsz+LtA0uW3ivL3VmWN7hmWMFUtmOSoJ6KexrsP21v8Aklmlf9hqL/0RPXxVQB+gXw3+H+peHfGd1rU1vo+jWEmmx2P9l6PIzxTSqwJuJCY4wHwMcL0PX1/P9QSQB1pKv2UO352HJ6e1TKXKrlQjzOxNZ2wj+99896vImDg9KdboNvpUoGVIKnNcM53ep6lOmoKyEVTwwqztWRNy8EdqjUDG0Z6dKl2FGDcEntmsZM2hroJ8oODmpYos5z09fSk4LelTQkAFeCD3rOT0K5WhVTbhTyOxFOVAeVz9KFPPXmpQAoJ6Z71m2ykIFwc449KVwA6vxz8pP8qcu5xgLnHqcU7y3ZSpC4I9zUXKTtuBTOPQ04KQSOw6U+BS3ysMOvYdCPUVaWEkjI4rOUrCbsV0Q5JFSnAHzVL5WPpTWQgf0qHK5N7mXd25hcz2v3v407NSCVZkDqOD1z2rQAUsRk5Xt6VmCMwX4QECOU5A9Pat4PmVnujVO+jLCJnnPH86DAAuccZqzJEoClSAe9PZcoBzUc5Fyg8YxyOaqXEZCgYOPStRosEHHPeoLlcDI5x2rSE9SbmUxByBnJFVZVPI289quzbc7hjBqErvc4IIFdUWKUbmZcRAoQwGO9ZM8JibkcHoa6OaLpxnJ4zVW5tg6EEda6qdWxx16KmrrcwKKlniaKQo1RV2J3PNatowr1X9lz/ku3hn/t6/9JZa8qr1X9lz/ku3hn/t6/8ASWWgD7/ooooA8A/bW/5JZpX/AGGov/RE9fFVfav7a3/JLNK/7DUX/oieviqgB8a7mArStUwwAHB9arW8XAzWraooxkcg1hVnodFKPUmiQgYHIp88O+L5fvDoan2DaGI6d6UiIYZZdh7g1w82t0dKI7JndQCcr39q0YgpyPXrVK2dI7gjcCrdMetakaAru9ayqvUqw2JAJvw6Zqx5e4nj6VFJGcB8dPSr1sA2CRmuacuozDubdrO5N2BuibiRfT3rUj8uRFaNgVPQirssJKn5cqeCKy47JrOTfBuMJ6xnt7in7RVFruWtS4Yi3AHFOEZOVIyantCJogevHWpWgY855rBzs7MRTtbYeYd5+UVoRgKflGAKqRIftRB9Ku7Rzk5PpUVHd6g1czbouZWxUMcZAJbr6Vqz2/mAEcEDp61ALdicAEmqjUVh9CqkYb607yfmCjgnr9K0rfTZOrd6fJCsFxFvYAHI5qXWV7IEV7eBh16UXyBbeUHgbTmtNTFtyGBx3rF1ueMWdxg87DUU5Oc0K12UtK3f2bEfbvVe/wDm47txVmB0+w26r/cHAqJlG4tIAW7e1di+Ns05dblOaNQoH5VmzxebJsyNi8n3PpWlcEYLNwO/0qjExYM2wnccj6V1020rkNEBh9BUEkJ71oujYzwP1qCRGwSW5+laxmZyRj3MOQc1nMCCQa3J0zx1rMu4sHcO3WuylO+hyVoW1KlFFFbnOfav7a3/ACSzSv8AsNRf+iJ6+Kq+1f21v+SWaV/2Gov/AERPXxYoJIA70ATWse98n7orUiwfxqvbptXA7VciHNc1SVzsoxsixGcDnpUqEk9MimIuQakUAdOa5Gd0diaHAySnFOYcgqcj+VEfGQBxUuz5Qe5rJvU0SAcjHtQsY7ZH0pyjc2OhFTKo68Gs27FpjBEduQxP4VPHFlRuJLDtSrHtIIJqdRyPcVnKQhqL6VMBn1NIVIxg9TipkQH1yKxch2HRRhwuc/LyCvBFWEEgXBKyfX5T/hSQqFTK/wD66nQA5INYSkJkSkHO4FSOcHrUMytkFc1deNHX5+gOQR1X3FQsjR/eG4dnH9RSjJDS7FN28vG5QMnk1UvoY7obSdnOUcfwmtIxq559PzpTZHkoMjHT1rWNRRd+pSsmY4uXVRHeDZIOBJj5W+prRhDMgDLjjqKuw2gMWx0Dxt1DCqktpNpxzDl7U/wHqn09qbqRnotGDs9hGXIPFVpUIU98Vo2yCWPcv1pJ7cqOBipVSzsZbPU5WaLfNtHJ9hxU0NpgDPUd60ZodsilThiCKbGuVB/P3rs9rdaFSd0Zc0BH4GoZocZziteaMEHuCKpSBmUED2q4VLmbjdGDqVrviyPvDpWEa6u8yqNk5Fc/fWzRBZCOG6+xr0sPO6szz8TSt76Kdeq/suf8l28M/wDb1/6Sy15VXqv7Ln/JdvDP/b1/6Sy11HGff9FFFAHgH7a3/JLNK/7DUX/oievi2NSWGBmvtL9tb/klmlf9hqL/ANET18Z2y96TdkVFXZYhbHUHj2q5HMOAAfyotkHpkVoW6IwOVwa46k12OyKsNt455l2sWVO9acFlBGq5UMR60y3VsbVXA9avQALgda4atR9CyOS1ikQgKFHoKjid4CUdSyDoepFaAjd+vAz2q5bwjbiRc+ma5nVstdS07FBZY5UzGwI9M/zp9udsgx07VYfTY5SWA2tngjj9armK4tX/AHiF4v7wHI+v+NRzRlojRJPY10AZRS/ZRJ0OKZZHzgPLwR9a01iJCoM5rjnJwYktTD0hRDeTWk52ODuTdxuB9K2zbDkCp7zS7e+hVbiPJT7jjhlPsapJokwXA1C5VAeATkiolVhUfNezLtF6kV1ZCJ1lLexA9Keu3ZkAYNQXttc2UbPJO00QHII5q7b2jTW0bLkBucd6cnaKbdxOJFAA7fN0q5bxoBhQDg1BNaPCDjk1WDyoDknrmpa51ow5TTuZhDGdoHFczqly0jBu4PFX53Z+CeKzpkV3QZzyelbYeCg7sqEdSANNj7x/CqF2klw7QhtoI+Zq0ZXZbmKBUJkkGceg9anNg68qD711qahqxvQz7dfLTYDwuAKbLnPNaMVi5fkcHnpSXlqBIsY5Zuce1CqRcib6mFPGbg7F/wBX3Pr7VLsAHAGBWm1r5ZwBgdqrSRjf04rVVU9EQ3coTLntx7VWlHye1aTqCD1qlcxkD0FbQlchsz3TrnFUrmPIPAxWiRn73btVedeOTj2rrhKzMJq5z8i7HIPamVZvB8+Rz2qtXendXONqzsfav7a3/JLNK/7DUX/oievjWxj3PuPbpX2V+2r/AMks0r/sNRf+iJ6+P7NdqqDxU1HZGlGPNIlROasxDHWjYABirSQDy93Q1xSkdyjy6DV6jaDj0FTcKAxBxnnimR4A4+92q1DGAVLZb+lYydjeI1JUIOWwPcU9ZY8EFxnsc1LgDIOBn1pUjVRtIB+tZNo0TsOiGW7HIqRHTftLBTTFt0Iwu5eOgPFTL5cUR4AQdvWs5NGtiSQgDC59eKcjR/eLD86hjt1+VZWZweik4A/CpBaQ7yFiUH6Vm+XYrlRJ5gJUkZAParcLADAxnvWW8TxyYgwwPOw8YqZboxyBZY2RvcdamULrQ05LrQ1gcLgkgVLEy44z9cVQjuN67IR5shPHoPqasRWRYYuXeU9hnao/AVzSil8RDgluTFyQ3IPPFT2+Qu1iRxVT7I8EoaNHaE/eQDJX3HtVrdMFH2WEzeu75ePb3qJJW0HyX0QS2mDujwq9Tjv+FWoVRgEJ2n0PFLburj97BN53TBXpWnbLEjpFcIIy3Ch+/wBK56lRpWZXs3sxI7UYHAz7Uy8sd6AYHLCugTT7faD5S/hTZ9LTbmFmQ9euR+VcKxKvuCoo4Xw3b7H1C3f/AFkU54PXBrQvrcJGT+Xua0L/AESZ7wXVmwgv0HzcfLKvvTLMi5lbz/luE48tv4fcV2SrKb9on6irUr+8jm57R0OcZY9TVYRbgcjH4V191bKVOMVgXERWQiuilX5kcrMmaJQrYHQVn3LJDD85wAOprauFPlMPasTUYt81qJF+TJPsTXdRd3qC10MpkNwwbBCDkA96rahBvidSOo4ropYFxkAVmX0QCkZwK7adW7VjGolJWOMYEEg9q9T/AGXP+S7eGf8At6/9JZa8zvkKzb8YV+RXpn7Ln/JdvDP/AG9f+ksteundXPIlHldmff8ARRRTEeAftq/8ks0r/sNRf+iJ6+OLdenWvsj9tP8A5JdpP/Yai/8ARE9fHVuw4AB/Konsa0lqalqo24B5PWr0CbWGMCsqORo25A2jvV6C6MuREjOB/F0FcFSLOtI2Ldckf0q7HEGYEcEDvWXaySmPPlbT/vZq5Z6lEziNztl/uniuCpGWtirXNeJRjDfWp1JPHeqccmec06S+jt498jAD+dcbi29ClG5r28YwBVryF9AwPrWDb6xJIf3NswUfxPxn6Vs6fei5JjlHlyjsf6VzVac46spQaEbS1B822Jik6kDo31FWLeQowWZdjD9fpV5XhiADzJnHQsMmnR+Xu3S4JP8AD1wK5nVbXvGkU+o+GSJwPnTH1qUGBcsHye+OaYi2bTBQsYb0I61dIgjX5QqnHSuWTSfU3jTuYGrqZrOYw8sCDt74FXtNuLe4t18s/MowRjoasKyzSsgQo46Ejg06K1CscIFOc5Uda0lUXLys1dKysRy2plIOBj0qhd2OOQK22RlAw1RSLuUg8n1rOFVozdI5O5t8ZBU4rN+zMrJt7N1rr7m2Hl5PJFYThPNKDr1Br0qNa60CMH0My3WWPWZnK5JRQCemO9aqXXOCgGaVFV2fjocZpTAoPOMmqnNSeqMpXe5PGyOpYgcck+1VreFJA1w3Mkh49l7Co3ikdWRW2qeG+lXHKuBs6KMYqPh2M2rLQz7qMHPGKzJocg1suplUFuBWRfSFJCFPSuii29EZmXL+7chhVa4yy+/pUtzKN/JLMew6mqkqyMCXbaD/AAr/AI16UF1YON9yrK6q2Cdz+i1VnR3HzfKD/CK0Y41AIC4qvcrz04rqjJX0MmjDu4ztPy1nVvXGG4xWJKNsjD0Nd9KV0clVWZ9q/tnLu+GOkD/qNRf+iJ6+Q7cDvX1/+2SM/DTRx/1Gov8A0nnr5GhT0FRWZrh11J0XGPT+VToTgAnKjpRGvy89aXYMgJ979K4m7ne7MeF+XA6VZjBz8wODTYt4UdAKnIfOcKQKwkxpDpIN33elMVJCxyvA71OhcjGzOOnNSIkjEZ2gfnWXNbctaFcRy7twbtj5qkEBkJ3AEKemcfnVkR7GzknHelt+jNjG87qlze6NoyGjzF5IyB0xTpHZVyAxPQcdTVkLheetNcb0YdCO5rLmuzaDXUZBHgEkMXPLGriKrKASvFPt0G3684qby0wPMANYyndg7XFhhVeR3q+EBCqihm/zyaqhI1X90MLjqa0NPgQOq7QcnHTOa5aktLiaW5PBaFRuwMEdc1tWGl+ZCZicMMkBu/vV6KC28mKFVVZgfmcjAB9K0NMVZ45JHJaRTgZ6H1rzKtdtEmfbafHMUO3J9at3mi280LpcJ5kR6juPp71oQxbNqoQB14rVsrLz2Bck7MEA1xVK8ou6ZtSte5ydvbXFi6LcN5tu2AsjDlT2Brdj0sud7qQB27V0j6fE0LJJGrqw5BrIudMa2iL2d3dKqcBC24D2+lcssR7R72Z2RcZ+Rk3WnM6O0Yw6AleP0/GsXUtEtr+NZtpjlA+8pwR7V0Vrqu+R7aWMrOoyPRh6is6aby7gx4wGbPNdNGdSD7MJ0HY4fUNMk08NNFcynbztc5B9qbNb71Vto+cZI9K3fF6k2gI4XeM/Sqow0akAHivYjUk4qT3OCrG8bs5i7g4IxWBqGwyQRZG/qBXaXsakgHvXJXMWLye5ZNxACIAa9HDTvucsVYgkXA4rC1R8KVHVjtrdmSfGHwhPQDmqM1miZZ+W9TXfRkou7M7JO7OS1dAIl4+Yfyrvv2XP+S7eGf8At6/9JZa5e9s1KPxksDzXU/sujHx38Mg9vtX/AKSy17OHmpRsebilad+59/UUUV0HMeB/toDPww0kf9RqL/0RPXx9BlQPWvsL9s7/AJJjpH/Yai/9ET18eo2QAvJrGqdNAnYhgqnqa1LcBVwOlZltEXdvmAPTpV8WsirkSmuOpba51pGlHIsagk0sFul4+6ZAYx90f1rPaF1iy0hIJ9K07SCR4xiZgv0xXLNKKumVaxa/s6LH7p5I/ZXOKsWulQiQSy7pZB0LnOKrhZoOfOzn1FW2eeOAPM+B6KOTXJKU9lIpXfU03EEEQZzjPAA55pLXTZLl/NmLLk/IAcbRVK2hkZhNI5JHQY+7XR21uJIRumZj125riqy9mtGVtsTWGhW9xKxmQTAfeduefStyDw9bpu8mMLkdiaTTJkWFEQAKvUdMVuJcDbgMAPWvGxGIq3smawXc5K90i5thttyHGc7WGSPoasW0cwhH2qMEj9K62CSFsseT6nvWZqCJI+F4AqFipT92S+Z6NOzMgS/PtwceuK0rRRNHjGO1RJabnDAZ9R61u6PaopIccZqK9WMY3Rs4Ix3t2iYhs4Peq08fygj8a7K9s4Ui45Fc5e2/zYQ4HtWVGupmThcwbgHnHIrFe2BuSx4+XpXQT5ViD1rK27mcscnOBXq0ZNIjksU443yqqvyk8mrf2UNICOw5qzAqrheN1TNhFyBk1Uqrvoc9SJmXUPloQtVolCD5jxjtWn5Uk2cjC56moJ7UlSBxVxmtmzllGxj3V2kasM7R2rBuXeVjsGAf4u9bV7ahW5GT6ntWZcxMvrXo0OVbEWSKIgVckDnrUE+3HtU77xnIx+NRPDkZY5rti+rZDKwKg8Gqt0eDgfjU+wKxOailIIxXRHcykjIm4JzWTc/60+9bd0vtWNdjElehRZy1j7W/bFXd8N9HHTOtR/8ApPcV8nRKAOetfWf7YWf+FdaLjr/bUf8A6T3FfKEUTEjeeKyxL1NsMrxJkGQAvI9amgjAb696eifLwQMCpYgMZ/WuCUjsYoXPAqaOPAyScUqYCkfyqeNMqDWEpFJDFAQHGKeAckgc9SKciZBOO9OY9lPzHr7Vm2NEe1pCyoQqnjdU6JtTbgACnIu0KE7CnOd2Fx759KhyvoaJ30EYYAwepp5h/d7VA/OlQYI9asIpIwKzcrGqkJAcggDGOoParUUXmEHaScU21hJZieOeK07ZzEcp97pXPUnbYpsg8navOKsWM32eWN1bc0bBsY9KX7OZJMHkYz9auR2JCj5Du659a5pVFbUVyaK8M90zSEAuSzD+tbMWoKFWLcAq4wy9x6msyOwb7PJnsRk+uaWCzwfn5APYdK5J8ki1Y6Gyuw1wu2QFh05rpLC+LTYOAx9PSuJhhCzIDyM5wPX1rfsrZ2ZfLcqT0Irz68Y2OmnGLOnbUY9wTdn14qefZJGCCB3B9KxYrMsN7HzDjBJPNT2uwTbJVJUYHJzXnumm7o6PZxSvFmPq0McOo2l0gGI2Mb7ewPemXlmHw/BHYj0rqboQm3cMq7SMYI7VxepGaxfEBaS2YcDOSp/wrvo3nbyH7XnVjL1aE3Fs8T8kdOKw7TcISGOMcVtveB2IcFcdTWLfxupD27BQSNwPcV61JPl5Wck430M++bLADPXms2GKOQFm5Cnj61au5OJOcs3QegotBGYQIuQB1x1967otxjoc1SnpoULmIZyRzWFqK4fGSfYck1qazeCIGKHc0p7Lzj61zzC5YkTOFT0HU/U16FCDtzM540nuyvcgjORk+gro/wBmhSn7QHh0EY+a6/8ASWauZnlZ8x2i7yOrn7orqv2cFkX9oPw6Jsbz9pPH/XrLXsYPRtM8/Gwskz70ooorvOA8E/bOGfhjpIP/AEGov/RE9fIEeAvTtX19+2ccfDHST/1Gov8A0RPXx/Aplxn7voKxqnVh9jQsEygOeTya01HykD0rOgj8sjk7PT0rRiGRtU9cZrzqru7nWkSLAXgLP+Aq/p2TCpPWiGMfd7UWiMl0yJ80fXHpXHOXMmh3uizHFvuA0nAHTNWb4IYNmce9QXN2iDyhyc8+1UbiVpFVQTgnH0rFQlJpsqKbZbs7tgCrHIBwT61uW1yXC+SdpHFczEhXGARjjFaNv5iH5RzU1qcWa2R0UV7InYE9/WrqasVjADZ9qwId7ffHH1q/HDuKFQMk5xjrXn1KUOpcUjWt9UZ2+XeB6Yq3BdSTNn+H3qjFbEtnnIq7bwn5s557VxTUOh10pmxZtypboa2oCMBl4PQVytsjxvkMf8K2obhmCbh35Arz69O70O3ms9zUnkljYbyDGB8w9RVK8iCDcBgHnimzPvT5n2juCear3V1ui4JwOKxhBpqwTkmjLv41bLBs+1YcmFZjjr6VoXVwWY7SMD9aovLEQcgjPpXrUYtLUytqSafAG+aQ7t3p1rTezPljcxA9qq2G9Y1KYIHc1PeTTBcl8jsAKmbk5WRnU1ILpliRmJ2qKxrvUwhCohkkbhYk5dvr6Co74T3DE72wP4axltrpGYQAqzHJc9a7qFCNryZzOEerJ7611Zm8+aWKBRyLdRnj3PrVC6mLD5sDHqK3VlY2gWaTfIo59qoSxpJnPIPtXVTqdJLbscUnqc1PeRliscc0zjjEaf1qtLNetwtosa/7bc10JHlwnsOwrMnbeTwOPWvQp1E9kTcyJWuiM7Yv1qnKLrOB5Vatw2TtGM1TfHJP0rrhLyIkZk4udvzGPnjpWRcBt/zHJrauZO2ax7tsvXfRZyVlofbP7X3/ACT3Rf8AsNR/+k9xXytH0AOc19U/te/8k90X/sNR/wDpPcV8uQrnGea58Y7SRvg1eLsPUAHB61PGqqcAgA8800R5Oe1SAKo5wea86TudSi76kyAFhhuB6etWVAIHbNVbf5Syrt2g8HNWolO7jOPesJlWJdh7D8RTtiqOmBUiDccCp0iG7BbJ71g5WGVApDc9DSnk8YzVmSPAyOe1RYO/I6dOlClcBseCeemKtRLgjBpqJ9KtxRZAPes5yNIvuTRJ8v071dtoTIB78VDChVe5rX02IHAbrXDVnZXKvcv2FjCIyWyc8euD/hWkIkdY40TkEMSBzV+10oNAGBGT15q9Z6Z94Z4XvnGa8Srildu4XMV7ZGJMSt5fZQepqJ7SWKJ3MShB/daulS0UEIgXjuTWlFpYltVaRQVc42g8nFYPGcpSmkcPYRvK7ybPlUY57Vv2OSmADz3FbsWkwneAgSPrtp/2SFIwuwbRWVTGRm9DZVYkduESNQcBhTZreNmLg7XY5JB4NV7mNwP3bN6DPOKi2MF+eRyR6mrppPW5op21TJbtXeMpnjsQaw7+EBiCNnHX1Fakl15eN20IBwSeao30q3EWUI+vWu+lCw1NnN3CKI2G0jvz3rA1JZUXESkkjgZ6V0N2WU/KuQKx/NjlmcyMCo6Y/lXo020rlp6mFHp+5Wa6k+Zjlh2xUlxbNKAsZZY8YxHx+vatJ4U3ZBGCasCMFMYG2ulVXcxrTscZdRQ2odcKgPX5slq5zVCHiJX92D19cV32pW0BJJjXPriudvbaMknYPxFejQqpas4/aK+py6YEOIgNorrP2ds/8NCeG8+lz/6Sy1i3NuqLwK2/2eT/AMZD+Hcdhcj/AMlZa9nBS5pto8/GyTXzPu+iiivSPOPAv20Bn4YaSP8AqNRf+iJ6+QbUhQB2r6//AG0P+SYaTj/oNRf+iJ6+PIucelY1TpobGmjs5ULwCa1bfG5MHvWGoYbWweDWlbzDjOc1wVY6aHWb8ZGM06wnXfM2OAapQu8keF6GporeSPmP7p9a8+UVZplRQ2Vd8jOOpqS1tWd1foO1SRIyvyOa0re0nlKGNTtHJxUTqcqNkRx2o6FjntWhBaYwATT4bSQy428g10umWAIAZRn3rzq+I5Fe40jLtbNsDgD8K0LexG/cRg+orpLXTFkbDbVGO1TzaQ0ZwDkdR715U8am7XNUrGNHZ5UGNSD/AHs0SIU+UEqfUiukgsWdRxjFVNQtAoOTjHeuaOIUpWNYvUxdxUg4Jq6kvygg8jqKgeLI2jkeoo2tnAH41rK0jZyuSzz/AC5PPPBphc+W2SCW60FVEeGzVOcY4TP40RinoUp6FadsyEqoOOCapGFTJkn8M8VaVjkgdaTaBJnPSuyL5Q5ixbZVOv5024l4IbknvUUrOoJUjHpVKSXknOKUYczuc85BcThVLYJrMjuXeRiCCPTGDViW5HOCKq+aM5OMe1dlOFlsczY1InMhZuFqOY/JhQM9yake4XdxjA9TWZfz7jgN9a6IRcmY2bIbt8FsHg1izzEEgYxV2WUHj061m3JAbgcZr0qMLaMdiGRvUkVUlbrg1O54qnIMnOcCu2CIZUmOc1l3B/eVp3GMVlSnMjfWu6kcVdn2/wDtef8AJPtE/wCw1H/6T3FfLkWVIOa+ov2vf+Se6J/2Go//AEnuK+W0HCnvXLjPiR0YN2j8y4pHQVLGgwTwT9KiReMjBHtUsZI7mvNkdg634lkTAGfmzVwgHABqoMfaYy33TxV44x8vBNYz3G11JLcszbEBaT17D3rstM0yH7ErNIAzA5zXGaXIPMdmPyk4B+ldDDdIEADE+lcOKi3ojNt3sQahaeU7Yxt7Gs9l5HoKu3dx5hxnODVMAlicc0U7qOpQ6E9hxV2DoOlU4ulW4iRjPWpmUjQh5HWtK0OzHb1NZcB7dquiTy0yTwa4qivoWjrdNvSUC7yR2Ga1GupTHhB365rjLS6UBeduOeveti2vgEA37m6V5NbD63SHZm9HKx2HkANzjvXRaXd+SGIjVkZQrKehPrXKwXKM8a8MCASfT2rodOJb5FVtrDK+vXpXm4iNlqivZ3RbSfClSDuboR1FRxW87JIPODqg5c+voPWlmtjLOY4TtYcSv/cHoPf+VaFrHDFEVfcAq/IByAfeueNltuzRvkj5nPTWkh5cc9juOar+RMFw75Pqtb0qBlOSojycgHJrPkZV4WvSpSkg52zEl09WbfIpZv8AaOTUU8O1c8hRxgVtXADDIxmsm9lwm05JPpXoUm5MpVG9DAv03K6puJxjisGGBY/lkwGXjpzXSzOUV8qMkce1c3qKFZUuFJLE4YH0rvpq6saKVtCOWXymHHy5wc9qfuJX7zEexxTJ0WRDnJBGPes+G4eGIQTsBKo4+lbxjdaHPUndDb9lIOCT7VjTOuDVu4myTWXc/Pndz7967KcbbnLfuZepvhSBWp+zg279oXw+fe6/9JZawdTLIDsbP+9Wv+zExf49+HGPUm6P/ktNXv5fGybODF9EffdFFFekcR4F+2kcfC/ST/1Gov8A0RPXx9ExXqBX1/8Atq/8ks0r/sNRf+iJ6+PkdJI1ZeDjn61lUR0Yd7osrIe/5VatpCWHOKpxleM1KuQw8vr6VzSSZ2o6bSpR5oRmxn1rp4hGF56VwNtcNvQfdIPWuus5t0UZJzgjNePi6TTuDRtR2HmANgCtbT4vJXYF696pwTbo8Ka0bR1ICk14taUmrMqLLlnZhpQzcCtiKMROQo4x1qjb4GAelakJGAR6V5laTe50QZesnEYBxzWi7eeExnI9Ky4Y8puB59KtRv5Sg7sCvPqRu7o6IxLsbeV/FnPao308zylpBwelR2m6aYSkEAfd/wAa2knAUJt59a55ydN+7uU1ynPXOnrG52rk1QaJF4PJrp9RTgPkVzt2yhiEAArooVHNahcy70bQcVjs5ZyGyOfzrZlIGST1rJnUBiy9a9Sj2EpEFxIIyGHTv7VEJFdNwpl+48sqcjPpVKBmAxzmuyMLxuKU9CxJceW5ViSp+6ao3cmAOaluoyyFm4PpWVPC+0jeSvbJ6V00oRepg5XGTSHdhTzULkhSWPPtxS24JLK4+YchvWmTZxyM12JWdiXoV5JnyQG59xVdwTk7+cdhUr8njqKqu3cH2roihXK8gYA/OaozBic7z+VXZDkHP51UkPHPSuqArlSRXzwwP1FVpWbHIGcdqtSnFUpTwc11w1MpMpXLHnpWdVy8bjHrVKu6C0POrO8j7g/a/wD+SeaL/wBhqP8A9J7ivly2y2K+nP2zJPK+Gejyf3dbhP8A5Anr5etJQygoflI4OO1cuLi9GdGEejiaEeV4J+T19KnTBGQc0kGCMk8+hpWXyzvXAI7eteVJ3dj0lG46RS0YIHKncPepYZdyEqSc/oaTdnBB7ZzUdsx3Ocj7xFZtXQmy1athAP7owc1chlYjpiqAXbKhI4OcmrceQpasZpCtfUn3ktjk00EbihzuY569qRXCvlmxT0dPtOSwxt6/jWVrFRiywowQcY+lTRtkjPQc59armRcYDAluMZqUEAABhx2rJoagW1fYwHT+lWEkO7OcgfnWeJFySpGfWpIGZ3DAHI/i6CsXA1UDTSdTgcqOnTFXYpNvIcDjisgjcQ+4A+gHAq3bKrPwoY+p5zXPOmi0kdLpV0w4Z1ZM+vNd5ozy3CrtzEn3fMP3iPb0+ted6ReDHC+Vg8gDFdlpWrqMRqDjGd3/ANavHxeHlL4Uat2WiOqWdLZvKKoUQZATgis691C4lJiso1Zu7scBRTYbyGU7hy3vTIhHK7tubcTwQehrlpYdQd2tTP3Vq0MtLKZZfMlm3HqyD7ufWpr7ykUDG6TGQq9aJvtEabUaNh1y3FVlmit1Z5zulY5Zj3PtXZGm5O+5DfM7mfcSSlvlhkQerDFZeoKVK7zt+veunaSGSES54PQkVy+vXCWtvNO64VRnFdlGLbtYSlrsUppF2kuQ3riuc1SQSSCONuAcmkF1c3qCRMJG/QDrToLLblmySfWu5KNP1CT5XqQYJ5zjHas3UIllUlx846HvW1PGIk54J6VjXXO7afwrale9zlczCY7J9jnOeRROikEZP4VDfxyQ3Iuo8uoGHQdQPUVA2oRPny3BPp3rvUG7OIT1V0YXiEmK1mc9NuBW5+y5/wAl28M/9vX/AKSy1yni+8DQxwqeWO4/QV1X7Ln/ACXbwz/29f8ApLLX0GCi1Tu+p5WIlefoff8ARRRXWYHgH7a3/JLNK/7DUX/oievjCGQqdvY19n/trf8AJLNK/wCw1F/6Inr4rBwc0mrji7O5qRHjmrkJywzWZA2QKu256k1zTiejTldGojBuAvPc1p2Tyxr8rfgayYJvkwByauR3BU4PFcFSLehstTo7HUmjYJJyfWt60vA33zg9q4kTI2CWGcflUsN9IrAId5HYdq8+rhVPVFKF9j0m21FfLwx5FbFleqY8luMV5dBfTSFckJXQ6dKHTDOxx6mvKxGBUUdEI23O4XUVUEIwyew61fsJfOYedjaOgzXH20oDDGAO1XRelOFPFebUw3SJ1xaWx2yX8SuVVgMfrU63ig5U5rgzftuGOferdtdydd+M9q5ZYG2oOKOvuLlpFLbhiuevZWDHC5zTkuS0YXd+NQzzqwwDzSpUuRmUrIoyyMVy3BqlKxHNW5mDZArI1mfybUsOO1ejSjzNJGbZDNchiQoz2pUJIHrVW2QeQp7kZq3HgLz1rrklHRGMmQXcmFOe1Z8rgkEVZvcLnmshpwDjtXRRhdaEbkDytYzsZQz2rHhx1j+vtSyzxSoBC4YD0NOd9wODWbdQKULW+I5hyCP5Gu2EVLfcq99ySU44B4qrK45PfpVf7ahhDMwDH7y9warS38XZxXXClLsOw6aQknbVNpCeO9PaQMODx61UYkMecV1QiSOkYmqk74BBqd3GMVQu5Nqk/wCc10U43MKjSVylcPukPoKhpTSV2JWPLbu7n2r+2r/ySzSv+w1F/wCiJ6+UtAug9sqsctHxj27V9W/tq/8AJLNK/wCw1F/6Inr420y4+z3Kk/dbg1FWHPFoulPkmmd5FLvXHf1qTzCF29ves20k3Y9quBhxxXjzp2Z6yk7Eqh0Pycp6d/wpqyos2Q2FIyc9sVHJNg7I/v8A6Ae9RquLmJmOTnBNTy9y0u5oiRplIUYU/wAR/pVmHc5w7tnuBxVYMOxzT0fE4ySAV/OueSvsaRfY0ogoPAA/CpsfMjdskVXhJxxjNWkdcEEdRzmuSW5pFDio/uAn0xSRhMcKvB6EU2JwUK5OAcZzUmQAT271G2hSTvYfEQpJX5SOeBVgMXCkHPrVTcQvFTRPtY8Y4qGhl1G+QDjrU65DAqxFUg2WBGOvSrCSqe5BHY1jKPYDWjcrKwGME1o2kypiQMA2MZFYDyEngjOBz2qe1k8rBJJJ5Pp+FYumaReh0+nXEryAOdqjkZOa6e2uPlBLV58bwqqhQRnv6Vr6dfOsI8x8nsfWsalHm1FUV1c7BrkDBJOP7ves+8McswaUbpP4QaybnVQq4jbc59Kri/WPcWbJbqx7040WjFJrU17u9WzjLFs47n+QFcZ4j1Sa70W48wAB3CgdOKt6leLcDAkUfTk1zuvyyHT/AJQFjVgSG+8a7KFNRa7lRtu9zYtQEtoguOEA5+lNmufLB4/+tVGK7V4F2nkKOM1DLPkEH6U407bnLUk23cfPNvByetY93KUYt/AeKmll2rjOR2qlPKNuAa6YQMtircTYxjnPcdq5/WFV0ZgAJF5DDg1pXUpiB2/d7gdq5nX73yrUlD8z/KtejhqbclYU5ezjzHL39y11cGRvoB7V6Z+y5/yXbwz/ANvX/pLLXlZr1T9lz/ku3hn/ALev/SWWvoEklZHkt3d2ff8ARRRTEeAftrf8ks0r/sNRf+iJ6+Kq+1f21v8Aklmlf9hqL/0RPXxVQBPbthtv5Vfh3ZIyKygcGtC1l3KD3HUVlUXU6sPPXlNBSyjtUqByMlqiVgVB61JG3GD0PSuRnfAsxKrsNxJPua0bYhDgdPSsguYznNW7W5DkY61hUg2jS5sW5BY/WtOxnKMcmsmKQKQVHB6ircMoJ4zn0rgqRuWpHT2k5YEk/QVegckHJ5rnLeUqM5xVsXbKBivNqUbvQ2UzbMyoCCalhuAwGDXPC4d25FTx3GOhrKVDQHM6P7RgHDc1F9pLHg5965ufUQJAm4Ak8+tSLfkD5QSBU/VWlczcjoGnwOtY2uuZ7NlXqCDVSW/lOfugVn3t6DEys5LEdq2o4dxkmRzG3AwNtFnnCjmozMEztYgis3T7pltQrHkU2efKkg1r7F8zRLdyS8vN4fPBA5rPDgp1zVW9mbjac56j2qLzx0B4rshRstAsTSSNGcqfl9KryXAIDAjFRSzYOKpySAEsT8p610wp3AkuFikYvsBbuaqTop/hX8qe8oxgGq7OSetdMItCv0K/lAZ2MV/Go2j6ks2asHpx/wDqqCUjHtXQmyWVZWYH72RVOckjk5xU95LtIA61TZy3WumC6nBXqLWIyiiitTkPtX9tb/klmlf9hqL/ANET18VjrX2p+2t/ySzSv+w1F/6Inr4qoA6TRbrzIdjH50/UVq+cSdiEA9z6f/XrjLad4JQ6HBrp7CVHiVkPBrkr0knzI78NVuuV7mrEoA+Tp6k8mnyKsg29x0NQpJsIxyKl3bufyrz5Rd7nch1vMclZeHHQHjNW1+cDnGOQfSqu1JF2uuaRZWg65aMdG7ispRvsWvI1bWdkcxy8PjOR0Iq9vBIwcisO3mEshfOVAwCKux3AGBnmuapT1NU7FyJgI8+rGnmTcQq/X8KznfaS4Py5yy/1qTzQjAg5DcZqHT6lc3Y1VbI6jJoBH5VUEmFwDyamRuBzzWLjYLk6Pxgnk9KkV2AwvLe/eoDJjGRSJIQOf0pcoJl5LvA2sdn1q1HdIOCx3Y7jFZi5IGBz2qXcoX5+c+tQ4Jj5kjUS5UnJcdMVKmoIFwuS3oOaxlmjBJKrjtxTTc9uFX0Hf60vZC50zb81pmDuxwP4QeP/AK9S+cpAyBisD7ds4B4FRSakFJwwx71SpSZMpt7G9LfKoPQVg318b3MMQJXPzN2rNmvHu32RnEf8TVahZYkAGBit1T9mvMzfu6vc0ItsMeB1PWo3n681UefPtVeSUgE5pKHcxerJrm4JyR261SkmyTzSyONhHbHWsx5gFxnFdEIXQWGX023PPX9K4/XWDspBOFP86va3qvly+XFhn/iz0Fc/PcPMcvj8K9jC0JRtJnFXrRacCGvVf2XP+S7eGf8At6/9JZa8qr1X9lz/AJLt4Z/7ev8A0llrvOE+/wCiiigDwD9tb/klmlf9hqL/ANET18VV9q/trf8AJLNK/wCw1F/6Inr4qoAKfG5RgwplFAJ21NW2myuQatxv8pHasOKUxtkcjuKvpOhAO8D6muedM9CjXTWu5olTJgAHA7Yq1Zps+bpmqltewoDukT8xTxeQ4J82P/voVzSjJ6WOlTT6mn5uGGOakW5ZWz3rKF5ARzNH/wB9ClW6tyDmeP8A77FYul3RfPHudDFqChfmbGelWob9SOcgDviuYivLYD/XxZ9dwqZNRgX/AJeIv++xWMsNfZDUo9zqRqEY/iGMVDLfOUO3Cg9+9YA1W3I5mh9vmFINQgJ3Ncw5HQbxxWawtug1KPc3IHCZY/ePc1KbgAZzWHHqVtt5uYc/74qC51WAZCTRMf8AfFH1eUnsJzi+prXd8djBTlqqW8jEl5CSfSs2K7gBLyXMJPp5gp5v7fOVni/76FbKjyqyRPNHubguyDhcY96Y90cHpjpWML633DNxFj/fFK99b7eLiLP++Kn2HkHNHuXI5QxLE8mqzybXI7dRVMXsO3/XR/8AfQqN7qE8+dHn/eFbxpO+wOce5ceYE9T7VA8vJ9KrNcxEZEsf/fQpn2iL/nqn/fQrWNMTlHuSsxHAxjtTWkxmo2mix/rEz/vCmNNHjiRPzFaKInJdyVpRt61UuJ9i9eewoknjVCdwb2BrPdi7EnrWtOn3OavW5VaO4jEsSTyTTaKK6DzwooooA+1f21v+SWaV/wBhqL/0RPXxVX2r+2t/ySzSv+w1F/6Inr4qoAKvabdm2l+blD19veqNFDSasxxk4u6OximDDIIKkZB61Zimzn0FcpYXzQfI/MZ/StpLuLvcwgf7wrhq0eU9nD1Y1VduzNdH2nOOtDSEkis5b6FT89xCw9Q4qZL21Iz9ph693FcsqbXQ6Pd2uWbJygKEcqc1dikO7tzWSby2E4YXMGCMf6wVPHf2ve6tx/20FZzg3rY0fL3RpmQFvakMhRNpBIH3SBmqSahZjrd2+R/00H+NSLqVnnm7t8/9dF/xrLkkugJxXU1Ipw7ZBBGKtLJnp/OsFr6yzuW8tlYekq/41Zj1ayKAm8th7eav+NZSpPdIfudzZEnI3YJ96erjPOKxTqtkT/x+2oH/AF1X/GlGrWXH+nWv/f5f8az9jLsJ8vc2jLjjpTZJyO/J7ViNq1kD8t5bfUyr/jUb6vZj/l7gYn/poP8AGqVCT6CXL3NkzHrxk+lRSTMOp/KsRtVgIOLq2/GVf8aibVbc/wDLzD/38X/GtVh5dh2XdGw0+Bgtiq4bz3bLEIOgrKe/hcEm6txx08wZP61JDqFqFA+1QD/toP8AGtPZOK0Qm4rW6NZJQmAvAHapRNnr2rEbULXPF1Bj/roP8aT+0rbH/H1B/wB/B/jU+xb6GTcX1Nwz+9RySfL1rIGpWoOftUH/AH8H+NRz6pbYAFxEeezimqEr7EvlXU0p7kKvJrndY1HyMiMgyOOB6e9RahqqBT5bK7npg5ArnpHaRy7klj1NehhsNb3pHFiK6j7sdxGJZiSSSetNoor0Dzgr1X9lz/ku3hn/ALev/SWWvKq9V/Zc/wCS7eGf+3r/ANJZaAPv+iiigDj/AIofEDSvhxoFvq+uW99PbTXS2irZojOHKOwJDMoxhD39K8w/4ar8D/8AQK8Sf+A8H/x6j9tb/klmlf8AYai/9ET1438Ivhj4O8Q/CrXPGPjLUdYtItMu5IXFjJGAUWOJhgMjEsWkI6gdPrQB7J/w1X4H/wCgV4k/8B4P/j1H/DVfgf8A6BXiT/wHg/8Aj1c74a/Z78Fa5MivbePtNilgFzBPeSWflzIcdGjV9rcg7X2tg9ODj5MoA+1f+Gq/A/8A0CvEn/gPB/8AHqP+Gq/A/wD0CvEn/gPB/wDHq+KqUDNAH2p/w1V4I/6BXiT/AMB4P/j1H/DVPgj/AKBXiT/wHg/+PV8WgY+tLSKSPtL/AIap8Ef9ArxJ/wCA8H/x6j/hqnwT/wBArxJ/4Dwf/Hq+LhTgP/r0XKULn2eP2qPBP/QK8Sf+A8H/AMeo/wCGqPBP/QK8Sf8AgPB/8er4x2/lQOD7Urj9mfZ//DU/gn/oE+JP/AeD/wCPUo/al8FkZGk+JMf9e8H/AMer4xAHpUsXHB6UnI0jRTep9k/8NS+Cv+gT4k/8B4P/AI9Sf8NTeCs4/snxJn/r3g/+PV8eFVXk8io5QCemCOlJTLlhkj7I/wCGpvBef+QT4l/8B4P/AI9R/wANS+Cv+gT4k/8AAeD/AOPV8ZBs4z1p+OOafMyFRiz7K/4al8F/9AjxJ/4Dwf8Ax6j/AIal8F/9AnxJ/wCA8H/x6vjYZHNLjOfalzspUIs+yP8AhqbwV/0CfEn/AIDwf/HqQ/tTeCh/zCfEv/gPB/8AHq+NyDjimsrcdhT5iXQSPsr/AIan8Ff9AnxJ/wCA8H/x6j/hqjwT/wBAnxJ/4Dwf/Hq+Ngn4mmsvynNHMJ0LH2V/w1T4J/6BXiT/AMB4P/j1If2qvBH/AECvEn/gPB/8er4yK9xUbCquZOFj7R/4ar8D/wDQK8Sf+A8H/wAeo/4ar8D/APQK8Sf+A8H/AMer4sxTaZB9q/8ADVfgf/oFeJP/AAHg/wDj1H/DVfgf/oFeJP8AwHg/+PV8VUUAfav/AA1X4H/6BXiT/wAB4P8A49R/w1X4H/6BXiT/AMB4P/j1fFVFAH6qUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHgH7a3/JLNK/7DUX/oieuZ/Z08Kp42/Zy8V+HpJzb/AG3VZFSXGdjrFbupI7jcoyPSum/bW/5JZpX/AGGov/RE9fFVAH6XeEk8VRJBb+I4dFjgt7cR+ZYzyyvPIMDfhkQRrgH5fn5PUY5/NGiigBcU4CheKeRzxSbLiuo0UuKAOaXHakUkAGeKcBjmgY609emDSZpFBgMKVQMe9Jg8+lPAyMg4NSaJXEHSpBjgdqRSBwetPQDOcZqWzSKHMpK9uuRURU4FWeCoGM1EQFbjp71KZrOKvcrsOSR1pUYkVKw3fSosYPBwatO5i4tPQfyF96QYHQ96FPY9afs5ORzSBJvYavvSt0HPNG3DdeKWThjgUF9BoPTPalbkZP4UxzmlxnHXFMm/QYUyKjZMDnirAAxx61HIvFNMicNLkGPSmsO/epWFMINWmc0o9CKinMOabVGQUUUUAfqpRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeAftrf8ks0r/sNRf8AoieviqvtX9tb/klmlf8AYai/9ET18VUAFOApBTwKBpAOKcKSgVJoh1OwT1GaROeDTuRSNEgReoPApwBHFOQ54NOC56VLZtGF9hoOBzTh1P8ASl259KUqRxjipuaWY1cBjzT9uScU0KR6U9eBmkxx7MQEjPSnY3Ln9KUgY44NMIIHH50ittBepxjimtHkg5qVVLdulWLe2eY7RgDuW7UnJRDluiptU/LzmmjIfBJx611mmeH4pRmZ9zEEqoYAk1r/APCMs6bTZooMfzf45rnli4RdjNzSdjz1kIUH3olwXyOO1ddpWj28hltbsGK+hPf+JezYPUVm+INFmsLsnZmB/mRh0b6Vca8ZS5RNrYwR1OBxTieaVs78Ae1J069K3KTFDc9KikO5uO1SbcD3NMVSVyTTVgld6Ee3tSEAVIRgcHJqMjNUmZNWIXHtUZFTsOKiIrRM5Zx1GUUUUzM/VSiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8A/bW/5JZpX/AGGov/RE9fFVfav7a3/JLNK/7DUX/oieviugBQKUUCnYzSKSAdaX60lOTk0jRdhVHFPXrg0BQDinBeR6VLZsogoqZRgDFMAINPBIPOahm8VYfk9aaDuHWlDDGeaMcEVJpe4FD2NKAMcnpSxglsVOYSFyBScrDUexX2k09V5welOCEYzwPepQhcD+QpORUY3CKIkk9MdOK6rw5bpFBE8jK5lY5QHkccGsbSLWS5uEhG4KxAzXqXh/w6txdkFQV2jYAOgHA/GvNxldR9zuXKKULnQ+EtGtL1VxbIIgqlSy889R9a6i88KJLL9o0eOOFBhXikbCSHrt56HHcetXfCvh9rVtsE7wGU74UHzKeOSVNdiLSSCIPd2bsI2BzE25QMdcdR/WvHqV2na9zl5UndHjPibwlZ61aLdWkbW88RO2QfK0LDqpHf6d64mbdbN/ZniGHYkx2xXS8xlux9j7V7n4nEUDHUrIbo5f3VwMDEy4+WUD1Xofb6V5/wCKbKO/0W8hVFJkhbAPPzAZBBrrw1VzspfeRUSirfZf4Hhmv6XLpmpSJIo2bsqw6MPashly3tXq1xp8GqaFYPeDJaIES55B71zV14YtgH+y38chXqpODXq08TG3vBGpb3ZdDjGBwxNNwfLA5ArZ1DSZ7WBi68ZAwPfpWVIrBivQjg+1dUJqSujTR7Fd1IPGc0hXirBXApjKf8a0UhOFiB+KhI5q0y5WoSvNWmY1IMruMGm1NKBioatHJJWZ+qlFFFMkKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPAP21v+SWaV/wBhqL/0RPXxWK+1P21v+SWaV/2Gov8A0RPXxYKAHDilHFIKUVJohR1pT6igfrTsY7UjRIepz2qRRkdaYg5IqRQB05qGdMBcGlA96VevHFSYHfmpbNoxGkDHANJ9akKgD2pD61Ny7DosZBFaKfPGCXwF6YFZ8YOcirUQJOBnkVlNXLixGAJPr70scLZLA4qVYsMM9BzWnZWYnkQHucAHisp1FFBKXKrmp4XtS+pWsaZJUGU+3GK9S8GXn2Ex/bDJ5aZVnXnYCcD6VyugaNLayMYFBnKYyTirkCPp+rCTezKx8tl6j6fWvNqrn1OSVbnlY9/0q/jubeG2gcNg7s/xZAHOfXBrZOoW6y+VcTHhQzE9A3TH9a848JRtDYZyFKk7g55HGBitiWXz9zTSv5YUs5U4+vNebOhdkKfcoa/KpuJvKj8uyI3MAMjd6gehHJ964HWFEbZtZc2ZIZWHzbD6e4rtdUSZrSHGXaRi5DLkLHnt74rlfE2ksEPljymxlSThmz0DAcV00WlozRxurnnF0TaT3FgrlrSYmaDPcH7y/geayntzkbwdqdCSOa7O68OSXtpuZvLEZykpHzIR3x3X1qnZ+HheWBlS4RJQSkkbIcKwODg+ncV1e1jvcbpTtzHG6jPNAkJUByJFKqeQxrOu4VdGLR4fJ3N3Jre1TTp7TUhFw/2U7pGX5lXI4H1rOkureVZIlR/NBxz93PpXTCVrWFyvRWOeaMop3jv1qNl64HHrWvJBgM7lfl67jxVZ0EzqkA3kjk4wBXXGpc3V5aGW8ZFRFAK3JNOYsMtuOOQBjFULm18s7SOa0hVTKlST2M1kB5HNVGGCRV6SMqT2NVZlKsM11QZ5leFtbH6n0UUVZzBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB4B+2t/ySzSv+w1F/6Inr4tFfaX7av/JLNK/7DUX/AKInr4tFA0OHSnDrTaeo9TUs1ihVGT3p4UZNNBHQCnpgY9alm0Uuo9c+gNOxlqF+9wOPanr83bNZtm6Q5BwcVIFGMU0DuOlSYHI7VDZsl3I+AMHmjacinhRn61OsJMe4D8aTkkWlcLZcsFOea1bSy82ZUUn5hwByaqxIAAVX6k16B4O8MzXdobtPvn5QPQetcOJrqmrkTnyLU4xrCeNhGygc/eNdH4b0ibU76O1typIwWOPugd67LTvBTX7Ax3tuYnbDupyx9h710Ufh99PXbbbVto+XbJG49PTmuCWLU1qzlniL+6jcTwvCy2rJdIssK5whyCMc1V1fw60ggiG0suGAYhRnPXPrW1pGmhiZwC5dFAx3x1A+vetWLTxfack052yKxBkckAgdPx7Vi66T3ONJ73M42r/YEVpWibG3I57dfpTLS5Xy/shcbnYRhlAIUdeSfbNSX0a2ke4ysZE/hJIAX0zXPyS+fcyiKMW8rL8rOcEduM9PrVOzjc1opyep21rp4dTcoPtEQ4CsONw5xn6dulZGqTCS9me+tDbQR4h3hc5Y8kH0x0/Gus8BXMc1g9p86vbHEiOMhie6k9R71V8XSLbo8EyoWk+YYOS/rn2ry4VG52Z3qfK+WxxDaZp8ZaYpI244SBHJDN2CrXF67b32jO0YRbU3D/fxv2r3KjoSK9L0G5tbe4ZolS27GTYD/P8ApXCeO4LuXV4pbl3uba4Jit9g+8+P4R34r0oPdHVRd5pPbzOYka3sytlb28sqt85jB3SzE9Wc/wAOfU1yeoaE8UkiFtu5/MKIv3Se2favQYWFon2SWExSEnbKyjdL7MR1IovWiFzDDLgO0YDAjHFVCrKGxNZ2eh5kukRoHYx5cdC/zZphsPnDltqr/d711fiOzSNs27qecA54Nc5dkwwMoPU8Y5rqjUlLqZQlK10VLycKvyjjucdawZn8xyd2auXshbapG3PU9qypWKsQuD7iu6hCyNGnDYimB5OPxqhcjjPpVxnYdKq3LZQg13Q0Zx4iziz9SaKKK3PNCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDwH9tT/AJJbpX/Yai/9ET18XKM19oftqf8AJLNK/wCw1F/6Inr4yQcUmaQVxVGO1PCnPtSL19qep9jWbZ0xSG7DuwBUiIQTxTk64PerC42scDJHHFS5G0KaepAox+NKpxT3Q54H4U0jaucE59qm9y2rEqNz/KpQAxquCSKkUntgGoaKiyZcLjirtqWn+RV3Ec56YqjCjSy7FGeKls9RS1vVWSKV7YH5kBwxrOcW1puXKooo6GztHKhRGX+YcAZr6G+GmnBdGgF0ix+YCWTGCD2/SvPPhgVuf9Jm063iSRwqIZAJBnndg9RivVbW6uXdInie2VhgK6jIGfUV8tmVWpL3EjgxNRydjZTw7bx3G5GVJG4BGNoH0qaazEdwsU6iUnlTnPy+1JJo0ktqz/aGlyQwyeQe9bHhmALGUljMhQl1LDGz2+lefUvSiupwxk5PcbYaahjVFTyRIc7eh+v6Va1VJomjSCJJEx84kwQfwrUYYhynDt94jt9KI4lRAIxtYjJdjk/UmrhUUrNspRd7HIT6AJz5xSbaW5BTgdzge1Zur6XZpC7alPDGrD5Hbhjxjn1+lekW7tMD5QKxkf61hyx9QP6muF8daMtjDJdWiszsuWJO92Oepz0A9q66dZvR7HXTjyvVnB6Rqup6Vf23kKNirtcykoCueOvPP9a0dc8S32rNCN1vBDIdo8tcKMc4b+IH09axNZE8+nyoieYEK3DFm+YbsAPn/HgVz12y2l15U8b7DLtzKfvN7Yx35q3CLd1uehFJnZ2t/bpLg7VcHPPOfcVj+NtUBu9JvJnYwwSmInGQm8YBNc5fPIWld5SzhunYe+O1ZHiC9vf7EuNwzC4UKzDOTkY/WumnTu1froKnL30ztbm2gmsp2ucLEBwM8luwHv71l6Oktxdg3EbSTlDJEzDIlj6cD1HQ+lMtFuLMwSXKM0QUhVfkBuM8evpVLWdZhufNiiBiVX82AxHHlMepXP6isrNrlKi1K6NTxlp9ulpE0saxErng859xXk1+wSRkVyCGyQDx9a2b7xNMyTWt3taUHKsCSH9xn+VclPceZNIzZy3THNejhaM0veNKMHGWuwl1JvY7sNjp2qhIPRTj1qUnLEkmoJTyMk/hXpwVtDack1exC4IHK1Un+42atyNnNVZx+6Y10QPPxCVnY/Ueiiiug8kKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPAf21P8Akluk/wDYai/9ET18aBTjBr7K/bV/5JZpX/Yai/8ARE9fGYYsOTUyNqTWtyQcYBp3HABqMZPSnDtmoZ0pkqnGauWwy6qBknjms/JH0q/pzruUvuLBhjH1rKa0ubU52N8aFLNCwRj54GVjK9R9awp4DHwc+nPGK7d9XRpFkijAYDncen0rktXuhdXUkn95s5xjJrhw1SpKVpGl3LczgFB78VIh3NxUZBz7Gnr97iu1hHQlRijBkODV1/KuY0eNtlyOHz0NUF6U9OvSspK+pduY7Pw7aWSW5m1S5uNyqSFV8AkdB616/wCAtSTWo5tM3SJPbr5kcpkzuUevoRXgukOC4Qkeoya6K01OfR7d7m0lKTSDy1A7gnnIrycTRc5NN7nPWotqx9T6JdyT+VasHEu3G4L0PfPvXV2Vs8SBS56c46E+teE+APiFrjeJILXVBaLpS2kbM7R/vmfGNoxyW/pXv8Ezz26ypAy7wCokYAj64zXzWJwtWE2nK6OT2HLq0S+SNuW+pNBthPgTA+WDnZ/e+v8AhU8SHALkFvpUh+ldVDBwj77He2iGMMKcYFcP4giury8lJd4QAQFdOoHoe+f8K7iTB4Nc1qU9xLqqxRw7YE+/Kedv9Oa0a9+yIcnHU5zS9Mt7CKWbU7cSWDxEKHiy6nPKrjnB4wPavOPH9vDNcWi2dibcuAGumbzWdcdWHbjqOCK9Qvtc0pZwl1cyPIhLCMP9w+oA6V5h488QW9xJ5cFxi3f5nYLgk9NxH+c1UMNNT52d9Cbm1ZHCyQvFN5qBmDny4lLblJ789azNUlaW/gsYZPOitnE03OPmH3R+FWL66hgEsyuM43IScMo/zzXN2pElr57OxuJcyE9e/wDOvQpRduZnfGmot3Nm88R3M0Txg5LZHTO36H1rl7i5eQt5kjdD8tOe6EcqpsY4OcjjNVrqcSS54BOfriu2nT5egRpxS90qMvmjHO3qDnpUQ4YKfwb1pzNtJBYD0qOJgch+hrsS0LSSaQqrsJJOSaglBc5AH0qSZHQZHIHbvUcTgHJ61a7ina/I9CHYobBzVS74U4AAzWiwGSeKzb48gDvW9N3ZwYuPJTZ+pFFFFdB44UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeAftrf8ks0r/sNRf8AoievjKM5Qc4NfZv7a3/JLNK/7DUX/oievi6Lk4pMum7MnUk8ZqQcLyKYnA96eATWTO2GwfezTo22MCDimt8vQ896BQV1LovJGXDOSKj35OTzUK8GngZIrPlS2NY3JOCuB+FOXrnpSZAPOKMg+v5UjSxMo4zUn+7USEgD5SRT0LnOMAVmzeKsTRnBzuwR3rQt72fG3K4z94rzWYoA68n1qxETxg5rKcU9zVJdTsvC+rPp99BMoLSoc7mPPHoe1fWfw68Rxa5o0TiQMSTjnnjrkV8VwT7WGDnFd94F8UtpMzEzMqEgsFOOnv8A0rysTh1NHLisO5rnW6PscU/PevIvD/xY0h7ULe3h3qwyWXBYe1S618W9NSSGHT3kJfG5tg+X6Z49q4lTqU3ax56ozk7WPQ9c1VNNtJZypbyyo24+/nsK8c8d+LHj+0bJri1idd7kkbpAegHtXNeK/H0t7LOqZWN3LIGb/Ven1rznXNQkv51ku5i5UbVO7oOwxWtCnyyuzqp4JyScjT/4SDy5W8hGw5wGz85PY5PpWNdajO00xZ1lZuC7Dr9KyjLmbcWACcD6+tTLKrHO4fOOB1wf6V2OFtT0adJctuxFrDSSWkshYeWBgANk/jVKMCKBMkh1Awynt707VpWa3CDaDnawH9arCQLBtP3gOOeprppxfIjepEguZmaXeScjjntTJG+UOR+OKU4Y7iMuOo7moZHAJPUdwe9dMV0Rk48upHId+RjGO9MRiGzjpShsEHgqOtSuoCo3GDWm2hmouTv2IXc7T1znNRcNzipMj5lJ4zwahPDYB4q0RN23B8gDDHFZ102ZMZzirzEAfMeO9ZjnLE+tbU0ebjZ6JH6pUUUVsecFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHgH7a3/JLNK/7DUX/oievixThga+0/21v+SWaV/2Gov/AERPXxVQBfTaoyT1FI0nGB0qsjnbj0p4x+FZ8p2KtdWRKvNPUZFRgjp2pVbnipZpFpbkmQMYpwJPSo84NOUnsKRqmTxqGNPIIbOaYp5AqQH2FZs64pNCqT93NTKMflUUYyePxqcnIX6c1nI2px0uxwAJApVJHFQ5O/FSYIGTxUtFblpG24wasR3JU88g1RLdO9KGJPoazcE9y/I1475VOQMn61cGqtxuycDGa5w8d6cZGIHzdKxlh4s1i0kbrXhk8znI64PNReeSvC/McgZ61lRyYzk1LHcHeGbAx0HpS9ilsXdT3HyS7flwCRVdJ2XIJ6025bc+Vz1qB32j3/nW8YaGbtFkzsXlBJJVfvZ9aZK/ByeKjQkIwPfmoyw24fNWokykrEpJDkHr2IqKZvmIPrQWUFeelRlySQ2OvSrSIk1axEMhiCelTly0Q3Hp2qKTbkEZ5PelYqBg81b1MY+7dXELfK2T9agZgD61KCPKaqzcc1UUc9WeiGXkmeB3qlU10SZOfSoa6IqyPJrzcptn6qUUUVRiFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHgH7a3/ACSzSv8AsNRf+iJ6+Kq+1f21v+SWaV/2Gov/AERPXxVQAo4NSqahp6ntSZUXZkwJNOHSmJ0PNOXJqGdMWPU5J9qkD8cVHjjGacny/e5qWbwbRYi5HYVMELEVVU7j9KmM3y4BrKSfQ7adSNtR7Nsyuee9AkwRUGd3JpyH5gKOUftG3oWEY5B708tnvVfdnvinI3Bz0qWjRS6FndxTxwOSKrFh605jkcVHKXzWJ947mm55JHQ1ACd3+FLuJP8As9zRyhzXH+YS24nntQ0nGc1G7j1xTGcYIyapRF7TzJBKSDzihHLAuenaq65yFOQDUxb5SO3tTaFGo2PL45747VEzH0+tJvw2R25pof5s/wAPWhIUp+Y4EEAk/NTCcSHmkLdePpTc5bI6irSMpT6E2QBzUTN8/wBaaWyDjvV7SbdZpFDjOTg+tJtRV2CbqPlRSTG4jJwRVeUgdSBXReLtLi014Li3YNDKoPHrXJyOXck96qhJVYqa2OHE1FD3eosrBm4qOiiuk89u7ufqpRRRQIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPAP21v+SWaV/2Gov/AERPXxVX2r+2t/ySzSv+w1F/6Inr4qoAKKKKAJUbPBqUN2qsKkRgTycVLRrCdtCyi5GfSkB+b2pnmDIGRihWUscsPzqLHTzrRIsAbVz600DmleVAgAZScdjUayL3YD8alXNpOKaVyZTzzS9DkVEjoD99fxNKZVz99fzosUpq25KM1MgwuarJImc71/OnC4X++v51LTNoVILVsm5LcHmnb8LUBnQdHXP1phlU9ZEH40uVle1itmT7/wAKUuSAFWoUeLPLrn6iriSW5PM0eB/tClLToVT9/wC0kQeXySxOaVtoAI60s08QJ2yIc9fmFV2lQjAdfzoSbJnKENEyXOWA+tKp+fB4qqsi7vvqPxqQTJkZdfzqnEiNZdyR16nPSowxC03zVORvH1zSGRMH5l596aREqkXqmSIckjFKgwciolkUEfOv51IZUyQJFxn1oaY4zjbVkvlDDD3oDyQkFGK47inLNFyPMQZH94VRvLkN+7jOV7t61MU5OzNK86dKPMnqO1LU7i+CJPIWROn19aoUUV0xioqyPElJzfMwooopkn6qUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (Panel A) A 35-year-old woman presented with massive subretinal abscess and optic nerve granuloma with neovascularisation in her left eye. Her mantoux test was necrotic positive, and ultrasonography demonstrated thickened choroid.",
"    <br/>",
"    (Panel B) Interval improvement was observed after one month of antituberculous therapy.",
"    <br/>",
"    (Panel C) Resolution of funduscopici findings and choroidal thickening was observed after three months of antituberculous therapy.",
"    <div class=\"footnotes\">",
"     TB: tuberculosis.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_17_3346=[""].join("\n");
var outline_f3_17_3346=null;
var title_f3_17_3347="Patient information: Asbestos exposure (The Basics)";
var content_f3_17_3347=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83057\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/17/41237\">",
"         Normal lungs",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?20/34/21027\">",
"         Patient information: Chest pain (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/34/35363\">",
"         Patient information: Lung cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/50/10018\">",
"         Patient information: Pleural effusion (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?4/45/4819\">",
"         Patient information: Pleuritic chest pain (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/46/18146\">",
"         Patient information: Quitting smoking (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/46/6883\">",
"         Patient information: Shortness of breath (dyspnea) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?1/3/1076\">",
"         Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Asbestos exposure (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/asbestos-exposure-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H9361215\">",
"      <span class=\"h1\">",
"       What is asbestos?",
"      </span>",
"      &nbsp;&mdash;&nbsp;&ldquo;Asbestos&rdquo; is the name of a group of minerals that are shaped like long, thin fibers. For many years, asbestos was commonly used in insulation, car brakes, ships, ceiling tiles, fabrics, fireproofing, and many other materials. But since the 1970s, people have mostly stopped using asbestos. That&rsquo;s because scientists learned that being around asbestos (&ldquo;asbestos exposure&rdquo;) can cause serious health problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9361230\">",
"      <span class=\"h1\">",
"       How do people get exposed to asbestos?",
"      </span>",
"      &nbsp;&mdash;&nbsp;When people are exposed to asbestos, it&rsquo;s usually because of the type of work they do. Asbestos is found in many types of construction materials. People who work with these materials can be exposed to asbestos. This includes plumbers, pipefitters, electricians, insulation workers, construction workers, roofers, welders, and many other types of workers.",
"     </p>",
"     <p>",
"      People can also be exposed to asbestos through the work clothes of someone they live with. This can happen when the person who works with asbestos brings their work clothes home. Plus, people are exposed to low levels of asbestos in nature.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9361245\">",
"      <span class=\"h1\">",
"       What health problems does asbestos exposure cause?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Asbestos fibers are very small. When these fibers get loose in the air, people can breathe them into the lungs, where they get trapped (",
"      <a class=\"graphic graphic_figure graphicRef67527 \" href=\"UTD.htm?40/17/41237\">",
"       figure 1",
"      </a>",
"      ). The trapped asbestos fibers can cause problems such as:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Asbestosis &ndash; This is scarring of the lungs, which makes it hard to breathe.",
"       </li>",
"       <li>",
"        Cancer &ndash; This includes lung cancer and &ldquo;mesothelioma,&rdquo; a rare cancer that happens in the lining around the lungs or in the belly.",
"       </li>",
"       <li>",
"        Pleural problems &ndash; These are problems in the thin layer of tissue that surrounds the lungs (called the &ldquo;pleura&rdquo;).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      It usually takes being exposed to asbestos at high levels or for a long time for the asbestos to cause illness. Many people who are exposed to asbestos never get sick from it, especially if they don&rsquo;t smoke.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9361260\">",
"      <span class=\"h1\">",
"       What are the symptoms of asbestos exposure?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people have no symptoms at all for up to 15 to 30 years after being exposed to asbestos.",
"     </p>",
"     <p>",
"      The first symptom is usually trouble breathing, which is also called &ldquo;shortness of breath&rdquo; or &ldquo;dyspnea.&rdquo; At first, the trouble breathing only happens when you are active and goes away when you rest. But as time goes on, it lasts longer, and it gets hard to breathe even when you are resting.",
"     </p>",
"     <p>",
"      Other symptoms can include chest pain, a cough, and coughing up blood.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9361275\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have shortness of breath, you should see your doctor or nurse. Tell him or her if you worked in a job that might have exposed you to asbestos. If you have severe shortness of breath with chest pain or nausea or if you cough up blood, you need to go to the hospital. Having those symptoms could mean that your condition is serious.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9361290\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. First, your doctor or nurse will ask you a lot of questions, especially about the types of work you have done. It is important to find out how long you were around asbestos and how much you were exposed to it. The doctor will also order tests to find out what kind of health problems you might have because of asbestos. These tests could include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Chest X-ray &mdash; A chest X-ray can show if the lungs are inflating all the way or if there is an abnormal growth on the lung. It can also show if there is fluid between the lungs and the ribcage.",
"       </li>",
"       <li>",
"        CT scan &mdash; A CT scan is like an X-ray but shows a more detailed picture.",
"       </li>",
"       <li>",
"        Breathing tests &mdash; These tests measure how well your lungs are working. During these tests, you take a deep breath and then blow out as fast and hard as you can into a tube. A machine connected to the tube measures how much air you can blow out of your lungs and how fast you can blow.",
"       </li>",
"       <li>",
"        Thoracentesis &ndash; If you have fluid around your lung, your doctor might need to take some of the fluid out for testing. This is called a thoracentesis. During this procedure, the doctor uses a needle to take some fluid from around the lungs.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9361305\">",
"      <span class=\"h1\">",
"       How is asbestos exposure treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on what problems you have from the asbestos exposure:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Asbestosis &ndash; People who have asbestosis might feel better if they get breathing treatments. Some might need oxygen. There is no specific treatment for asbestosis.",
"       </li>",
"       <li>",
"        Cancers &ndash; People with lung cancer or mesothelioma might have surgery, chemotherapy, or radiation therapy.",
"       </li>",
"       <li>",
"        Pleural problems &ndash; The treatment depends on what type of pleural problem you have. For example, if you have fluid around your lungs, your doctor might put in a tube to drain the fluid. If you have inflammation of the pleura but no cancer, you might be treated with an NSAID such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        &nbsp;(sample brand names: Advil&reg;, Motrin&reg;) or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        &nbsp;(sample brand names: Aleve&reg;, Naprosyn&reg;).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor will help you decide the best treatment for the type of health problem you have.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9361320\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you smoke, the most important thing you can do is STOP SMOKING! It does not matter how long you have smoked or how much you smoke. The problems caused by asbestos exposure get much worse with smoking. Quitting can slow your disease and help you feel better.",
"     </p>",
"     <p>",
"      It is also important to keep from having any more asbestos exposure. This might mean wearing a mask and special clothing at work or maybe even changing jobs. Talk to your doctor about this to see if your current job might be a source of asbestos.",
"     </p>",
"     <p>",
"      Get the flu shot every fall, and the pneumonia vaccine at least once.&nbsp;Infections like the flu and pneumonia can be very hard on your lungs. It's important to try to prevent them.",
"     </p>",
"     <p>",
"      A cold or the flu can make it harder to breathe. If your shortness of breath or cough get worse, call your doctor right away.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9361334\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/46/6883?source=see_link\">",
"       Patient information: Shortness of breath (dyspnea) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=see_link\">",
"       Patient information: Quitting smoking (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/34/21027?source=see_link\">",
"       Patient information: Chest pain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/45/4819?source=see_link\">",
"       Patient information: Pleuritic chest pain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/34/35363?source=see_link\">",
"       Patient information: Lung cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/50/10018?source=see_link\">",
"       Patient information: Pleural effusion (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/3/1076?source=see_link\">",
"       Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?3/17/3347?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83057 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-B2700F0D78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_17_3347=[""].join("\n");
var outline_f3_17_3347=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361215\">",
"      What is asbestos?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361230\">",
"      How do people get exposed to asbestos?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361245\">",
"      What health problems does asbestos exposure cause?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361260\">",
"      What are the symptoms of asbestos exposure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361275\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361290\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361305\">",
"      How is asbestos exposure treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361320\">",
"      Is there anything I can do on my own?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361334\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83057\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/17/41237\">",
"      Normal lungs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/34/21027?source=related_link\">",
"      Patient information: Chest pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/34/35363?source=related_link\">",
"      Patient information: Lung cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/3/1076?source=related_link\">",
"      Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/50/10018?source=related_link\">",
"      Patient information: Pleural effusion (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/45/4819?source=related_link\">",
"      Patient information: Pleuritic chest pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=related_link\">",
"      Patient information: Quitting smoking (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/46/6883?source=related_link\">",
"      Patient information: Shortness of breath (dyspnea) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_17_3348="Contact dermatitis chronic";
var content_f3_17_3348=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F69623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F69623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Chronic allergic contact dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The skin is dry, scaly, and thick, as a result of hyperkeratosis, acanthosis, and lymphomononuclear cell infiltration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_17_3348=[""].join("\n");
var outline_f3_17_3348=null;
var title_f3_17_3349="T2 rectal ca EUS and Endosc";
var content_f3_17_3349=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rectal cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 600px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic ultrasound image of a T2 rectal cancer invading through submucosa and extending into superficial muscularis propria (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gavin C Harewood, MD and Mauritis J Wiersema, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_17_3349=[""].join("\n");
var outline_f3_17_3349=null;
var title_f3_17_3350="Chloroprocaine: Drug information";
var content_f3_17_3350=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chloroprocaine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/60/43971?source=see_link\">",
"    see \"Chloroprocaine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/31/9716?source=see_link\">",
"    see \"Chloroprocaine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F149713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nesacaine&reg;;",
"     </li>",
"     <li>",
"      Nesacaine&reg;-MPF",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F149714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nesacaine&reg;-CE",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F149730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Local Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F149716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage varies with anesthetic procedure, the area to be anesthetized, the vascularity of the tissues, depth of anesthesia required, degree of muscle relaxation required, and duration of anesthesia; range.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Maximum single dose (without epinephrine): 11 mg/kg; maximum dose: 800 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum single dose (with epinephrine): 14 mg/kg; maximum dose: 1000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infiltration and peripheral nerve block:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mandibular: 2%: 2-3 mL; total dose 40-60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infraorbital: 2%: 0.5-1 mL; total dose 10-20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Brachial plexus: 2%; 30-40 mL; total dose 600-800 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Digital (without epinephrine): 1%; 3-4 mL; total dose: 30-40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pudendal: 2%; 10 mL each side; total dose: 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Paracervical: 1%; 3 mL per each of four sites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caudal block: Preservative-free: 2% or 3%: 15-25 mL; may repeat at 40-60 minute intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lumbar epidural block: Preservative-free: 2% or 3%: 2-2.5 mL per segment; usual total volume: 15-25 mL; may repeat with doses that are 2-6 mL less than initial dose every 40-50 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F149724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/31/9716?source=see_link\">",
"      see \"Chloroprocaine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage varies with anesthetic procedure, the area to be anesthetized, the vascularity of the tissues, depth of anesthesia required, degree of muscle relaxation required, and duration of anesthesia; range.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Children &gt;3 years (normally developed): Maximum dose (without epinephrine): 11 mg/kg; for infiltration, concentrations of 0.5% to 1% are recommended; for nerve block, concentrations of 1% to 1.5% are recommended",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F149717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustments provided in manufacturer&rsquo;s labeling. Use with caution due to increased risk of adverse effects.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustments provided in manufacturer&rsquo;s labeling. Use with caution due to increased risk of adverse effects.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F149695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 2% [20 mg/mL] (30 mL [DSC]); 3% [30 mg/mL] (30 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nesacaine&reg;: 1% [10 mg/mL] (30 mL); 2% [20 mg/mL] (30 mL) [contains edetate disodium, methylparaben]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [preservative free]: 2% [20 mg/mL] (20 mL); 3% [30 mg/mL] (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nesacaine&reg;-MPF: 2% [20 mg/mL] (20 mL); 3% [30 mg/mL] (20 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F149680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F149697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Before injecting, withdraw syringe plunger to ensure injection is not into vein or artery.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F149696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infiltration anesthesia, peripheral nerve block, epidural anesthesia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F149737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Nesacaine&reg; may be confused with Neptazane&trade;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (epidural administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F149728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Frequency not always defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, cardiac arrest, hypotension, ventricular arrhythmia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety, dizziness, restlessness, tinnitus, unconsciousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Angioneurotic edema, erythema, pruritus, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Chondrolysis (continuous intra-articular administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Respiratory arrest",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, anaphylactoid reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Seizure (0.1%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F149700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to chloroprocaine, other ester type anesthetics, or any component of the formulation; do not use for subarachnoid administration",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F149684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS toxicity: Careful and constant monitoring of the patient's state of consciousness should be done following each local anesthetic injection; at such times, restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression, or drowsiness may be early warning signs of CNS toxicity. Treatment is primarily symptomatic and supportive.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intra-articular infusion related chondrolysis: Continuous intra-articular infusion of local anesthetics after arthroscopic or other surgical procedures is",
"     <b>",
"      not",
"     </b>",
"     an approved use; chondrolysis (primarily in the shoulder joint) has occurred following infusion, with some cases requiring arthroplasty or shoulder replacement.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory arrest: Local anesthetics have been associated with rare occurrences of sudden respiratory arrest.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Convulsions due to systemic toxicity leading to cardiac arrest have also been reported, presumably following unintentional intravascular injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease or compromised blood supply.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with extreme caution in patients with myasthenia gravis; may cause significant weakness (Haroutiunian, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acutely ill patients: Use with caution in acutely ill; reduce dose consistent with age and physical status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; reduce dose consistent with age and physical status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; reduce dose consistent with age and physical status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use with caution in children; reduce dose consistent with age and physical status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Preservative-containing solutions:",
"     <b>",
"      Do not use solutions containing preservatives for caudal or epidural block.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Test dose: A test dose is recommended prior to epidural administration (prior to initial dose) and all reinforcing doses with continuous catheter technique.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Trained personnel: Clinicians using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F149689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F149691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F149702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Local anesthetics rapidly cross the placenta and may cause varying degrees of maternal, fetal, and neonatal toxicity. Close maternal and fetal monitoring (heart rate and electronic fetal monitoring advised) are required during obstetrical use. Maternal hypotension has resulted from regional anesthesia. Positioning the patient on her left side and elevating the legs may help. Epidural, paracervical, or pudendal anesthesia may alter the forces of parturition through changes in uterine contractility or maternal expulsive efforts. The use of some local anesthetic drugs during labor and delivery may diminish muscle strength and tone for the first day or two of life. Administration as a paracervical block is not recommended with toxemia of pregnancy, fetal distress, or prematurity. Administration of a paracervical block early in pregnancy has resulted in maternal seizures and cardiovascular collapse. Fetal bradycardia and acidosis also have been reported. Fetal depression has occurred following unintended fetal intracranial injection while administering a paracervical and/or pudendal block.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F149719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Chloroprocaine HCl Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (20 mL): $15.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3% (20 mL): $17.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Nesacaine Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (30 mL): $21.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (30 mL): $22.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Nesacaine-MPF Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (20 mL): $25.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3% (20 mL): $26.86",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F149693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cardiovascular and respiratory status; mental status",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ivracain (CH);",
"     </li>",
"     <li>",
"      Nesacaine (CH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F149683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chloroprocaine HCl is benzoic acid, 4-amino-2-chloro-2-(diethylamino) ethyl ester monohydrochloride. Chloroprocaine is an ester-type local anesthetic, which stabilizes the neuronal membranes and prevents initiation and transmission of nerve impulses thereby affecting local anesthetic actions. Local anesthetics including chloroprocaine, reversibly prevent generation and conduction of electrical impulses in neurons by decreasing the transient increase in permeability to sodium. The differential sensitivity generally depends on the size of the fiber; small fibers are more sensitive than larger fibers and require a longer period for recovery. Sensory pain fibers are usually blocked first, followed by fibers that transmit sensations of temperature, touch, and deep pressure. High concentrations block sympathetic somatic sensory and somatic motor fibers. The spread of anesthesia depends upon the distribution of the solution. This is primarily dependent on the volume of drug injected.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F149699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 6-12 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Depends upon route of administration; high concentrations found in highly perfused organs such as liver, lungs, heart, and brain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Plasma cholinesterases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"     <i>",
"      In vitro,",
"     </i>",
"     plasma: Adults: 21 seconds; Neonates: 43 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Coda B, Bausch S, Haas M, et al, &ldquo;The Hypothesis That Antagonism of Fentanyl Analgesia by 2-Chloroprocaine Is Mediated by Direct Action on Opioid Receptors,&rdquo;",
"      <i>",
"       Reg Anesth",
"      </i>",
"      , 1997, 22(1):43-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/17/3350/abstract-text/9010946/pubmed\" id=\"9010946\" target=\"_blank\">",
"        9010946",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Corke BC, Carlson CG, and Dettbarn WD, &ldquo;The Influence of 2-Chloroprocaine on the Subsequent Analgesic Potency of Bupivacaine,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1984, 60(1):25-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/17/3350/abstract-text/6691592/pubmed\" id=\"6691592\" target=\"_blank\">",
"        6691592",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dix SK, Rosner GF, Nayar M, et al, &ldquo;Intractable Cardiac Arrest Due to Lidocaine Toxicity Successfully Resuscitated With Lipid Emulsion,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2011, 39(4):872-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/17/3350/abstract-text/21263316/pubmed\" id=\"21263316\" target=\"_blank\">",
"        21263316",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Freeman DW and Arnold NI, &ldquo;Paracervical Block With Low Doses of Chloroprocaine: Fetal and Maternal Effects,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1975, 231(1):56-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/17/3350/abstract-text/1243568/pubmed\" id=\"1243568\" target=\"_blank\">",
"        1243568",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jankowsky EC, &ldquo;Pharmacologic Aspects of Local Anesthetic Use,&rdquo;",
"      <i>",
"       Anesth Clin North Am",
"      </i>",
"      , 1990, 8:1-25.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neal JM, Mulroy MF, and Weinberg GL, &ldquo;American Society of Regional Anesthesia and Pain Medicine Checklist for Managing Local Anesthetic Systemic Toxicity: 2012 Version,&rdquo;",
"      <i>",
"       Reg Anesth Pain Med",
"      </i>",
"      , 2012, 37(1):16-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/17/3350/abstract-text/22189574/pubmed\" id=\"22189574\" target=\"_blank\">",
"        22189574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9245 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-6A22C7A760-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_17_3350=[""].join("\n");
var outline_f3_17_3350=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149713\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149714\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149730\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149716\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149724\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149717\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682597\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682598\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149695\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149680\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149697\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149696\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149737\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149728\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149700\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149684\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299021\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149689\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149691\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149702\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149719\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323059\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149693\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038558\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149683\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149699\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9245\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9245|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/60/43971?source=related_link\">",
"      Chloroprocaine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/31/9716?source=related_link\">",
"      Chloroprocaine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_17_3351="Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment";
var content_f3_17_3351=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/17/3351/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/17/3351/contributors\">",
"     David R Schwartz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/17/3351/contributors\">",
"     Atul Malhotra, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/17/3351/contributors\">",
"     Steven E Weinberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/17/3351/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/17/3351/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/17/3351/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/17/3351/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/17/3351/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/17/3351/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/17/3351/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy and the puerperium are well-established risk factors for deep vein thrombosis (DVT) and pulmonary embolism (PE), which are collectively referred to as venous thromboembolic disease (VTE). Treatment of VTE in pregnant patients is unique in several ways. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link\">",
"     \"Anticoagulation during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      is generally not used, particularly in the first trimester, because it may be teratogenic.",
"     </li>",
"     <li>",
"      Synthetic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      pentasaccharides (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      , idraparinux) are avoided because there is a paucity of safety data for these agents.",
"     </li>",
"     <li>",
"      Monitoring of anticoagulant activity tends to be more vigilant because less is known about the appropriate dosing of anticoagulants during pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of VTE during pregnancy and the puerperium will be reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3351/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. The epidemiology, pathogenesis, diagnosis, and prevention of VTE during pregnancy and the puerperium are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14055?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial management of suspected VTE depends upon the degree of clinical suspicion for acute PE, whether there are contraindications to anticoagulation, and whether PE, DVT, or both are suspected:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When there is a high clinical suspicion for acute PE, empiric anticoagulant therapy is indicated prior to the diagnostic evaluation. Anticoagulant therapy is discontinued if VTE is excluded.",
"     </li>",
"     <li>",
"      When there is low or moderate clinical suspicion for PE, empiric anticoagulant therapy prior to diagnostic evaluation is determined on a case-by-case basis.",
"     </li>",
"     <li>",
"      For those patients in whom PE is suspected but anticoagulant therapy is contraindicated, diagnostic evaluation should be expedited. Anticoagulation-independent therapy (eg, inferior vena cava filter) is indicated if VTE is confirmed.",
"     </li>",
"     <li>",
"      When there is suspicion for DVT alone (no clinical evidence or suspicion of acute PE), anticoagulant therapy is generally withheld until VTE is confirmed, assuming that diagnostic evaluation can be performed in a timely fashion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANTICOAGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following approach is generally consistent with the 2012 American College of Chest Physicians (ACCP) guidelines on VTE and pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3351/abstract/1\">",
"     1",
"    </a>",
"    ]. Once it is determined that anticoagulation is indicated, it should be initiated using subcutaneous low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (SC LMWH), intravenous unfractionated heparin (IV UFH), or subcutaneous unfractionated heparin (SC UFH) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3351/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25690?source=see_link\">",
"     \"Anticoagulation in acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subcutaneous LMWH is preferred over IV UFH or SC UFH in most patients because it is easier to use and it appears to be more efficacious with a better safety profile. These findings are extrapolated from clinical trials in non-pregnant patients. In a meta-analysis of 22 randomized trials (8867 patients), SC LMWH decreased mortality (odds ratio 0.76, 95% CI 0.62-0.92) and recurrent thrombosis (odds ratio 0.68, 95% CI 0.55-0.84) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3351/abstract/8\">",
"     8",
"    </a>",
"    ]. It was also more likely to reduce thrombus size (odds ratio 0.69, 95% CI 0.59-0.81) and less likely to cause major hemorrhage (odds ratio 0.57, 95% CI 0.39-0.83).",
"   </p>",
"   <p>",
"    In contrast, IV UFH is preferred in patients who have a markedly elevated risk of bleeding or persistent hypotension due to PE. This preference is based on clinical experience. The rationale is that its short half-life and near complete reversal with protamine make it the most desirable anticoagulant if it needs to be discontinued due to bleeding or to perform a procedure.",
"   </p>",
"   <p>",
"    UFH (either IV or SC) is preferred over SC LMWH in patients who have severe renal failure. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Dosing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little information exists about the appropriate dosing of anticoagulants during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3351/abstract/9\">",
"     9",
"    </a>",
"    ]. Thus, additional caution seems prudent, including weight-adjusted dosing and more vigilant monitoring of anticoagulant activity. The following regimens are reasonable for the initial treatment of VTE during pregnancy or the puerperium. Regardless of the regimen, anticoagulant therapy should continue through the pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     LMWH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reasonable initial doses of SC LMWH include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    200",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    once daily,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/44/21191?source=see_link\">",
"     tinzaparin",
"    </a>",
"    175",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    once daily, dalteparin 100",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    every 12 hours, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 12 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3351/abstract/1\">",
"     1",
"    </a>",
"    ]. The dose is then titrated to an anti-Xa level of 0.6 to 1.0",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    for twice daily administration, or 1 to 2",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    for once daily administration [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3351/abstract/1,10\">",
"     1,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first anti-Xa level is generally measured six hours after the third or fourth dose if the dosing is every 12 hours, or six hours after the second or third dose if the dosing is once daily. Most adjustments should be an increase or decrease of 10 to 25 percent. The anti-Xa level may be measured six hours after the third injection that follows a dose adjustment. Once a satisfactory anti-Xa level is reached, some clinicians recheck the level every one to three months, although this is controversial because few women require dose adjustments [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3351/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     IV UFH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial dosing of IV UFH consists of an IV UFH bolus of 80",
"    <span class=\"nowrap\">",
"     units/kg,",
"    </span>",
"    followed by a continuous infusion of 18",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per hour [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3351/abstract/7\">",
"     7",
"    </a>",
"    ]. The infusion is titrated every six hours to achieve a therapeutic activated partial thromboplastin time (aPTT), defined as the aPTT that corresponds to an anti-Xa level of 0.3 to 0.7 U. The target aPTT range will be laboratory-specific. Once the target aPTT level is achieved, it should be rechecked once or twice daily. IV UFH can be transitioned to SC UFH or SC LMWH if long-term or outpatient anticoagulant therapy is planned [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3351/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     SC UFH",
"    </span>",
"    &nbsp;&mdash;&nbsp;A reasonable initial dose of SC UFH is 17,500 units every 12 hours. The dose is then titrated to achieve a therapeutic aPTT, defined as the aPTT that corresponds to an anti-Xa level of 0.3 to 0.7 U [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3351/abstract/1\">",
"     1",
"    </a>",
"    ]. The target aPTT range will be laboratory-specific.",
"   </p>",
"   <p>",
"    The first aPTT is generally measured six hours after the second dose. Most adjustments should be an increase or decrease of 10 to 30 percent. The aPTT may be measured six hours after the second injection that follows each dose adjustment. Once a stable dose is achieved, the aPTT may be measured after three to four days of treatment and then every few weeks. During the last 10 weeks of the pregnancy, more frequent monitoring is warranted.",
"   </p>",
"   <p>",
"    Many clinicians prefer to begin with IV UFH and then transition to SC UFH in order to achieve a rapid therapeutic effect for treatment. The transition is traditionally done after the patient has received IV UFH for 5 to 10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3351/abstract/11\">",
"     11",
"    </a>",
"    ]. In this situation, the first aPTT can be checked six hours after the first SC UFH dose and then six hours after every dose adjustment until a stable dose that produces the desired therapeutic level is achieved. Once a stable dose of SC UFH is achieved, the aPTT may be initially checked once or twice daily for three to four days and then every few weeks. During the last 10 weeks of the pregnancy, more frequent monitoring is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Labor and delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with SC LMWH should be discontinued at least 24 hours prior to delivery if the delivery time is predictable (eg, induction of labor, planned cesarean section). This allows the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    to resolve, which is particularly important for patients who desire neuraxial anesthesia because anticoagulation during insertion (or removal) of a neuraxial anesthesia catheter increases the risk for spinal hematoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39562?source=see_link&amp;anchor=H12561180#H12561180\">",
"     \"Adverse effects of neuraxial analgesia and anesthesia for obstetrics\", section on 'Neuraxial analgesia and the anticoagulated patient'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A period of 24 to 36 hours without anticoagulant therapy may be undesirable in pregnant women who are at high risk for recurrent VTE (eg, those with an acute PE or proximal DVT that developed within the past month). Such patients may benefit from having their SC LMWH or SC UFH switched to IV UFH, which can be discontinued 4 to 6 hours prior to delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3351/abstract/1\">",
"     1",
"    </a>",
"    ]. A neuraxial catheter may be placed when the aPTT has returned to normal [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3351/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinician may be unwilling to tolerate even a short interval without anticoagulant therapy in rare circumstances, such as a patient with reduced cardiopulmonary reserve and a recent PE. A temporary inferior vena cava (IVC) filter can be inserted in this situation, or delivery can proceed despite full anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3351/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Delivery despite full anticoagulation may also occur if labor begins unexpectedly. Many patients who deliver while anticoagulated will not have excessive intrapartum bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3351/abstract/13\">",
"     13",
"    </a>",
"    ]. However, anticoagulated patients are at increased risk for a spinal hematoma if a neuraxial anesthesia catheter is inserted [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3351/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Neuraxial anesthesia should not be administered to an anticoagulated patient.",
"   </p>",
"   <p>",
"    In cases in which preterm delivery is anticipated (eg, triplets, preterm rupture of membranes, significant cervical dilation, preeclampsia, growth restriction), it is common to discontinue SC LMWH or SC UFH at 36 weeks of gestation. IV UFH is then used instead.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     After delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;A",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    regimen (SC LMWH, IV UFH, or SC UFH) should be restarted 12 hours after a cesarean delivery or 6 hours after a vaginal birth, assuming that significant bleeding has not occurred. Options for long-term anticoagulant therapy include SC LMWH, SC UFH, or an oral vitamin K antagonist (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ). If warfarin therapy is chosen, the patient should receive both warfarin and heparin for at least five days. The heparin should not be stopped until the international normalized ratio (INR) has been within therapeutic range (usually 2 to 3) for two consecutive days. Warfarin is considered safe during lactation because it does not accumulate in breast milk to a substantial degree [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3351/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Length of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulant therapy generally continues for at least six weeks postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3351/abstract/1\">",
"     1",
"    </a>",
"    ]. This is primarily based on clinical experience.",
"   </p>",
"   <p>",
"    The total duration of anticoagulant therapy (pregnancy plus the postpartum period) should be at least six months for women whose only risk factors for VTE were transient (eg, pregnancy, cesarean section) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3351/abstract/1,17,18\">",
"     1,17,18",
"    </a>",
"    ]. In one trial, 897 non-pregnant patients were randomly assigned to receive six months or six weeks of an oral anticoagulant (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or dicumarol) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3351/abstract/19\">",
"     19",
"    </a>",
"    ]. Patients who received oral anticoagulants for six months had fewer episodes of recurrent VTE than patients who received oral anticoagulants for six weeks (9.5 versus 18.1 percent).",
"   </p>",
"   <p>",
"    Patients with persistent risk factors for VTE may require a longer duration of therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25690?source=see_link&amp;anchor=H38#H38\">",
"     \"Anticoagulation in acute pulmonary embolism\", section on 'Duration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INFERIOR VENA CAVA FILTERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inferior vena cava (IVC) filters have been used during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3351/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Indications for insertion of an IVC filter are the same in pregnant and non-pregnant patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3351/abstract/20,21\">",
"     20,21",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16840?source=see_link\">",
"     \"Placement of inferior vena cava filters and their complications\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conventional anticoagulation is contraindicated, such as during active bleeding, following recent surgery, or following a hemorrhagic stroke.",
"     </li>",
"     <li>",
"      Conventional anticoagulation has proven ineffective, such as in patients who develop new VTE despite being anticoagulated.",
"     </li>",
"     <li>",
"      A complication of anticoagulation develops (eg, significant bleeding), which prohibits continuation of anticoagulant therapy.",
"     </li>",
"     <li>",
"      The pulmonary vascular bed is already significantly compromised (eg, massive pulmonary embolism, chronic thromboembolic pulmonary hypertension) and unlikely to tolerate another insult.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Temporary, retrievable IVC filters may prove well-suited to use in patients who develop VTE during pregnancy or the puerperium, since the patient population tends to be quite young and have temporary risk factors for VTE (ie, pregnancy) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3351/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16840?source=see_link\">",
"     \"Placement of inferior vena cava filters and their complications\"",
"    </a>",
"    .) However, inability to later retrieve a filter placed during the third trimester of pregnancy has been reported due to filter tilt [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3351/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     THROMBOLYTIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Teratogenicity due to thrombolytic agents has not been reported, but the risk of maternal hemorrhage is high. As a result, thrombolytic therapy should be reserved for pregnant patients with life-threatening acute PE (ie, persistent and severe hypotension due to the PE) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3351/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28697?source=see_link\">",
"     \"Fibrinolytic (thrombolytic) therapy in acute pulmonary embolism and lower extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Observational studies provide the only data about the efficacy and safety of thrombolytic therapy during pregnancy (ie, there are no controlled trials). In a systematic review of case series and case reports (172 pregnant women treated with thrombolytic agents), the maternal mortality rate was 1 percent, the incidence of fetal loss was 6 percent, and incidence of maternal hemorrhagic complications was 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3351/abstract/26\">",
"     26",
"    </a>",
"    ]. The risk of postpartum hemorrhage appears to be greatest among women treated within eight hours of delivery, although only a few cases have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3351/abstract/27-31\">",
"     27-31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    has several side effects, including bleeding, thrombocytopenia, skin necrosis, and osteoporosis. These adverse effects can occur even at prophylactic doses and are more likely with long-term use.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Bleeding",
"      </strong>",
"      &mdash; The management of bleeding during",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      therapy depends upon the location and severity of the bleeding, the degree of anticoagulation (ie, the anti-Xa level or aPTT), and the risk of discontinuing the anticoagulant. In many cases, the heparin can be stopped and restarted after the bleeding is controlled. However, insertion of an inferior vena caval (IVC) filter should be considered if the bleeding is sufficiently severe to prohibit resumption of anticoagulant therapy. Clinicians should NOT resume anticoagulant therapy if the bleeding is related to a placenta previa or abruption, although this recommendation is based on low quality evidence.",
"     </li>",
"     <li>",
"      <strong>",
"       Thrombocytopenia",
"      </strong>",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      -induced thrombocytopenia (HIT) is a potentially fatal complication of heparin therapy. The diagnosis and management of HIT are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link\">",
"       \"Heparin-induced thrombocytopenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Skin necrosis",
"      </strong>",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      -induced skin necrosis is a manifestation of HIT and may occur in the absence of thrombocytopenia. The diagnosis and management of HIT are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link\">",
"       \"Heparin-induced thrombocytopenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Osteoporosis",
"      </strong>",
"      &mdash; Long-term",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      therapy (longer than seven weeks) can reduce bone mineral density by reducing bone formation. This effect appears to be more common with unfractionated heparin than low molecular weight heparin. This issue is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=see_link&amp;anchor=H3#H3\">",
"       \"Drugs that affect bone metabolism\", section on 'Anticoagulants'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnancy and the puerperium are well-established risk factors for deep vein thrombosis (DVT) and pulmonary embolism (PE), which are collectively referred to as venous thromboembolic disease (VTE). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial management of suspected VTE during pregnancy depends on the degree of clinical suspicion, whether anticoagulation is contraindicated, and whether PE, DVT, or both are suspected. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pregnant women, we recommend adjusted dose subcutaneous low molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (SC LMWH), rather than adjusted dose intravenous unfractionated heparin (IV UFH) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ) or vitamin K antagonists (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We recommend against the use of oral direct thrombin inhibitors (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      ) or anti-Xa inhibitors (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/62/39911?source=see_link\">",
"       apixaban",
"      </a>",
"      ) in pregnant women (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest that anticoagulant therapy continue at least six weeks postpartum (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest a total duration of anticoagulant therapy of at least three months for women whose only risk factors for VTE were transient (eg, pregnancy) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients with persistent risk factors for VTE may require longer therapy (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Length of therapy'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Thrombolytic therapy should be reserved for pregnant or postpartum patients with life-threatening acute PE (ie, persistent and severe hypotension due to the PE). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Thrombolytic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/1\">",
"      Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e691S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/2\">",
"      Marik PE, Plante LA. Venous thromboembolic disease and pregnancy. N Engl J Med 2008; 359:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/3\">",
"      Bourjeily G, Paidas M, Khalil H, et al. Pulmonary embolism in pregnancy. Lancet 2010; 375:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/4\">",
"      Brown HL, Hiett AK. Deep vein thrombosis and pulmonary embolism in pregnancy: diagnosis, complications, and management. Clin Obstet Gynecol 2010; 53:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/5\">",
"      Arya R. How I manage venous thromboembolism in pregnancy. Br J Haematol 2011; 153:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/6\">",
"      Middeldorp S. How I treat pregnancy-related venous thromboembolism. Blood 2011; 118:5394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/7\">",
"      Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:141S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/8\">",
"      van Dongen CJ, van den Belt AG, Prins MH, Lensing AW. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2004; :CD001100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/9\">",
"      Romualdi E, Dentali F, Rancan E, et al. Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature. J Thromb Haemost 2013; 11:270.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Thromboembolism in pregnancy. ACOG Practice Bulletin 19. ACOG 2000; Washington, DC.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/11\">",
"      Toglia MR, Weg JG. Venous thromboembolism during pregnancy. N Engl J Med 1996; 335:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/12\">",
"      Horlocker TT, Wedel DJ, Benzon H, et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 2003; 28:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/13\">",
"      Dulitzki M, Pauzner R, Langevitz P, et al. Low-molecular-weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies. Obstet Gynecol 1996; 87:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/14\">",
"      Lumpkin MM. FDA public health advisory. Anesthesiology 1998; 88:27A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/15\">",
"      Wysowski DK, Talarico L, Bacsanyi J, Botstein P. Spinal and epidural hematoma and low-molecular-weight heparin. N Engl J Med 1998; 338:1774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/16\">",
"      Bates SM, Ginsberg JS. How we manage venous thromboembolism during pregnancy. Blood 2002; 100:3470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/17\">",
"      Barbour LA. Current concepts of anticoagulant therapy in pregnancy. Obstet Gynecol Clin North Am 1997; 24:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/18\">",
"      Ginsberg JS, Brill-Edwards P, Burrows RF, et al. Venous thrombosis during pregnancy: leg and trimester of presentation. Thromb Haemost 1992; 67:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/19\">",
"      Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 1995; 332:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/20\">",
"      Thomas LA, Summers RR, Cardwell MS. Use of Greenfield filters in pregnant women at risk for pulmonary embolism. South Med J 1997; 90:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/21\">",
"      Milford W, Chadha Y, Lust K. Use of a retrievable inferior vena cava filter in term pregnancy: case report and review of literature. Aust N Z J Obstet Gynaecol 2009; 49:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/22\">",
"      Zwaan M, Lorch H, Kulke C, et al. Clinical experience with temporary vena caval filters. J Vasc Interv Radiol 1998; 9:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/23\">",
"      K&ouml;cher M, Krcova V, Cerna M, Prochazka M. Retrievable G&uuml;nther Tulip Vena Cava Filter in the prevention of pulmonary embolism in patients with acute deep venous thrombosis in perinatal period. Eur J Radiol 2009; 70:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/24\">",
"      McConville RM, Kennedy PT, Collins AJ, Ellis PK. Failed retrieval of an inferior vena cava filter during pregnancy because of filter tilt: report of two cases. Cardiovasc Intervent Radiol 2009; 32:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/25\">",
"      Ahearn GS, Hadjiliadis D, Govert JA, Tapson VF. Massive pulmonary embolism during pregnancy successfully treated with recombinant tissue plasminogen activator: a case report and review of treatment options. Arch Intern Med 2002; 162:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/26\">",
"      Turrentine MA, Braems G, Ramirez MM. Use of thrombolytics for the treatment of thromboembolic disease during pregnancy. Obstet Gynecol Surv 1995; 50:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/27\">",
"      Patterson DE, Raviola CA, D'Orazio EA, et al. Thrombolytic and endovascular treatment of peripartum iliac vein thrombosis: a case report. J Vasc Surg 1996; 24:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/28\">",
"      Roberts DH, Rodrigues EA, Ramsdale DR. Postpartum acute myocardial infarction successfully treated with intravenous streptokinase--a case report. Angiology 1993; 44:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/29\">",
"      Cincotta RB, Davis SM, Gerraty RP, Thomson KR. Thrombolytic therapy for basilar artery thrombosis in the puerperium. Am J Obstet Gynecol 1995; 173:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/30\">",
"      Fagher B, Ahlgren M, Astedt B. Acute massive pulmonary embolism treated with streptokinase during labor and the early puerperium. Acta Obstet Gynecol Scand 1990; 69:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3351/abstract/31\">",
"      Hall RJ, Young C, Sutton GC, Cambell S. Treatment of acute massive pulmonary embolism by streptokinase during labour and delivery. Br Med J 1972; 4:647.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1350 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.65.66-4367187BB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_17_3351=[""].join("\n");
var outline_f3_17_3351=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANTICOAGULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - LMWH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - IV UFH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - SC UFH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      After delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Length of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INFERIOR VENA CAVA FILTERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      THROMBOLYTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39562?source=related_link\">",
"      Adverse effects of neuraxial analgesia and anesthesia for obstetrics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=related_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25690?source=related_link\">",
"      Anticoagulation in acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14055?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=related_link\">",
"      Drugs that affect bone metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28697?source=related_link\">",
"      Fibrinolytic (thrombolytic) therapy in acute pulmonary embolism and lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16840?source=related_link\">",
"      Placement of inferior vena cava filters and their complications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_17_3352="Sinus pause tutorial";
var content_f3_17_3352=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1051px;\">",
"  <div class=\"figure\" style=\"width: 475px\">",
"   <div class=\"ttl\">",
"    Sinus pause",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 455px; height: 121px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sinus pause is the result of intermittent failure of sinus node impulse generation. This is manifest as a long RR cycle length (in this tracing P to P interval) which is longer than the RR interval of the underlying sinus rhythm. There is no relationship between the cycle length of the pause and that of the intrinsic sinus rhythm. The P-P interval for the beats before and after the pause are less than two times the underlying sinus P-P interval.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 456px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 103px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_17_3352=[""].join("\n");
var outline_f3_17_3352=null;
var title_f3_17_3353="Postnatal use of glucocorticoids in bronchopulmonary dysplasia";
var content_f3_17_3353=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Postnatal use of glucocorticoids in bronchopulmonary dysplasia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/17/3353/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/17/3353/contributors\">",
"     James M Adams, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/17/3353/contributors\">",
"     Ann R Stark, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/17/3353/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/17/3353/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/17/3353/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/17/3353/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/17/3353/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials have shown that postnatal glucocorticoid therapy administered systemically improves short-term lung function and outcome of infants with established bronchopulmonary dysplasia (BPD) and reduces the risk of BPD in high-risk preterm infants. However, systemic glucocorticoid administration (primarily",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ) is associated with serious adverse effects. As a result, currently available evidence suggests that the potential benefits of routine administration of postnatal glucocorticoids are outweighed by its short- and long-term complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathogenesis and clinical features of bronchopulmonary dysplasia\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of postnatal glucocorticoid therapy, including its complications in preterm infants for prevention or treatment BPD, will be reviewed here. The overall prevention and treatment of BPD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27880?source=see_link\">",
"     \"Prevention of bronchopulmonary dysplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/24/15753?source=see_link\">",
"     \"Management of bronchopulmonary dysplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postnatal glucocorticoid administration is an area of intense clinical interest because of the desire to reduce the incidence and severity of BPD. Despite numerous studies, however, it remains unclear whether the benefits of postnatal glucocorticoid therapy outweigh its risks, due in part to difficulties in interpreting the data because of numerous methodologic issues.",
"   </p>",
"   <p>",
"    These issues include variations in the preparation of glucocorticoid used, the dosing and timing of administration, length of therapy, and the open label use of glucocorticoids in patients in control groups. Open label use is defined as the use of prescribed glucocorticoids by clinicians, in addition to the administration of the masked study drug. As a result, patients in the placebo group sometimes received glucocorticoids, thereby minimizing differences between treatment and control groups. Because of these issues, the postnatal use of either systemic or inhaled glucocorticoids in bronchopulmonary dysplasia is a controversial and continuously evolving subject.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SYSTEMIC STEROIDS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous clinical trials have shown the beneficial pulmonary effects of postnatal systemic glucocorticoids in preterm infants. Two meta-analyses have divided these trials based upon the timing of administration and their focus on either prevention or treatment of established bronchopulmonary dysplasia (BPD) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first meta-analysis included 28 trials that administered glucocorticoid therapy up to and including seven days of age to preterm infants at risk for BPD [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/1\">",
"     1",
"    </a>",
"    ]. This study showed postnatal glucocorticoid therapy compared with placebo was associated with earlier extubation (RR 0.73, 95% CI 0.62-0.82) and decreased incidence of BPD at both 28 (RR 0.87, 95% CI 0.81-0.93) and 36 weeks postmenstrual age (PMA) (RR 0.79, 95% CI 0.71-0.88). There were no differences in mortality and the proportion of survivors discharged home on oxygen.",
"   </p>",
"   <p>",
"    The second meta-analysis included 19 trials that administered",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    to infants with established chronic lung disease who were greater than seven days of age [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/2\">",
"     2",
"    </a>",
"    ]. This study showed postnatal glucocorticoid therapy compared with placebo reduced mortality at 28 days of age (RR 0.84, 95% CI 0.78-0.89) but not at discharge (RR 0.87, 95% CI 0.65-1.17), extubation failure rates (RR 0.76, 95% CI 0.64-0.89), and the incidence of BPD at 28 (RR 0.87, 95% CI 0.81-0.94) and 36 weeks PMA (RR 0.72, 95% CI 0.61-0.85).",
"   </p>",
"   <p>",
"    Although these reviews demonstrated the benefits of postnatal systemic glucocorticoids in reducing the incidence of BPD at 28 and 36 weeks PMA and increasing the likelihood of earlier extubation, glucocorticoid therapy was associated with significant short- and long-term complications regardless of the timing of its administration. These meta-analyses concluded that the potential benefit of routine postnatal glucocorticoid therapy in either prevention or treatment of established BPD may not outweigh its known adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the late administration of glucocorticoids may reduce neonatal mortality, it remains unclear whether there are long-term neurologic sequelae. As a result, these reviews concluded that postnatal glucocorticoid therapy",
"    <strong>",
"     not",
"    </strong>",
"    be used routinely until further research shows that its benefits clearly outweigh its known complications, but late administration may be considered in certain selected infants who cannot be weaned from mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/3\">",
"     3",
"    </a>",
"    ]. These infants are at high risk for BPD, and other systematic reviews suggest that administration of glucocorticoids to these patients decreases the risk of death or cerebral palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/4\">",
"     4",
"    </a>",
"    ]. In these patients, if glucocorticoids are administered, the dose and duration should be minimized. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Risk/benefit of systemic therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H6\">",
"     'Long-term outcome'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H11\">",
"     'Our approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Short-term adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The previously mentioned meta-analyses have shown that postnatal systemic glucocorticoids (particularly",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ) are associated with the following short-term complications [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hyperglycemia",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Gastrointestinal bleeding",
"     </li>",
"     <li>",
"      Gastrointestinal perforation",
"     </li>",
"     <li>",
"      Infection",
"     </li>",
"     <li>",
"      Hypertrophic cardiomyopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In most of the above studies,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    has been the glucocorticoid used. However, adverse effects have been seen with other glucocorticoid preparations. As an example, a multicenter study trial that compared low-dose",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    with placebo in mechanically ventilated extremely low birth weight (ELBW) infants (birth weight less than 1000 g) stopped enrollment because of increased spontaneous intestinal perforation in the hydrocortisone-treated group compared with controls (nine versus two) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Long-term outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up studies have raised concerns that postnatal systemic glucocorticoid therapy contributes to neurodevelopmental impairment, especially cerebral palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/4,6-8\">",
"     4,6-8",
"    </a>",
"    ]. In most of these studies, infants were treated with pharmacologic doses of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    In a review of 20 randomized controlled trials, the risk of cerebral palsy was greater in infants who received glucocorticoid therapy than control infants (15.2 versus 10.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/4\">",
"     4",
"    </a>",
"    ]. In nine studies, the relative risk of cerebral palsy appeared to increase with administration of early glucocorticoids (before one week of age) to prevent BPD compared with controls (15.4 versus 8.9 percent).",
"   </p>",
"   <p>",
"    Because the majority of trials had contamination of the control group, as many received glucocorticoid therapy at the discretion of their care providers [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/4,8\">",
"     4,8",
"    </a>",
"    ], a subgroup analysis was performed using two trials of 154 patients in which no glucocorticoid therapy was given to control patients. In this analysis, glucocorticoids compared with placebo reduced the mortality rate but was associated with an increased risk of cerebral palsy compared with the overall group (relative difference, 12 percent).",
"   </p>",
"   <p>",
"    The two previously discussed Cochrane meta-analyses also evaluated long-term outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the meta-analysis of trials with early administration of glucocorticoid therapy (before eight days of age), long-term data from 12 of the 28 trials showed early",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      treatment was associated with increased risk of an abnormal neurologic examination, developmental delay, cerebral palsy, and the combined outcomes of death and cerebral palsy, and death and abnormal neurologic examination [",
"      <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the meta-analysis of trials with late administration of glucocorticoid therapy (after seven days of age), long-term data from 11 of 19 trials showed no difference between the glucocorticoid and placebo-treated groups in the rates of cerebral palsy, major disabilities, combined outcome of death and cerebral palsy, and combined outcome of death and major disabilities [",
"      <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/2\">",
"       2",
"      </a>",
"      ]. However, glucocorticoid therapy was associated with an increased likelihood of an abnormal neurologic examination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a trial that was not included in the above reviews, long-term outcome was reported in 150 adolescents (13 to 17 years of age) who were originally enrolled in a randomized multicenter trial of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    in preterm infants who were greater than two weeks of age and dependent on oxygen therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. There were no differences between the two groups in academic performance, pulmonary function and symptoms, growth, or blood pressure. However, there was a trend towards an increase in the incidence of cerebral palsy in patients who received dexamethasone compared with controls (24 versus 15 percent). There was open-label use of glucocorticoids in the placebo group.",
"   </p>",
"   <p>",
"    Changes in brain anatomy have also been reported with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    administration. As an example, magnetic resonance imaging (MRI) performed at a mean age of 40 weeks PMA detected a reduction in total and regional cerebral volume in an observational study of 11 infants treated with dexamethasone compared with 30 infants who did not receive postnatal glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/11\">",
"     11",
"    </a>",
"    ]. The authors postulated that these changes may be the structural antecedents of neuromotor and cognitive abnormalities reported after postnatal administration of dexamethasone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Glucocorticoid dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;It remains uncertain whether lowering the dose of glucocorticoid therapy lowers the incidence of adverse effects so that the risks are clearly outweighed by the benefits of glucocorticoid therapy.",
"   </p>",
"   <p>",
"    Several cohort studies have reported an increasing risk of neurological impairment with higher doses of glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multicenter prospective cohort study, infants exposed to postnatal glucocorticoid therapy (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      in 92 percent of cases) compared with nonexposed infants were more likely to have neurodevelopmental impairment [",
"      <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/12\">",
"       12",
"      </a>",
"      ]. Each increase of 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in dexamethasone dose was associated with a 2-point reduction in the Bayley Mental Developmental Index (Bayley MDI) score, and a 40 percent increase in risk for disabling cerebral palsy at 18 to 22 months corrected age.",
"     </li>",
"     <li>",
"      In the EPICure study (a large English prospective cohort study of preterm infants born &lt;26 weeks gestation), postnatal glucocorticoid therapy was associated with an increased risk for CP in a dose-dependent fashion [",
"      <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, a meta-analysis of six small randomized controlled trials reported no differences between preterm infants exposed to high (&gt;2.7",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    versus low cumulative",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    dosage (&lt;2.7",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    in mortality or the incidence of neurodevelopmental impairment (cerebral palsy, Bayley MDI score &lt;2 SD, and visual impairment) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/15\">",
"     15",
"    </a>",
"    ]. The high cumulative dexamethasone dose group had a lower rate of BPD than the low dose group. Interpretation of these data is limited by the small sample size of each of the clinical trials, the heterogeneity of study populations, and, in some studies, the lack of follow-up data and the uncontrolled use of late rescue glucocorticoid therapy.",
"   </p>",
"   <p>",
"    These studies demonstrate that while high-dose",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    is associated with both short and long-term adverse outcomes, it remains uncertain whether low dose glucocorticoid therapy is effective and safe in preterm infants at-risk for or with established BPD [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Hydrocortisone vs dexamethasone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    has been the glucocorticoid preparation most commonly used in the prevention and treatment of BPD. Adverse effects, including cerebral palsy, have been primarily associated with postnatal dexamethasone therapy. In contrast, several studies reported that postnatal",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    therapy was not associated with significant neurologic sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/16-19\">",
"     16-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one trial, follow-up neurodevelopmental evaluation was performed at 18 to 24 months corrected age in patients who were randomly assigned as mechanically ventilated ELBW infants (BW &lt;1000 g) to either early administration of low-dose",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for 12 days) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/18\">",
"     18",
"    </a>",
"    ]. The initial trial had been stopped because of increased incidence of spontaneous intestinal perforation in the hydrocortisone-treated group compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/5\">",
"     5",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were no differences in the rates of cerebral palsy (13 versus 14 percent), neurological impairment (39 versus 44 percent), or physical growth parameters",
"     </li>",
"     <li>",
"      Fewer patients who received",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      compared with controls had a Bayley MDI score below 70",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"       Hydrocortisone",
"      </a>",
"      -treated group compared with controls had a higher rate of spontaneous intestinal perforation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In an observational study, 62 of 226 school age children (between 7 and 10 years of age) of an original cohort of 375 preterm infants (birth weight &lt;1500 g) received postnatal",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    to treat their BPD at a starting dose of 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for a median duration of 27.5 days [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/17\">",
"     17",
"    </a>",
"    ]. The neurodevelopmental outcome of these patients and the remaining 164 patients who did not receive postnatal glucocorticoid therapy were compared. After adjusting for confounding variables, there were no differences in cognitive and motor skill function, MRI findings, or rate of cerebral palsy (11 versus 7 percent) between the two groups. The authors reported there was no increased risk of intestinal perforation with hydrocortisone administration, although no data were provided.",
"   </p>",
"   <p>",
"    The authors of these studies and others suggest that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    compared with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    may be associated with a better neurodevelopmental outcome because of differences in effective glucocorticoid dose due to variations in activity, half-life, and binding to brain receptor sites between the two glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/3,16-18,20,21\">",
"     3,16-18,20,21",
"    </a>",
"    ]. Differences in binding receptors may have a long-term effect on the hypothalamus-pituitary-adrenal axis. In one small study, children (age range 7 to 10 years) who as neonates received dexamethasone treatment had lower cortisol levels in response to a social stress test compared with those who received neonatal hydrocortisone therapy or matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/22\">",
"     22",
"    </a>",
"    ]. In addition, the cardiovascular stress response of eight year-old children born before 32 weeks gestation may be decreased in those who received dexamethasone compared with others who received hydrocortisone during the neonatal period [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/23\">",
"     23",
"    </a>",
"    ]. However, the clinical significance of these results is uncertain.",
"   </p>",
"   <p>",
"    The differences in neurodevelopmental outcome between the two glucocorticoids may be explained by the differences in the effective glucocorticoid dose [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, animal studies report differential binding of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    and cortisol to glucocorticoid and mineralocorticoid receptors that may result in differences in stress response and brain cell damage, particularly in the area of the hippocampus, which is critical to learning, memory, and spatial processing [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. A study in a neonatal mouse model reported the effects of different glucocorticoids upon brain development on the sonic hedgehog (Shh) signaling pathway, a regulator of brain development [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/27\">",
"     27",
"    </a>",
"    ]. The chronic use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/30/35296?source=see_link\">",
"     prednisolone",
"    </a>",
"    , and dexamethasone suppressed Shh-induced proliferation of cerebellar progenitor cells. However, in animals treated with hydrocortisone and prednisolone, Shh signaling was also protective against glucocorticoid-induced cerebellar injury by inducing the enzyme 11 beta-hydroxysteroid dehydrogenase type 2 (11 beta-HSD2), which converted these two glucocorticoids to inactive cortisone. But, 11 beta-HSD2 is unable to inactivate dexamethasone, so animals treated with dexamethasone do not benefit from the induction of this enzyme.",
"   </p>",
"   <p>",
"    Still unresolved is the question of whether",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    is associated with an increased risk of spontaneous intestinal perforation. It has been suggested that the increased rate of intestinal perforation seen in the trial of early administration of hydrocortisone may be due to an interaction with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    , and that avoiding concomitant therapy may prevent this complication [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/17,20\">",
"     17,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the results are encouraging regarding the neurodevelopmental outcome in preterm infants treated with low-dose",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    , large clinical randomized trials are required to determine whether postnatal hydrocortisone therapy is efficacious and safe in treating infants with established BPD or those at high risk for BPD, and the most appropriate dosing regimen. Until such data exist, we recommend",
"    <strong>",
"     not",
"    </strong>",
"    to routinely administer hydrocortisone, but only use it as part of a clinical trial. The one possible exception is that of the infant with established BPD and severe respiratory failure who requires high levels of ventilator and oxygen support. If the decision is made to administer glucocorticoid therapy, limited data suggest hydrocortisone is the preferred agent. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Our approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Risk/benefit of systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the above discussion, it appears that the routine administration of postnatal glucocorticoid therapy would result in needless exposure of the known adverse effects of this intervention to a large number of preterm infants. In particular, the use of postnatal glucocorticoid to prevent BPD may result in unnecessary treatment to the majority of at-risk patients, as the incidence of BPD is about 20 percent in very low birth weight (VLBW) infants (birth weight &lt;1500 g) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathogenesis and clinical features of bronchopulmonary dysplasia\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, it remains unclear whether there is a select population of preterm infants, at highest risk, in whom the benefits of glucocorticoid therapy clearly outweigh the known adverse effects. In particular, data conflict on whether glucocorticoid therapy increases the survival rate of infants with established BPD.",
"   </p>",
"   <p>",
"    Data from several studies suggested that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    improved survival in infants who were at increased risk of neurologic impairment as opposed to the alternative theory that dexamethasone independently contributed to brain injury and cerebral palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/4,29\">",
"     4,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a previously mentioned meta-analysis, postnatal glucocorticoid therapy in a population of preterm infants with established BPD decreased the combined risk of death or major neurological disabilities [",
"      <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a trial of 118 infants who were ventilator-dependent at 15 and 25 days of age,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      -treated survivors were more likely than controls to have cerebral palsy (25 versus 7 percent) and abnormal neurological examinations (45 versus 16) at one year of age [",
"      <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/29\">",
"       29",
"      </a>",
"      ]. However, survival to one year tended to be greater in the dexamethasone-treated infants versus those who received placebo (88 versus 74 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One interpretation of these results is that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    improved the survival rate of infants with BPD, who are at risk for neurodevelopment impairment.",
"   </p>",
"   <p>",
"    In contrast, other studies have demonstrated that a decrease in glucocorticoid use was associated with either a decrease or no change in mortality.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of three large neonatal network databases, a reduction in steroid use was not associated with significant changes in the mortality, and the incidence and severity of BPD [",
"      <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An analysis of the Israel National VLBW Neonatal Database demonstrated a reduction in postnatal glucocorticoid use was associated with a decrease in mortality but an increase in BPD [",
"      <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/31\">",
"       31",
"      </a>",
"      ]. The increase in incidence of BPD was associated with only moderate increases in oxygen requirements, suggesting that postnatal glucocorticoids may only have a modest beneficial effect on lung function of preterm infants with BPD [",
"      <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective study of ELBW infants born in Victoria, Australia during three distinct eras, similar results were noted of a decrease use of postnatal glucocorticoid therapy in 2005 compared with earlier time periods, which was",
"      <strong>",
"       not",
"      </strong>",
"      associated with a change in mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/32\">",
"       32",
"      </a>",
"      ]. In addition, there was no change in the rate of major neurologic disabilities (defined as",
"      <span class=\"nowrap\">",
"       severe/moderate",
"      </span>",
"      cerebral palsy, scores on cognitive tests below two standard deviations below the mean, blindness or deafness), but there was an increase in the incidence of BPD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these studies demonstrated that a reduction in the use of postnatal steroids did not result in an increase in mortality, the increased or no change in survival rate may be due to improvements in other areas of neonatal intensive care. These confounding factors may have masked any beneficial effect of glucocorticoid therapy on mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Unanswered questions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In summary, despite many studies, it remains unknown whether there is a role for postnatal glucocorticoid therapy in certain select premature infants with BPD, because the treatment decision is complex, risks are significant, confounding factors are present, and data are insufficient.",
"   </p>",
"   <p>",
"    Well designed, randomized controlled trials are required to answer the following questions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Is there a population of preterm infants in whom the benefits outweigh the risks of postnatal glucocorticoids?",
"     </li>",
"     <li>",
"      If there is a subset of infants who have an overall benefit from postnatal glucocorticoids, what is the most appropriate form of glucocorticoid to use and the most optimal drug regimen (ie, timing and dosing)? (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Hydrocortisone vs dexamethasone'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Do short-term improvements in pulmonary function associated with glucocorticoid administration exert any beneficial effect on the development of severe pulmonary hypertension and cor pulmonale, the most significant long-term pulmonary complication? (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17034?source=see_link\">",
"       \"Pulmonary outcomes of bronchopulmonary dysplasia\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Until clinical trials can conclusively answer these questions, clinicians must review the currently available data and use their best judgement in deciding whether the potential benefits outweigh the adverse effects of systemic glucocorticoid therapy for their individual patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5429943\">",
"    <span class=\"h3\">",
"     AAP guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the available limited data, the 2010 revised American Academy Pediatrics (AAP) policy statement provided the following conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the absence of data from randomized control trials (RCT), high-dose",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (about 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) cannot be recommended in the management and prevention of BPD.",
"     </li>",
"     <li>",
"      Data are insufficient to make a recommendation in the use of low-dose",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (&lt;0.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) in the management of BPD.",
"     </li>",
"     <li>",
"      Data are insufficient to recommend early treatment with low-dose",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      treatment (1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) in the first two weeks of life, although, there may be a subpopulation of patients that may benefit from such therapy.",
"     </li>",
"     <li>",
"      Data are insufficient to recommend the use of higher dose",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      (3 to 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) after the first week of life in the management of BPD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concerns about long-term neurologic sequelae have led to the recommendations of restrictive use of glucocorticoid therapy in the preterm infant by both the AAP and the Canadian Paediatric Society",
"    <span class=\"nowrap\">",
"     (AAP/CPS).",
"    </span>",
"   </p>",
"   <p>",
"    In",
"    our practice, the following approach is used in decision making regarding the use of postnatal glucocorticoid therapy based upon the data presented above:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The early use of systemic glucocorticoids to prevent BPD unnecessarily exposes the majority of preterm infants, who would not develop BPD, to the known short-term and long-term adverse effects of glucocorticoids. As a result, we do",
"      <strong>",
"       not",
"      </strong>",
"      recommend the routine use of glucocorticoids to prevent BPD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=see_link&amp;anchor=H6#H6\">",
"       \"Pathogenesis and clinical features of bronchopulmonary dysplasia\", section on 'Epidemiology'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H9\">",
"       'Risk/benefit of systemic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although systemic glucocorticoid therapy improves lung function in infants with BPD, the magnitude of both the short- and long-term benefits are unclear. Based upon the current evidence, the use of systemic glucocorticoid therapy in patients is not justified, because potential benefit is outweighed by established short and long-term adverse events. As a result, for most preterm infants, we recommend",
"      <strong>",
"       not",
"      </strong>",
"      treating infants with BPD with postnatal glucocorticoids outside of a clinical trial.",
"     </li>",
"     <li>",
"      We consider the use of systemic glucocorticoid therapy to infants greater than two to three weeks of age with severe BPD who require sustained substantial maximal ventilatory and oxygen support (FiO2 &gt;80 percent) in an attempt to reduce further injury from high airway pressure and high oxygen concentration. In some cases, these infants have reached term PMA or beyond and are experiencing an episode of acute deterioration, which may be associated with severe pulmonary hypertension. In these circumstances, we use",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      in a starting dose of 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day based upon limited evidence from cohort studies [",
"      <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/21\">",
"       21",
"      </a>",
"      ] that hydrocortisone may have lower risk of adverse neurologic sequelae than",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      . A clinical response (defined as a decrease in respiratory support) is typically seen on the second or third day following initiation of treatment. If there is no response, we recommend discontinuing hydrocortisone therapy. If there is a response (defined as a decrease in respiratory support), the infant is treated with this dose for 24 to 48 hours, and then hydrocortisone is tapered over a period of 7 to 10 days. We do not recommend continuing treatment beyond this time. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Hydrocortisone vs dexamethasone'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     INHALED GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although inhaled glucocorticoids may provide some short-term benefit while avoiding the adverse effects of systemic administration, little evidence supports their use in the prevention or treatment of bronchopulmonary dysplasia (BPD) in preterm infants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Prevention of BPD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postnatal administration of inhaled glucocorticoids does not prevent BPD, as illustrated by the following systematic reviews:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis of trials that enrolled mechanically ventilated preterm infants with birth weights &lt;1500 g who received inhaled glucocorticoid therapy within the first two weeks of life, there were no differences in the incidence of BPD at 28 days of age or 36 weeks postmenstrual age (PMA), mortality, and the composite outcome of BPD and death between patients who assigned inhaled glucocorticoid and the placebo-treated group [",
"      <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/34\">",
"       34",
"      </a>",
"      ]. There was also no difference in the risk of adverse events between the two groups.",
"     </li>",
"     <li>",
"      Similar findings were noted in a second meta-analysis that included trials of preterm infants &ge;7 days postnatal age but before 36 weeks PMA who received supplemental oxygen or mechanical ventilation, or both [",
"      <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/35\">",
"       35",
"      </a>",
"      ]. There were no differences in the risk of BPD, mortality, or composite outcome of BPD and death between patients who were treated with inhaled glucocorticoids and those who received placebo. Inhaled steroids also did not affect short-term respiratory outcomes, including failure to extubate and total duration of mechanical ventilation or oxygen dependency. Data were limited regarding adverse effects as the number of patients in this review was small and there was a great deal of heterogeneity amongst the included trials. There was a trend towards a decrease in the use of systematic glucocorticoid therapy in the group of patients assigned to inhaled glucocorticoid therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on these results, we do not recommend the use of inhalation glucocorticoids to reduce the risk of BPD.",
"   </p>",
"   <p>",
"    A trial of 116 of preterm infants (birth weight less than 1500 g) demonstrated improved combined outcome of death and or BPD in those who were randomly selected to receive intratracheal",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/48/35584?source=see_link\">",
"     budesonide",
"    </a>",
"    instillation with surfactant administration compared with controls who only received surfactant (32 versus 61 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/36\">",
"     36",
"    </a>",
"    ]. Follow-up evaluation of 67 of the 75 survivors between two and three years of age found similar physical growth, neurologic examinations, and Bayley MDI and PDI scores between the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/37\">",
"     37",
"    </a>",
"    ]. Larger trials are needed to confirm the beneficial effects of intratracheal budesonide before this intervention can be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment of BPD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current studies provide little evidence of benefit of inhaled glucocorticoids for infants with established BPD [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Neonatal European Study of Inhaled Steroids (NEUROSIS) is currently enrolling 850 infants who are 23 to 27 weeks postmenstrual age and require either mechanical ventilation or continuous positive airway pressure (CPAP) to a randomized trial of inhaled steroids versus placebo in the first 12 hours of life [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There also appears to be no difference in the effectiveness of inhaled versus systemic glucocorticoid therapy in ventilator-dependent preterm infants. In a meta-analysis that included five trials, there were no differences in mortality, duration of oxygen therapy or intubation, or the incidences of BPD and short-term adverse effects between infants treated with inhaled or systemic glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3353/abstract/41\">",
"     41",
"    </a>",
"    ]. There were no data on long-term outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Our approach to inhaled steroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our approach to inhaled glucocorticoid therapy to prevent and treat BPD is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Based upon currently available data, we do",
"      <strong>",
"       not",
"      </strong>",
"      recommend the early use of inhaled glucocorticoids to prevent BPD.",
"     </li>",
"     <li>",
"      Despite the limited data on the efficacy of inhaled glucocorticoids, we will occasionally use inhaled glucocorticoids in selected infants greater than 40 weeks PMA who have severe BPD, are dependent upon substantial ventilator and oxygen support, and have signs of severe airway obstruction or reactive airway disease. Our goal in such patients is to improve short-term pulmonary function and reduce the number of days of mechanical ventilation and exposure to high oxygen concentration. The appropriate doses are uncertain and the long-term effects of this approach have not been evaluated.",
"      <br/>",
"      <br/>",
"      If there are signs of improvement in pulmonary function (decreasing PCO2, improved oxygenation, or diminished wheezing), treatment may be continued for 7 to 10 days. We do not administer systematic steroids concurrently, and we do not recommend chronic use of inhaled steroids in BPD patients (with the exception of older infants who develop the typical course of asthma).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants with a birth weight less than 1250 g or a gestational age less than 30 weeks are at high-risk for developing bronchopulmonary dysplasia (BPD) with an incidence of about 20 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=see_link&amp;anchor=H6#H6\">",
"       \"Pathogenesis and clinical features of bronchopulmonary dysplasia\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Postnatal glucocorticoid therapy administered systemically has been shown to improve the pulmonary outcome of infants with established bronchopulmonary dysplasia (BPD) and prevent BPD in high-risk preterm infants. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Benefits'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic glucocorticoid therapy has significant adverse effects during its administration, which include hyperglycemia, hypertension, and gastrointestinal bleeding and perforation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Short-term adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postnatal systemic glucocorticoid therapy, particularly",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , increases the risk of cerebral palsy in preterm infants. It is unclear whether systemic glucocorticoid therapy is associated with other significant long-term neurologic disabilities, such as decreased cognitive function, because the limited available data are inconsistent. In addition, it remains unknown whether specific glucocorticoids (ie,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      and dexamethasone) differ in their long-term adverse effects. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Long-term outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inhaled glucocorticoids may provide some short-term pulmonary benefit while avoiding the adverse effects of systemic administration. However, postnatal administration of inhaled glucocorticoids does not prevent BPD, and it is unclear whether inhaled glucocorticoids provide any long-term benefit in infants with BPD. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Inhaled glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In our practice, we follow the revised 2010 American Academy of Pediatrics (AAP) published guidelines in the use of postnatal glucocorticoid therapy for BPD as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend",
"      <strong>",
"       NOT",
"      </strong>",
"      to use postnatal systemic glucocorticoid therapy to prevent BPD (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The early routine use of systemic glucocorticoids to prevent BPD unnecessarily exposes the majority of preterm infants, who would not develop BPD, to the known short-term and long-term adverse effects of glucocorticoids. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Systemic steroids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most preterm infants with established BPD, we recommend",
"      <strong>",
"       NOT",
"      </strong>",
"      routinely treating infants with BPD with postnatal systemic glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Based upon current data, the potential benefit of glucocorticoid therapy is not justified because of its known short and long-term adverse effects. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Systemic steroids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In our practice, we consider the use of systemic glucocorticoid therapy in infants greater than two to three weeks of age with severe BPD who require substantial ventilatory and oxygen support. Under these circumstances, we suggest the use of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      (starting dose of 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) rather than",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Our approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Hydrocortisone vs dexamethasone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do",
"      <strong>",
"       NOT",
"      </strong>",
"      recommend the use of inhaled glucocorticoids to prevent BPD (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In our practice, we use inhaled steroids only in selected infants with severe BPD who are dependent upon substantial pulmonary support (eg, mechanical ventilation and high concentrations of supplemental oxygen). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Inhaled glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/1\">",
"      Halliday HL, Ehrenkranz RA, Doyle LW. Early (&lt; 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2009; :CD001146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/2\">",
"      Halliday HL, Ehrenkranz RA, Doyle LW. Late (&gt;7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2009; :CD001145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/3\">",
"      Watterberg KL, American Academy of Pediatrics. Committee on Fetus and Newborn. Policy statement--postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics 2010; 126:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/4\">",
"      Doyle LW, Halliday HL, Ehrenkranz RA, et al. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics 2005; 115:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/5\">",
"      Watterberg KL, Gerdes JS, Cole CH, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 2004; 114:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/6\">",
"      O'Shea TM, Kothadia JM, Klinepeter KL, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics 1999; 104:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/7\">",
"      Doyle L, Davis P. Postnatal corticosteroids in preterm infants: systematic review of effects on mortality and motor function. J Paediatr Child Health 2000; 36:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/8\">",
"      Barrington KJ. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr 2001; 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/9\">",
"      Jones RA, Collaborative Dexamethasone Trial Follow-up Group. Randomized, controlled trial of dexamethasone in neonatal chronic lung disease: 13- to 17-year follow-up study: II. Respiratory status, growth, and blood pressure. Pediatrics 2005; 116:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/10\">",
"      Jones RA, Collaborative Dexamethasone Trial Follow-up Group. Randomized, controlled trial of dexamethasone in neonatal chronic lung disease: 13- to 17-year follow-up study: I. Neurologic, psychological, and educational outcomes. Pediatrics 2005; 116:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/11\">",
"      Parikh NA, Lasky RE, Kennedy KA, et al. Postnatal dexamethasone therapy and cerebral tissue volumes in extremely low birth weight infants. Pediatrics 2007; 119:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/12\">",
"      Wilson-Costello D, Walsh MC, Langer JC, et al. Impact of postnatal corticosteroid use on neurodevelopment at 18 to 22 months' adjusted age: effects of dose, timing, and risk of bronchopulmonary dysplasia in extremely low birth weight infants. Pediatrics 2009; 123:e430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/13\">",
"      Wood NS, Costeloe K, Gibson AT, et al. The EPICure study: associations and antecedents of neurological and developmental disability at 30 months of age following extremely preterm birth. Arch Dis Child Fetal Neonatal Ed 2005; 90:F134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/14\">",
"      Needelman H, Evans M, Roberts H, et al. Effects of postnatal dexamethasone exposure on the developmental outcome of premature infants. J Child Neurol 2008; 23:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/15\">",
"      Onland W, De Jaegere AP, Offringa M, van Kaam AH. Effects of higher versus lower dexamethasone doses on pulmonary and neurodevelopmental sequelae in preterm infants at risk for chronic lung disease: a meta-analysis. Pediatrics 2008; 122:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/16\">",
"      Lodygensky GA, Rademaker K, Zimine S, et al. Structural and functional brain development after hydrocortisone treatment for neonatal chronic lung disease. Pediatrics 2005; 116:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/17\">",
"      Rademaker KJ, Uiterwaal CS, Groenendaal F, et al. Neonatal hydrocortisone treatment: neurodevelopmental outcome and MRI at school age in preterm-born children. J Pediatr 2007; 150:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/18\">",
"      Watterberg KL, Shaffer ML, Mishefske MJ, et al. Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. Pediatrics 2007; 120:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/19\">",
"      Needelman H, Hoskoppal A, Hoskappal A, et al. The effect of hydrocortisone on neurodevelopmental outcome in premature infants less than 29 weeks' gestation. J Child Neurol 2010; 25:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/20\">",
"      Watterberg KL. Postnatal steroids for bronchopulmonary dysplasia: where are we now? J Pediatr 2007; 150:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/21\">",
"      van der Heide-Jalving M, Kamphuis PJ, van der Laan MJ, et al. Short- and long-term effects of neonatal glucocorticoid therapy: is hydrocortisone an alternative to dexamethasone? Acta Paediatr 2003; 92:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/22\">",
"      Karemaker R, Kavelaars A, ter Wolbeek M, et al. Neonatal dexamethasone treatment for chronic lung disease of prematurity alters the hypothalamus-pituitary-adrenal axis and immune system activity at school age. Pediatrics 2008; 121:e870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/23\">",
"      Karemaker R, Karemaker JM, Kavelaars A, et al. Effects of neonatal dexamethasone treatment on the cardiovascular stress response of children at school age. Pediatrics 2008; 122:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/24\">",
"      Hassan AH, von Rosenstiel P, Patchev VK, et al. Exacerbation of apoptosis in the dentate gyrus of the aged rat by dexamethasone and the protective role of corticosterone. Exp Neurol 1996; 140:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/25\">",
"      De Kloet ER, Vreugdenhil E, Oitzl MS, Jo&euml;ls M. Brain corticosteroid receptor balance in health and disease. Endocr Rev 1998; 19:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/26\">",
"      McEwen BS. The brain is an important target of adrenal steroid actions. A comparison of synthetic and natural steroids. Ann N Y Acad Sci 1997; 823:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/27\">",
"      Heine VM, Rowitch DH. Hedgehog signaling has a protective effect in glucocorticoid-induced mouse neonatal brain injury through an 11betaHSD2-dependent mechanism. J Clin Invest 2009; 119:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/28\">",
"      Lemons JA, Bauer CR, Oh W, et al. Very low birth weight outcomes of the National Institute of Child health and human development neonatal research network, January 1995 through December 1996. NICHD Neonatal Research Network. Pediatrics 2001; 107:E1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/29\">",
"      Kothadia JM, O'Shea TM, Roberts D, et al. Randomized placebo-controlled trial of a 42-Day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants. Pediatrics 1999; 104:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/30\">",
"      Walsh MC, Yao Q, Horbar JD, et al. Changes in the use of postnatal steroids for bronchopulmonary dysplasia in 3 large neonatal networks. Pediatrics 2006; 118:e1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/31\">",
"      Shinwell ES, Lerner-Geva L, Lusky A, Reichman B. Less postnatal steroids, more bronchopulmonary dysplasia: a population-based study in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2007; 92:F30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/32\">",
"      Cheong JL, Anderson P, Roberts G, et al. Postnatal corticosteroids and neurodevelopmental outcomes in extremely low birthweight or extremely preterm infants: 15-year experience in Victoria, Australia. Arch Dis Child Fetal Neonatal Ed 2013; 98:F32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/33\">",
"      Bose CL, Laughon MM. Corticosteroids and chronic lung disease: time for another randomized, controlled trial? Pediatrics 2005; 115:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/34\">",
"      Shah V, Ohlsson A, Halliday HL, Dunn MS. Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev 2007; :CD001969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/35\">",
"      Onland W, Offringa M, van Kaam A. Late (&ge; 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev 2012; 4:CD002311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/36\">",
"      Yeh TF, Lin HC, Chang CH, et al. Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study. Pediatrics 2008; 121:e1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/37\">",
"      Kuo HT, Lin HC, Tsai CH, et al. A follow-up study of preterm infants given budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants. J Pediatr 2010; 156:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/38\">",
"      Beresford MW, Primhak R, Subhedar NV, Shaw NJ. Randomised double blind placebo controlled trial of inhaled fluticasone propionate in infants with chronic lung disease. Arch Dis Child Fetal Neonatal Ed 2002; 87:F62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/39\">",
"      Dugas MA, Nguyen D, Frenette L, et al. Fluticasone inhalation in moderate cases of bronchopulmonary dysplasia. Pediatrics 2005; 115:e566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/40\">",
"      Bassler D, Halliday HL, Plavka R, et al. The Neonatal European Study of Inhaled Steroids (NEUROSIS): an eu-funded international randomised controlled trial in preterm infants. Neonatology 2010; 97:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3353/abstract/41\">",
"      Shah SS, Ohlsson A, Halliday HL, Shah VS. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database Syst Rev 2012; 5:CD002057.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5023 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-201.211.0.116-CD31FC9A36-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_17_3353=[""].join("\n");
var outline_f3_17_3353=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SYSTEMIC STEROIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Benefits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Short-term adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Long-term outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Glucocorticoid dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Hydrocortisone vs dexamethasone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Risk/benefit of systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Unanswered questions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5429943\">",
"      - AAP guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      INHALED GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Prevention of BPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment of BPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Our approach to inhaled steroids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/24/15753?source=related_link\">",
"      Management of bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=related_link\">",
"      Pathogenesis and clinical features of bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27880?source=related_link\">",
"      Prevention of bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17034?source=related_link\">",
"      Pulmonary outcomes of bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_17_3354="Treatment of severe asthma in adolescents and adults";
var content_f3_17_3354=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of severe asthma in adolescents and adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/17/3354/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/17/3354/contributors\">",
"     Sally Wenzel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/17/3354/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/17/3354/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/17/3354/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/17/3354/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/17/3354/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classification of \"severe asthma\" refers to patients who require high dose inhaled glucocorticoid (GC), or continuous or near continuous oral GC treatment to maintain asthma control. In addition to at least one of these two major criteria, the working definition of severe asthma proposed by the American Thoracic Society requires the presence of at least two of seven minor criteria (",
"    <a class=\"graphic graphic_table graphicRef68983 \" href=\"UTD.htm?12/20/12620\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The NAEPP and GINA guidelines have a slightly different category of \"severe persistent asthma\" that describes patients who have frequent and severe asthma symptoms and evidence of airflow limitation, but are not on asthma controller medication (",
"    <a class=\"graphic graphic_table graphicRef58247 \" href=\"UTD.htm?32/48/33549\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Patients with severe asthma (by ATS criteria) generally require high doses of controller medications to achieve control; without these medications their asthma is either \"not well controlled\" or \"very poorly controlled\" by",
"    <span class=\"nowrap\">",
"     NAEPP/GINA",
"    </span>",
"    criteria (",
"    <a class=\"graphic graphic_table graphicRef65972 \" href=\"UTD.htm?15/31/15869\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Achieving the usual goals of asthma treatment (prevent chronic and troublesome symptoms, normalize pulmonary function, maintain normal activity levels, prevent exacerbations, improve health-related quality of life, and provide optimal pharmacotherapy with minimal or no adverse effects) may not be fully possible in patients with severe asthma. It may be necessary to accept some degree of reduced activity and persistent airflow limitation, and to focus instead on reducing the frequency and severity of exacerbations and hospitalizations, avoiding further loss of pulmonary function, and limiting toxicity from medications.",
"   </p>",
"   <p>",
"    The evaluation of patients with severe asthma symptoms, a general overview of asthma management, and a review of nonpharmacologic management are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14105?source=see_link\">",
"     \"Evaluation of severe asthma in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=see_link\">",
"     \"Trigger control to enhance asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment issues that pertain to patients with severe asthma are reviewed here. Treatment approaches to mild and moderate persistent asthma are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18154?source=see_link\">",
"     \"Treatment of intermittent and mild persistent asthma in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26745?source=see_link\">",
"     \"Treatment of moderate persistent asthma in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL TREATMENT PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of severe asthma frequently requires a multidisciplinary approach to address patient education needs, remediate irritant and allergic triggers, treat comorbidities, and design an optimal medication regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;A written asthma action plan is recommended for all patients with severe asthma (",
"    <a class=\"graphic graphic_form graphicRef55900 \" href=\"UTD.htm?36/39/37498\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/2\">",
"     2",
"    </a>",
"    ]. Either a symptom or peak flow based plan may be used; although evidence shows similar benefits, patients who are poor perceivers of dyspnea may benefit from a plan based on objective measure of airflow limitation. We frequently provide a prescription for a short course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (eg, 40 mg daily for 5 days) for patients to keep on hand and to start based on specific criteria in their action plan. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31991?source=see_link\">",
"     \"What do patients need to know about their asthma?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients may still not know how to use their inhalers correctly despite a long history of asthma; each patient's technique should be observed and correct technique carefully demonstrated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18856?source=see_link\">",
"     \"The use of inhaler devices in adults\"",
"    </a>",
"    and",
"    <span class=\"nowrap\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=see_link\">",
"      \"Delivery of inhaled medication in adults\"",
"     </a>",
"     .)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Compliance/adherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compliance/adherence",
"    to medications should be addressed at each visit, in partnership with the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/4\">",
"     4",
"    </a>",
"    ]. There are many reasons for non-adherence. Strategies to maintain adherence can be discussed while developing the action plan. If a medication is not subjectively or objectively improving the patient's symptoms or respiratory function after a three month trial, it should be stopped. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12789?source=see_link\">",
"     \"Enhancing patient adherence to asthma therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Controlling asthma triggers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ongoing exposure to asthma triggers is an important cause of poor asthma control in some patients. For patients with severe asthma who have no allergic component to their disease, allergen control measures will have little effect. Potential triggers that are identified during evaluation (eg, pets, dust mites, workplace exposures, tobacco smoke) need renewed strategies for control (",
"    <a class=\"graphic graphic_table graphicRef58870 \" href=\"UTD.htm?35/14/36076\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=see_link\">",
"     \"Trigger control to enhance asthma management\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H26\">",
"     'Treatment of comorbidities'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a regimen has been developed, we usually request that patients with severe asthma return for follow up visits at four to eight week intervals. We evaluate control using standardized questions, either the Asthma Control Questionnaire (ACQ) or Asthma Control Test (ACT) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Objective measures of airflow limitation (eg, peak expiratory flow, spirometry) are important; spirometry may need to be performed more frequently than in patients with milder asthma. In particular, we perform spirometry when there is a significant change in clinical status and to confirm that a step-down in medication has not caused a clinically-silent decline in lung function. Spirometry may also have utility in comparing the efficacy of various add-on controller agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SHORT-ACTING BETA AGONISTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled short-acting beta agonists (SABAs) should be prescribed for the relief of acute symptoms.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     Albuterol",
"    </a>",
"    , at a dose of 2 to 4 puffs, is commonly prescribed, although other equivalent agents are available (",
"    <a class=\"graphic graphic_table graphicRef72467 \" href=\"UTD.htm?15/34/15917\">",
"     table 5",
"    </a>",
"    ). This dose may be repeated twice within an hour if needed for an acute exacerbation. SABAs should only be used on an as needed basis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8618?source=see_link\">",
"     \"Beta agonists in asthma: Acute administration and prophylactic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients with severe asthma derive better symptom relief from nebulized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    , compared with the metered dose preparation. Patients should be advised to seek emergency department evaluation, if they are unimproved after two home nebulizer treatments within an hour.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INITIATING CONTROLLER THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients presenting with symptoms and objective measures consistent with NAEPP and GINA definitions of \"severe persistent asthma\" are not on controller therapy (",
"    <a class=\"graphic graphic_table graphicRef58247 \" href=\"UTD.htm?32/48/33549\">",
"     table 2",
"    </a>",
"    )&nbsp;(see",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. With addition of controller medication, many will improve enough that they do not meet ATS criteria for severe asthma (",
"    <a class=\"graphic graphic_table graphicRef68983 \" href=\"UTD.htm?12/20/12620\">",
"     table 1",
"    </a>",
"    ). This section will describe our approach to patients who meet",
"    <span class=\"nowrap\">",
"     NAEPP/GINA",
"    </span>",
"    criteria for \"severe persistent asthma\" at their initial visit.",
"   </p>",
"   <p>",
"    Initial controller agents for severe persistent asthma include oral and inhaled GCs, and long acting beta agonists. Generally, combination therapy with two or more controller agents will be needed to achieve improved control in patients with severe persistent asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Oral glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients who are not on any controller medication and meet NAEPP criteria for \"severe persistent asthma\" will need an initial, brief course of oral GC therapy to bring their asthma under control (",
"    <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/2\">",
"     2",
"    </a>",
"    ]. In deciding when to prescribe oral GC, we consider the severity of symptoms, degree of airflow limitation, and whether symptoms have been stable or worsening. In general, we prescribe a brief course of an oral GC to patients with frequent daytime or nocturnal symptoms, recent deterioration (eg, increased need for SABA), or a forced expiratory volume in one second (FEV1) less than 60 percent of predicted. The treatment of acute asthma exacerbations is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link\">",
"     \"Treatment of acute exacerbations of asthma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A reevaluation in two weeks will assess the response to therapy and determine the need for longer term, low dose oral GC versus transition to inhaled GC alone.",
"   </p>",
"   <p>",
"    A two to three week course of oral GC may also be considered in patients who have baseline stable airflow obstruction that does not reverse with inhaled bronchodilator. In this way, the degree of reversibility to GCs can be determined. The forced expiratory volume in one second (FEV1) at the end of the trial may be used as a goal for ongoing controller therapy, instead of the usual target of 80 percent of the predicted value.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Inhaled glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled GCs (called inhaled corticosteroids (ICS) in the NHLBI guidelines) that are high potency and used at a high dose are the foundation of long term controller therapy in severe asthma (",
"    <a class=\"graphic graphic_table graphicRef78011 \" href=\"UTD.htm?15/35/15934\">",
"     table 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef68143 \" href=\"UTD.htm?37/48/38668\">",
"     table 7",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/2,5,8,9\">",
"     2,5,8,9",
"    </a>",
"    ]. Several formulations are available; we usually choose one from the \"high potency\" group that allows for the least number of puffs per day. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=see_link\">",
"     \"Delivery of inhaled medication in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dose of inhaled GC is adjusted at subsequent visits based on asthma control. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Adjusting controller therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Long acting beta agonists (LABA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with severe asthma are treated with a combination of inhaled GC and a LABA (either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef68143 \" href=\"UTD.htm?37/48/38668\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/2,3,8\">",
"     2,3,8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Combination inhaled GC/LABA'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ADJUSTING CONTROLLER THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a patient who presents with severe asthma is receiving controller therapy with inhaled GCs and a LABA, subsequent visits are usually scheduled at four to eight week intervals. At these visits, therapy is adjusted based upon an assessment of asthma control and any adverse effects of medication, remembering that the degree of asthma control is determined by the most severe indicator of impairment (",
"    <a class=\"graphic graphic_table graphicRef65972 \" href=\"UTD.htm?15/31/15869\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who fail to achieve asthma control on inhaled GC doses around the equivalent of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    800 to 1000 mcg per day, or who have difficulty tapering oral GCs, should be reassessed for accuracy of the diagnosis, lack of adherence, ongoing exposure to asthma triggers, and comorbid conditions.",
"   </p>",
"   <p>",
"    If severe asthma is confirmed, based on ATS criteria (",
"    <a class=\"graphic graphic_table graphicRef68983 \" href=\"UTD.htm?12/20/12620\">",
"     table 1",
"    </a>",
"    ), explanations for persistent symptoms despite high dose combination therapy include: residual inflammation is relatively GC resistant, remodeling (not inflammation) is causing airflow limitation, and inflammation in the distal airways is not reached by the inhaled GCs. At this point, we consider several choices, which are discussed in more detail in the sections that follow:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trying a course of oral GC or an injection of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Systemic glucocorticoids'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Increasing the inhaled GC dose up to 1600 to 2000 mcg per day. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Inhaled glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adding or substituting an inhaled GC that has a small particle size. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Inhaled glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Addition of a third controller agent, such as an antileukotriene agent or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Antileukotriene agents'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H17\">",
"       'Theophylline'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Adding anti-IgE therapy in atopic allergic patients. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Anti-IgE therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Exploring alternative and experimental therapies. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Experimental approaches'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33354?source=see_link\">",
"       \"Alternative and experimental agents for the treatment of asthma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Referral to an asthma specialist is suggested for all patients with this degree of asthma severity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Systemic glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral GCs are the most potent and effective controller agent for asthma, but have substantial side effects when used for months to years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. We always try to use the lowest dose of oral GC for the shortest duration possible, because of the side effects of systemic GCs. We use high dose inhaled GC, LABA, and other controller medications to maintain asthma control and allow tapering of oral GC, because these other controller medications have fewer systemic effects.",
"   </p>",
"   <p>",
"    When a patient has frequent exacerbations despite high doses of inhaled GCs, it is helpful to determine whether the patient's asthma is actually responsive to GCs. This can be accomplished with injection of a long acting GC, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/11\">",
"     11",
"    </a>",
"    ]. With this approach,",
"    <span class=\"nowrap\">",
"     adherence/compliance",
"    </span>",
"    is no longer an issue. In a randomized trial, patients with a high level of lung eosinophils, despite high dose inhaled (and even oral) GCs, responded to 3 mL (40",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    of intramuscular triamcinolone acetonide with improved FEV1, reduced rescue medication, and decreased lung eosinophils when assessed two weeks later [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients who respond to triamcinolone are not steroid resistant, but rather poorly adherent or poorly steroid responsive, requiring very high doses of GC that may be associated with substantial side effects. After intramuscular triamcinolone, the anti-inflammatory effect and hypothalamic-pituitary-adrenal suppression last for about two to six weeks. It is reasonable to reassess symptom control and spirometry in three to four weeks.",
"   </p>",
"   <p>",
"    Patients who fail to respond to systemic GCs may rarely have GC resistant asthma. For clinical purposes, this is defined by a forced vital capacity in one second (FEV1) that is less than 75 percent of predicted and fails to improve by 15 percent after a two week trial of oral GC (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    40 mg per day). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/42/7849?source=see_link\">",
"     \"Glucocorticoid-resistant asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Consideration should be given to daily low dose oral GCs (5 to 10",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    when bursts of oral GCs are required every two to three months despite high dose inhaled GC, long acting inhaled beta agonist, and trials of other controller agents described below. The lowest possible daily should be used.",
"   </p>",
"   <p>",
"    Patients on chronic oral GC need to be monitored for GC side effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=see_link\">",
"     \"Major side effects of inhaled glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Inhaled glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled GCs have broad anti-inflammatory effects in asthma and are effective in many patients with severe asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/2,3,13,14\">",
"     2,3,13,14",
"    </a>",
"    ]. They have been shown to reduce asthma symptoms; improve peak expiratory flow rate (PEFR), spirometry, and quality of life; diminish airway hyperresponsiveness; and prevent or reduce the frequency of exacerbations. We usually use a high potency GC that allows for the least number of puffs per day. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=see_link\">",
"     \"Delivery of inhaled medication in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When asthma is not well controlled on high dose inhaled GC (eg, about 1000 mcg per day), but appears to be GC responsive, we consider a further increase in dose or use of an inhaled GC with a smaller particle size. The evidence for increasing the dose of inhaled GC above 1000 mcg per day is limited and not all patients will improve with higher inhaled GC doses. As an example, a double blind, parallel group study of 671 patients with severe asthma found slightly greater efficacy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    2 mg per day compared to fluticasone 1 mg per day or to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    1.6 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/15\">",
"     15",
"    </a>",
"    ]. Outcome measures were morning peak flow, rescue medication, daily symptom scores and diurnal peak flow variation. However, systemic GC side effects are likely to occur in this dose range.",
"   </p>",
"   <p>",
"    Most of the currently available inhaled GCs are delivered in aerosols of a particle size that do not reach the distal airways. Hydrofluoroalkane (HFA)-beclomethasone has a particle size of approximately one micron, which enhances its delivery to the distal airways [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Although evidence is lacking, adding an HFA or other small particle size formulation (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    DPI) of inhaled GCs to a traditional",
"    <span class=\"nowrap\">",
"     GC/LABA",
"    </span>",
"    combination preparation (eg, 160 to 320 mcg of inhaled GC at midday in addition to the twice daily dosing of a combination product) may improve measures of small airway disease, and perhaps clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Monitoring for GC related side effects is appropriate for patients on chronic high dose inhaled GC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=see_link\">",
"     \"Major side effects of inhaled glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Combination inhaled GC/LABA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with severe asthma should receive a trial of combination therapy with inhaled GC and a long acting beta agonist (LABA) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/2,3,8\">",
"     2,3,8",
"    </a>",
"    ]. These can be prescribed as separate inhalers or as a combination inhaler (",
"    <a class=\"graphic graphic_table graphicRef72467 \" href=\"UTD.htm?15/34/15917\">",
"     table 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78011 \" href=\"UTD.htm?15/35/15934\">",
"     table 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef68143 \" href=\"UTD.htm?37/48/38668\">",
"     table 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The evidence in favor of combined",
"    <span class=\"nowrap\">",
"     GC/LABA",
"    </span>",
"    therapy comes largely from extrapolation from trials in patients with moderately severe asthma and a few trials that studied addition of a LABA in patients with severe asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/8,19,20\">",
"     8,19,20",
"    </a>",
"    ]. In contrast, one randomized, placebo-controlled trial found only minimal improvement with addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    to high dose inhaled or oral GC treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concerns have been raised about the safety of LABA because of reports in a small subgroup of patients of severe exacerbations and increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Patients should be monitored for any deterioration in asthma control after initiation of LABA therapy. LABAs are never used as monotherapy in severe asthma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/19/16698?source=see_link\">",
"     \"Beta agonists in asthma: Controversy regarding chronic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If asthma symptoms, SABA use, and objective measures are unimproved after a trial of LABA therapy, consideration should be given to stopping the LABA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Antileukotriene agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence for the efficacy of leukotriene receptor antagonists (LTRAs) as add-on therapy in severe asthma is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. One study evaluated LTRAs as additive therapy in patients whose asthma was not controlled with inhaled GC and LABA and did not find a benefit, but the study duration was only two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/26\">",
"     26",
"    </a>",
"    ]. On the other hand, we believe that leukotriene modifiers and receptor antagonists are often helpful in patients with late onset disease, particularly those with a history of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. If a LTRA does not improve asthma control within three months, we frequently try the 5-lipoxygenase inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/33/17940?source=see_link\">",
"     zileuton",
"    </a>",
"    as an alternative [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The NAEPP guidelines also suggest a trial of an antileukotriene agent in patients with severe asthma who are not controlled on high dose inhaled GC and LABA [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/2\">",
"     2",
"    </a>",
"    ]. Currently available agents include the 5-lipoxygenase inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/33/17940?source=see_link\">",
"     zileuton",
"    </a>",
"    (Zyflo) and the cysLT receptor antagonists (LTRAs)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    (Singulair) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/54/20325?source=see_link\">",
"     zafirlukast",
"    </a>",
"    (Accolate) (",
"    <a class=\"graphic graphic_table graphicRef77367 \" href=\"UTD.htm?20/12/20683\">",
"     table 8",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30746?source=see_link\">",
"     \"Agents affecting the 5-lipoxygenase pathway in the treatment of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Theophylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    has been used as an additional controller agent, although data are lacking regarding its efficacy when added to inhaled GC and a LABA. It is usually not as efficacious as LABAs when compared head-to-head [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/3,33-35\">",
"     3,33-35",
"    </a>",
"    ]. Studies of withdrawal of theophylline from patients with severe asthma have demonstrated a high rate of asthma flares, suggesting that theophylline may play a role beyond its weak bronchodilator capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11161?source=see_link\">",
"     \"Theophylline use in asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16608339\">",
"    <span class=\"h2\">",
"     Tiotropium",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/34/27173?source=see_link\">",
"     Tiotropium",
"    </a>",
"    , a once daily inhaled anticholinergic bronchodilator, has been evaluated as a potential therapy for severe asthma. Tiotropium is administered via a soft mist Respimat inhaler in Europe (2 inhalations of 2.5 mcg), which is roughly comparable to the dry powder Handihaler device (18 mcg per inhalation) used in the United States. Tiotropium is widely used for COPD, but is not included in the NAEPP or GINA guidelines for asthma management [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Evidence in favor of using tiotropium for severe asthma includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In two replicate trials with a total of 912 patients with severe asthma, the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      5 mcg delivered via a soft mist inhaler was compared to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/37\">",
"       37",
"      </a>",
"      ]. At study entry, participants&rsquo; asthma was poorly controlled despite an inhaled glucocorticoid and a LABA and their baseline FEV",
"      <sub>",
"       1",
"      </sub>",
"      after bronchodilator was 80 percent or less than the predicted value. At 24 weeks, the two tiotropium groups had a significant improvement in the adjusted peak FEV",
"      <sub>",
"       1",
"      </sub>",
"      . The addition of tiotropium also increased the time to the first severe exacerbation by 56 days over placebo. However, the minimal clinically important difference for the ACQ-7 score was not achieved in either trial. The baseline degree of airflow limitation may have selected for patients who are more &ldquo;COPD-like&rdquo; and therefore more likely to demonstrate a response. Adherence to asthma medications other than the study medications was not monitored, but any nonadherence would likely have been similar across groups.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/34/27173?source=see_link\">",
"       Tiotropium",
"      </a>",
"      was assessed as add-on therapy in patients with severe asthma whose symptoms were not controlled despite high dose inhaled glucocorticoids plus a long-acting beta agonist [",
"      <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/38\">",
"       38",
"      </a>",
"      ]. In this cross-over trial, 107 patients were randomly assigned to one of two doses of tiotropium via a Respimat inhaler (5 mcg or 10 mcg) once daily or placebo for three eight-week periods. At the end of each eight-week period, the forced expiratory volume in one second (FEV",
"      <sub>",
"       1",
"      </sub>",
"      ) was higher in the tiotropium groups than control. Daily home (PEF) measurements were higher in the tiotropium groups, but no significant differences were noted in asthma symptoms. Dry mouth was more common with the higher dose of tiotropium.",
"     </li>",
"     <li>",
"      The efficacy and safety of",
"      <a class=\"external\" href=\"file://www.uptodate.com/contents/tiotropium-drug-information?source=see_link\">",
"       tiotropium",
"      </a>",
"      &nbsp;were compared to",
"      <a class=\"external\" href=\"file://www.uptodate.com/contents/salmeterol-drug-information?source=see_link\">",
"       salmeterol",
"      </a>",
"      &nbsp;and placebo in 388 patients with moderate-to-severe asthma not controlled by inhaled glucocorticoids and the beta2-adrenergic receptor",
"      <span class=\"nowrap\">",
"       B16-Arg/Arg",
"      </span>",
"      genotype [",
"      <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/39\">",
"       39",
"      </a>",
"      ]. Participants were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      5mcg once a day by Respimat inhaler,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      50 mcg twice a day via metered dose inhaler, or placebo for 16 weeks. Tiotropium was not inferior to salmeterol in the primary outcome of changes in morning peak expiratory flow (PEF); both active treatments were better than placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The main adverse effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    in these asthma trials was dry mouth. In the first of the trials above, drug-related cardiac events occurred in two patients in the tiotropium group and one in the placebo group. The soft mist inhaler used in that trial is thought to increase plasma concentrations of tiotropium more than the dry powder device, so concerns have been raised regarding a potential increase in risk of death from cardiovascular causes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33305?source=see_link&amp;anchor=H12#H12\">",
"     \"Role of anticholinergic therapy in COPD\", section on 'Tiotropium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We typically reserve",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    for patients who have ongoing asthma symptoms and airflow limitation despite combination therapy with inhaled",
"    <span class=\"nowrap\">",
"     glucocorticoid/LABA.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Chromones",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37712?source=see_link\">",
"     Cromolyn sodium",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=see_link\">",
"     nedocromil",
"    </a>",
"    , two mast cell stabilizing medications from the chromone class (also called cromoglycates), are useful in the management of some patients with mild-to-moderate asthma. In general, these medications are not effective enough to be of benefit in severe asthma and have only limited availability [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/29/471?source=see_link\">",
"     \"The use of chromones (cromoglycates) in the treatment of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ANTI-IGE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anti-IgE agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    is approved by the Food and Drug Administration in the United States for use in patients age 12 and above with moderate-to-severe persistent allergic asthma, an IgE level of 30 to 700",
"    <span class=\"nowrap\">",
"     IU/mL,",
"    </span>",
"    positive allergen skin or specific IgE tests to a perennial allergen, and&nbsp;incomplete symptom control with inhaled glucocorticoid treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Omalizumab is administered by subcutaneous injection every two to four weeks in a dose that is determined by body weight and the levels of serum IgE (0.016",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    of IgE per month). A dose of 150 to 375 mg is injected subcutaneously every two to four weeks to achieve the monthly target. No more than 150 mg is administered at a single injection site, to prevent local reactions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17130?source=see_link&amp;anchor=H12#H12\">",
"     \"Anti-IgE therapy\", section on 'Dosing and administration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    in patients with severe asthma (poor symptom control on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    1000",
"    <span class=\"nowrap\">",
"     microg/d",
"    </span>",
"    and a LABA with or without other controller medications) was assessed in a trial that randomly assigned 850 such patients to omalizumab or placebo for 48 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/43\">",
"     43",
"    </a>",
"    ]. A 25 percent reduction in the rate of asthma exacerbations was noted in the omalizumab group compared with placebo, although the results are somewhat limited by the 20 percent early discontinuation rate. No reduction in exacerbations was noted in the subgroup taking daily oral glucocorticoids. However, the lack of effect in this subgroup may be due to an insufficient sample size. Further study is needed to determine the effect of omalizumab among patients who require daily oral glucocorticoids to control their asthma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17130?source=see_link&amp;anchor=H7#H7\">",
"     \"Anti-IgE therapy\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    therapy is variable and difficult to predict, with overall response rates in patients with moderate to severe asthma averaging 30 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/44\">",
"     44",
"    </a>",
"    ]. A minimum of 12 weeks of treatment is needed to determine the efficacy of anti-IgE therapy; we typically use a three to six month trial before concluding benefit or lack thereof (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17130?source=see_link&amp;anchor=H12#H12\">",
"     \"Anti-IgE therapy\", section on 'Dosing and administration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TAPERING THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;When asthma control is achieved, oral GCs are tapered, as tolerated, and discontinued. Reducing the dose of other controller medications is based on perceived efficacy, presence of adverse effects, patient preference, and cost considerations.",
"   </p>",
"   <p>",
"    Reducing the dose of inhaled GCs may be considered in patients who achieve complete asthma control, once oral GCs have been discontinued. Guidelines for tapering of inhaled GCs have not been validated, but we usually decrease by 20 to 25 percent increments at one to three month intervals to a medium or low dose [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/45\">",
"     45",
"    </a>",
"    ]. We usually do not discontinue inhaled GCs in patients with a history of severe asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     EXPERIMENTAL APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various pharmacologic and nonpharmacologic agents have been used in an attempt to improve asthma control and ameliorate the many adverse effects of chronic oral GC therapy in patients with severe asthma. These therapies are reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33354?source=see_link\">",
"     \"Alternative and experimental agents for the treatment of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Immunomodulatory therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous agents with antiinflammatory properties have been studied in an effort to eliminate or decrease the inflammation that underlies chronic asthma.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    have shown glucocorticoid sparing effects in some small trials, but side effects, especially with cyclosporine, are substantial and likely outweigh any potential benefit. Other immunomodulatory drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and mycophenolic acid have not undergone treatment trials in severe asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Anti-IL-5 antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monoclonal antibodies to anti-interleukin 5 (IL-5) have been studied for use in asthma because of the potent effect of IL-5 on eosinophil recruitment to the airways. Treatment with the anti-IL-5 monoclonal antibodies, mepolizumab and reslizumab, may be beneficial in a small subgroup of patients with persistent airways eosinophilia despite glucocorticoid therapy. This class of medication is not approved by the US Food and Drug Administration or readily available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33354?source=see_link&amp;anchor=H20#H20\">",
"     \"Alternative and experimental agents for the treatment of asthma\", section on 'Anti-IL-5 antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Tumor necrosis factor-alpha inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibitors of tumor necrosis factor (TNF)-alpha have been studied in the treatment of asthma. The largest trial did not achieve the primary endpoints (reduction in exacerbations and improvement in FEV1), and substantial side effects were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33354?source=see_link&amp;anchor=H18#H18\">",
"     \"Alternative and experimental agents for the treatment of asthma\", section on 'Anti-TNFa agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Macrolide antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macrolide antibiotics have both antimicrobial and anti-inflammatory actions. In a randomized, placebo controlled trial in 46 patients with refractory asthma, eight weeks of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    improved asthma specific quality of life and reduced sputum neutrophils and IL-8, but did not improve physiologic measures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/48\">",
"     48",
"    </a>",
"    ]. Patients who provide a history of onset of disease after an acute respiratory illness may respond to macrolide antibiotics on the basis of a mycoplasma or chlamydia-related initiating event [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. We usually prescribe clarithromycin for a four to six week trial in patients who report onset of asthma after a respiratory illness suggestive of these organisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17414461\">",
"    <span class=\"h2\">",
"     Bronchial thermoplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchial thermoplasty (BT) refers to a technique of applying controlled radiofrequency waves to the airways during bronchoscopy to theoretically reduce the increased mass of airway smooth muscle associated with asthma. BT is associated with a transient increase in respiratory adverse events, mainly worsening of asthma. BT is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33354?source=see_link&amp;anchor=H30#H30\">",
"     \"Alternative and experimental agents for the treatment of asthma\", section on 'Bronchial thermoplasty'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     TREATMENT OF COMORBIDITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once comorbid conditions that may influence a patient's response to asthma treatment have been identified, every effort should be made to control their impact. However, evidence that this will improve the course of a patient's asthma is limited.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergic rhinitis should be treated with allergen avoidance and intranasal GCs [",
"      <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/51,52\">",
"       51,52",
"      </a>",
"      ]. If surgically amenable naso-sinus disease (eg, chronic rhinosinusitis in a patient with nasal polyposis) is identified, then referral to an otolaryngologist should be considered.",
"     </li>",
"     <li>",
"      Symptomatic GERD should be treated with proton pump inhibitors, although data to suggest that this therapy improves asthma (as opposed to GERD) are limited. Therapy with proton pump inhibitors does not improve asthma-related outcomes in patients who do not have symptoms of GERD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39816?source=see_link&amp;anchor=H9#H9\">",
"       \"Gastroesophageal reflux and asthma\", section on 'Asymptomatic patients'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"       \"Medical management of gastroesophageal reflux disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vocal cord dysfunction, when present with severe asthma, should be treated by a knowledgeable speech therapist. Underlying causes (eg, post nasal drip, GERD, and anxiety) should be treated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16567?source=see_link\">",
"       \"Paradoxical vocal cord motion\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who smoke should be counseled that this is a risk factor for fatal asthma and that cessation is imperative. Smoking cessation classes, counseling, and pharmacologic aids may be helpful [",
"      <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/53\">",
"       53",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"       \"Overview of smoking cessation management in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/26/13735?source=see_link\">",
"       \"Identifying patients at risk for fatal asthma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of obstructive sleep apnea may improve nocturnal symptoms of dyspnea and choking [",
"      <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/54-56\">",
"       54-56",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=see_link\">",
"       \"Overview of obstructive sleep apnea in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Obese patients may benefit from counseling regarding ways to improve nutrition and increase activity [",
"      <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/57\">",
"       57",
"      </a>",
"      ]. In certain cases, obesity may be so severe that bariatric surgery is considered, but in patients on chronic oral GCs, there are likely to be increased complications with this approach as well.",
"     </li>",
"     <li>",
"      Anxiety and depression (or other psychiatric issues) should be evaluated and treated [",
"      <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     TREATMENT BY PHENOTYPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients have refractory asthma despite the best efforts to identify and reduce exposure to asthma triggers, develop a combined modality treatment plan, and treat comorbidities. Attempts to characterize these patients have lead to the concept of severe asthma phenotypes and it is hoped that treatments tailored to the particular phenotype of each patient may improve asthma outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/17/3354/abstract/30,59-62\">",
"     30,59-62",
"    </a>",
"    ]. The description of severe asthma phenotypes and associated treatment suggestions are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36278?source=see_link\">",
"     \"Severe asthma: Evidence for heterogeneity of the disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"       \"Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The American Thoracic Society (ATS) classification of \"severe asthma\" refers to patients who require high dose inhaled or near continuous oral glucocorticoid (GC) treatment to maintain asthma control (",
"      <a class=\"graphic graphic_table graphicRef68983 \" href=\"UTD.htm?12/20/12620\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The NAEPP and GINA guidelines have a slightly different category of \"severe persistent asthma\" that describes patients who have frequent and severe asthma symptoms and evidence of airflow limitation, but are not on asthma controller medication (",
"      <a class=\"graphic graphic_table graphicRef58247 \" href=\"UTD.htm?32/48/33549\">",
"       table 2",
"      </a>",
"      ). Some of these patients will achieve asthma control with modest doses of controller medication; others will require high doses of controller medications to achieve control or will continue to have poor asthma control despite medication. These latter patients have \"severe asthma\" by ATS criteria.",
"     </li>",
"     <li>",
"      A written action plan should be provided to all patients with severe asthma; the plan may be symptom or peak flow based, or both. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Patient education'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inhaler technique should be observed and corrected when necessary. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Patient education'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend initial controller therapy with high dose inhaled GC in patients with severe persistent asthma (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Inhaled glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients with severe asthma may need intermittent or chronic oral GC therapy in addition to high dose inhaled GC. For patients with chronic airflow limitation, a two week trial of oral GCs may help determine the potential for reversibility and define a goal for future adjustments in inhaled GC. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Systemic glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to inhaled GCs, we suggest that patients with severe asthma be started on a long acting beta agonist (LABA) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, if asthma symptoms, SABA use, and objective measures are unimproved after a trial of LABA therapy, the LABA is probably not helping and can be discontinued. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Long acting beta agonists (LABA)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who do not achieve adequate control with a combination of a high dose inhaled GC and LABA, we suggest adding an additional controller medication.&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Choices include an antileukotriene agent,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      . If asthma control does not improve after a reasonable trial the added medication should be discontinued. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Antileukotriene agents'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Theophylline'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Independent of other therapies, in patients with atopic severe asthma, who have a serum IgE level of 30 to 700",
"      <span class=\"nowrap\">",
"       IU/mL",
"      </span>",
"      and documented sensitivity to a perennial allergen, we suggest adding",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       omalizumab",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). If asthma control does not improve after a reasonable trial (three to six months) the added medication should be discontinued. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Anti-IgE therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of comorbid diseases may be helpful. In particular, every effort should be made to achieve smoking cessation, because ongoing smoking is a risk factor for fatal asthma. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Treatment of comorbidities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potential alternative and experimental therapies include immunomodulatory therapy and macrolide antibiotics. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Experimental approaches'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the future, treatments tailored to asthma phenotypes may improve asthma outcomes. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Treatment by phenotype'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/1\">",
"      Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med 2000; 162:2341.",
"     </a>",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on January 05, 2012).",
"    </li>",
"    <li>",
"     GINA report. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2012. www.ginasthma.org (Accessed on March 12, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/4\">",
"      Bender BG. Overcoming barriers to nonadherence in asthma treatment. J Allergy Clin Immunol 2002; 109:S554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/5\">",
"      Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/6\">",
"      Schatz M, Sorkness CA, Li JT, et al. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol 2006; 117:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/7\">",
"      Juniper EF. Assessing asthma control. Curr Allergy Asthma Rep 2007; 7:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/8\">",
"      Pauwels RA, L&ouml;fdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/9\">",
"      Nelson HS, Busse WW, deBoisblanc BP, et al. Fluticasone propionate powder: oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma. J Allergy Clin Immunol 1999; 103:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/10\">",
"      Haselkorn T, Fish JE, Zeiger RS, et al. Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol 2009; 124:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/11\">",
"      Ogirala RG, Aldrich TK, Prezant DJ, et al. High-dose intramuscular triamcinolone in severe, chronic, life-threatening asthma. N Engl J Med 1991; 324:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/12\">",
"      ten Brinke A, Zwinderman AH, Sterk PJ, et al. \"Refractory\" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am J Respir Crit Care Med 2004; 170:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/13\">",
"      Masoli M, Weatherall M, Holt S, Beasley R. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax 2005; 60:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/14\">",
"      Noonan M, Chervinsky P, Busse WW, et al. Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Am J Respir Crit Care Med 1995; 152:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/15\">",
"      Ayres JG, Bateman ED, Lundb&auml;ck B, Harris TA. High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. International Study Group. Eur Respir J 1995; 8:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/16\">",
"      Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998; 12:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/17\">",
"      Hauber HP, Gotfried M, Newman K, et al. Effect of HFA-flunisolide on peripheral lung inflammation in asthma. J Allergy Clin Immunol 2003; 112:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/18\">",
"      Corren J, Nelson H, Greos LS, et al. Effective control of asthma with hydrofluoroalkane flunisolide delivered as an extrafine aerosol in asthma patients. Ann Allergy Asthma Immunol 2001; 87:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/19\">",
"      Faurschou P, Steffensen I, Jacques L. Effect of addition of inhaled salmeterol to the treatment of moderate-to-severe asthmatics uncontrolled on high-dose inhaled steroids. European Respiratory Study Group. Eur Respir J 1996; 9:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/20\">",
"      O'Byrne PM. Acute asthma intervention: insights from the STAY study. J Allergy Clin Immunol 2007; 119:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/21\">",
"      Nightingale JA, Rogers DF, Barnes PJ. Comparison of the effects of salmeterol and formoterol in patients with severe asthma. Chest 2002; 121:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/22\">",
"      Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993; 306:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/23\">",
"      Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/24\">",
"      Walters EH, Gibson PG, Lasserson TJ, Walters JA. Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database Syst Rev 2007; :CD001385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/25\">",
"      Price DB, Hernandez D, Magyar P, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003; 58:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/26\">",
"      Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet 2001; 357:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/27\">",
"      Rabinovitch N, Zhang L, Gelfand EW. Urine leukotriene E4 levels are associated with decreased pulmonary function in children with persistent airway obstruction. J Allergy Clin Immunol 2006; 118:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/28\">",
"      Virchow JC Jr, Prasse A, Naya I, et al. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med 2000; 162:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/29\">",
"      Dahl&eacute;n B, Nizankowska E, Szczeklik A, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1998; 157:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/30\">",
"      The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003; 22:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/31\">",
"      Berger W, De Chandt MT, Cairns CB. Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. Int J Clin Pract 2007; 61:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/32\">",
"      Nathan, RA, Prenner, BM, Bernstein, JA, Walton-Bowen, K. Zileuton Provides Significant Improvement in Asthma Symptoms and beta-agonist and Rescue Medication Use Compared to Placebo in Asthma Patients with Reduced or Low Lung Function. J Allergy Clin Immunol 2006; 117 Suppl 2:S156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/33\">",
"      American Lung Association Asthma Clinical Research Centers. Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. Am J Respir Crit Care Med 2007; 175:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/34\">",
"      Davies B, Brooks G, Devoy M. The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies. Respir Med 1998; 92:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/35\">",
"      Inoue H, Komori M, Matsumoto T, et al. Effects of salmeterol in patients with persistent asthma receiving inhaled corticosteroid plus theophylline. Respiration 2007; 74:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/36\">",
"      Kidney J, Dominguez M, Taylor PM, et al. Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy. Am J Respir Crit Care Med 1995; 151:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/37\">",
"      Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012; 367:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/38\">",
"      Kerstjens HA, Disse B, Schr&ouml;der-Babo W, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol 2011; 128:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/39\">",
"      Bateman ED, Kornmann O, Schmidt P, et al. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol 2011; 128:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/40\">",
"      Bousquet J, Wenzel S, Holgate S, et al. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004; 125:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/41\">",
"      Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/42\">",
"      Brown R, Turk F, Dale P, Bousquet J. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 2007; 62:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/43\">",
"      Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011; 154:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/44\">",
"      Holgate ST, Chuchalin AG, H&eacute;bert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/45\">",
"      Hawkins G, McMahon AD, Twaddle S, et al. Stepping down inhaled corticosteroids in asthma: randomised controlled trial. BMJ 2003; 326:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/46\">",
"      FitzGerald JM, Boulet LP, Follows RM. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. Clin Ther 2005; 27:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/47\">",
"      Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009; 179:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/48\">",
"      Simpson JL, Powell H, Boyle MJ, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008; 177:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/49\">",
"      Kraft M, Cassell GH, Pak J, Martin RJ. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest 2002; 121:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/50\">",
"      Sutherland ER, Martin RJ. Asthma and atypical bacterial infection. Chest 2007; 132:1962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/51\">",
"      Corren J, Adinoff AD, Buchmeier AD, Irvin CG. Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma. J Allergy Clin Immunol 1992; 90:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/52\">",
"      Adams RJ, Fuhlbrigge AL, Finkelstein JA, Weiss ST. Intranasal steroids and the risk of emergency department visits for asthma. J Allergy Clin Immunol 2002; 109:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/53\">",
"      Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette smoking. Eur Respir J 2004; 24:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/54\">",
"      Teodorescu M, Consens FB, Bria WF, et al. Correlates of daytime sleepiness in patients with asthma. Sleep Med 2006; 7:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/55\">",
"      Yigla M, Tov N, Solomonov A, et al. Difficult-to-control asthma and obstructive sleep apnea. J Asthma 2003; 40:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/56\">",
"      Bonekat HW, Hardin KA. Severe upper airway obstruction during sleep. Clin Rev Allergy Immunol 2003; 25:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/57\">",
"      Laforest L, Van Ganse E, Devouassoux G, et al. Influence of patients' characteristics and disease management on asthma control. J Allergy Clin Immunol 2006; 117:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/58\">",
"      ten Brinke A, Ouwerkerk ME, Bel EH, Spinhoven P. Similar psychological characteristics in mild and severe asthma. J Psychosom Res 2001; 50:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/59\">",
"      Miranda C, Busacker A, Balzar S, et al. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004; 113:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/60\">",
"      Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/61\">",
"      Green RH, Brightling CE, Bradding P. The reclassification of asthma based on subphenotypes. Curr Opin Allergy Clin Immunol 2007; 7:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/17/3354/abstract/62\">",
"      Green RH, Brightling CE, Woltmann G, et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57:875.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 551 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-C88E1676B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_17_3354=[""].join("\n");
var outline_f3_17_3354=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL TREATMENT PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Patient education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Compliance/adherence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Controlling asthma triggers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SHORT-ACTING BETA AGONISTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INITIATING CONTROLLER THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Oral glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Long acting beta agonists (LABA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ADJUSTING CONTROLLER THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Combination inhaled GC/LABA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Antileukotriene agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Theophylline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16608339\">",
"      Tiotropium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Chromones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ANTI-IGE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TAPERING THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      EXPERIMENTAL APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Immunomodulatory therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Anti-IL-5 antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Tumor necrosis factor-alpha inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Macrolide antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17414461\">",
"      Bronchial thermoplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      TREATMENT OF COMORBIDITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      TREATMENT BY PHENOTYPE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/551\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/551|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/33/44563\" title=\"figure 2\">",
"      Stepwise asthma Rx 12 and up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/551|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?36/39/37498\" title=\"figure 1\">",
"      Asthma action plan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/551|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/20/12620\" title=\"table 1\">",
"      ATS severe asthma criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/48/33549\" title=\"table 2\">",
"      Initiating Rx 12 and up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/31/15869\" title=\"table 3\">",
"      Asthma control 12 and up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/14/36076\" title=\"table 4\">",
"      Indoor allergen reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/34/15917\" title=\"table 5\">",
"      Doses beta agonist preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/35/15934\" title=\"table 6\">",
"      Inhaled GC doses for adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/48/38668\" title=\"table 7\">",
"      Usual doses inhaled GC-LABA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/12/20683\" title=\"table 8\">",
"      Usual doses antileukotriene",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30746?source=related_link\">",
"      Agents affecting the 5-lipoxygenase pathway in the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33354?source=related_link\">",
"      Alternative and experimental agents for the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17130?source=related_link\">",
"      Anti-IgE therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8618?source=related_link\">",
"      Beta agonists in asthma: Acute administration and prophylactic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/19/16698?source=related_link\">",
"      Beta agonists in asthma: Controversy regarding chronic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=related_link\">",
"      Delivery of inhaled medication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12789?source=related_link\">",
"      Enhancing patient adherence to asthma therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14105?source=related_link\">",
"      Evaluation of severe asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39816?source=related_link\">",
"      Gastroesophageal reflux and asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/42/7849?source=related_link\">",
"      Glucocorticoid-resistant asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/26/13735?source=related_link\">",
"      Identifying patients at risk for fatal asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=related_link\">",
"      Major side effects of inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=related_link\">",
"      Overview of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16567?source=related_link\">",
"      Paradoxical vocal cord motion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=related_link\">",
"      Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33305?source=related_link\">",
"      Role of anticholinergic therapy in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36278?source=related_link\">",
"      Severe asthma: Evidence for heterogeneity of the disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/29/471?source=related_link\">",
"      The use of chromones (cromoglycates) in the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18856?source=related_link\">",
"      The use of inhaler devices in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11161?source=related_link\">",
"      Theophylline use in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=related_link\">",
"      Treatment of acute exacerbations of asthma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18154?source=related_link\">",
"      Treatment of intermittent and mild persistent asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26745?source=related_link\">",
"      Treatment of moderate persistent asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=related_link\">",
"      Trigger control to enhance asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31991?source=related_link\">",
"      What do patients need to know about their asthma?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_17_3355="Favorable predict oral devices";
var content_f3_17_3355=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Factors reported to favor a better response with mandibular advancement splints",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Younger age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Female gender",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lower body mass index",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Smaller neck circumference",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Less severe OSA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Supine-dependent OSA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Healthy dentition with good protrusive range",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Longer maxilla",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Smaller oropharynx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Smaller overjet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shorter soft palate",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_17_3355=[""].join("\n");
var outline_f3_17_3355=null;
var title_f3_17_3356="Normal anogenital variants";
var content_f3_17_3356=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Normal variants in the anogenital examination",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Female genitalia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Periurethral bands",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vestibular bands",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intravaginal ridge or column",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Linea vestibularis (midline avascular area)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dilation of the urethral opening with application of labial traction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Hymen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hymenal tags or septal remnants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hymenal bump or mound",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hymenal cleft/notch in the anterior",
"(superior) half of the hymenal rim (above the line drawn through 3",
"o'clock to 9 o'clock, with the patient supine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        External hymenal ridge",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Septate hymen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Thickened hymen (may be due to estrogen effect, folded edge of hymen, or swelling from infection or trauma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Shallow or superficial notch or cleft in the posterior (inferior) rim of hymen (below the line drawn through 3 o'clock to 9 o'clock, with the patient supine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Perianal area",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diastasis ani (smooth area)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perianal skin tag",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperpigmentation of the skin of the labia majora or perianal tissues in Mexican American and African American children",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Adams, JA. Medical evaluation of suspected child sexual abuse. J Pediatr Adolesc Gynecol 2004; 17:191.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_17_3356=[""].join("\n");
var outline_f3_17_3356=null;
var title_f3_17_3357="Misoprost abortion rupture";
var content_f3_17_3357=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Reported cases of uterine rupture with misoprostol induction for pregnancy termination",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Lead author [publication date]",
"      </td>",
"      <td class=\"subtitle1\">",
"       Gestational age, weeks",
"      </td>",
"      <td class=\"subtitle1\">",
"       Previous uterine scar",
"      </td>",
"      <td class=\"subtitle1\">",
"       Gravidity",
"      </td>",
"      <td class=\"subtitle1\">",
"       Misoprostol dose (mcg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Ruptures of previously scarred uteri",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Jwarah [2007]",
"      </td>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       G3",
"      </td>",
"      <td>",
"       800 miso PV",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Mazouni [2006]",
"      </td>",
"      <td>",
"       16",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       ?",
"      </td>",
"      <td>",
"       600 mg mife followed 36 hours later by 200 miso PV every 3 hours up to 3 doses; miso doses repeated 24 hours later as needed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Daskalaikis [2005]",
"      </td>",
"      <td>",
"       23",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       G2",
"      </td>",
"      <td>",
"       400 miso PO plus 400 PV given at first, then 400 PV dose 8 hours later",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Berghahn [2001]",
"      </td>",
"      <td>",
"       23",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       G2(?)",
"      </td>",
"      <td>",
"       400 miso PV then 400 buccal 6 hours later",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Chen [1999]",
"      </td>",
"      <td>",
"       23",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       G3",
"      </td>",
"      <td>",
"       200 miso PV",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Mazouni [2006]",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       ?",
"      </td>",
"      <td>",
"       600 mg mife followed 36 hours later by 200 miso PV every 3 hours up to 3 doses; miso doses repeated 24 hours later as needed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Nayki [2005]",
"      </td>",
"      <td>",
"       26",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       G2(?)",
"      </td>",
"      <td>",
"       200 miso PV every 3 hours up to 4 doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Ruptures involving major malformation of uterus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Samuels [2005]",
"      </td>",
"      <td>",
"       18",
"      </td>",
"      <td>",
"       No (pregnancy in noncommunicating rudimentary horn)",
"      </td>",
"      <td>",
"       G1",
"      </td>",
"      <td>",
"       200 miso PV",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Ruptures involving relatively high doses of misoprostol",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Phillips [1996]",
"      </td>",
"      <td>",
"       18",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       G4",
"      </td>",
"      <td>",
"       200 mg mife followed by 600 miso PV every 6 hours for 2 doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Ruptures involving high cumulative  doses of misoprostol",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Bagga [2004]",
"      </td>",
"      <td>",
"       20",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       G4",
"      </td>",
"      <td>",
"       200 mg mife followed by 200 miso PV every 6 hours for 6 doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Letourneur [2002]",
"      </td>",
"      <td>",
"       25",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       G1",
"      </td>",
"      <td>",
"       600 mg mife followed by 200 miso PO for 7 doses",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Miso: misoprostol; Mife: mifepristone; PV: per vaginam; PO: per oral route; ?: indicates that the article is not fully clear on the given point.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_17_3357=[""].join("\n");
var outline_f3_17_3357=null;
var title_f3_17_3358="Risk of stroke and intracranial bleeding based on INR";
var content_f3_17_3358=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F87025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F87025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Odds ratios for ischemic stroke and intracranial bleeding in relation to intensity of anticoagulation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 332px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Adjusted odds ratios for ischemic stroke and intracranial bleeding in relation to intensity of anticoagulation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2011; 123:e269. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_17_3358=[""].join("\n");
var outline_f3_17_3358=null;
var title_f3_17_3359="Diagnosis and treatment of intestinal ischemia V";
var content_f3_17_3359=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diagnosis and treatment of intestinal ischemia V",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 332px; height: 572px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Solid lines indicate accepted management plan; dashed lines indicate alternate management plan.",
"    <div class=\"footnotes\">",
"     DVT: deep vein thrombosis; SMA: superior mesenteric artery.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the American Gastroenterological Association. Brandt, LJ, Boley, SJ, Gastroenterology 2000; 118:951.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_17_3359=[""].join("\n");
var outline_f3_17_3359=null;
